

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2006290814 B2**

(54) Title
2-aniline-4-aryl substituted thiazole derivatives

(51) International Patent Classification(s)
C07D 277/42 (2006.01) **C07D 417/04** (2006.01)
A61K 31/426 (2006.01) **C07D 417/12** (2006.01)
A61K 31/427 (2006.01) **C07D 417/14** (2006.01)
A61K 31/4436 (2006.01) **C07D 471/04** (2006.01)
A61P 25/18 (2006.01) **C07D 513/04** (2006.01)
A61P 25/28 (2006.01)

(21) Application No: **2006290814** (22) Date of Filing: **2006.09.05**

(87) WIPO No: **WO07/031440**

(30) Priority Data

(31) Number	(32) Date	(33) Country
05108395.4	2005.09.13	EP

(43) Publication Date: **2007.03.22**

(44) Accepted Journal Date: **2012.06.07**

(71) Applicant(s)
Janssen Pharmaceutica N.V.

(72) Inventor(s)
Lesage, Anne Simone Josephine; MacDonald, Gregor James; Thuring, Johannes Wilhelmus John F.; Grantham, Christopher James; Dinklo, Theodorus

(74) Agent / Attorney
Shelston IP, Level 21 60 Margaret Street, Sydney, NSW, 2000

(56) Related Art
EP 0 275 312
WO 1997005131
WO 2002024200
WO 2001064674
WO 2004110350

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 March 2007 (22.03.2007)

PCT

(10) International Publication Number
WO 2007/031440 A3

(51) International Patent Classification:

C07D 277/42 (2006.01) A61K 31/426 (2006.01)
 C07D 417/04 (2006.01) A61K 31/427 (2006.01)
 C07D 417/12 (2006.01) A61K 31/436 (2006.01)
 C07D 471/04 (2006.01) A61P 25/18 (2006.01)
 C07D 513/04 (2006.01) A61P 25/28 (2006.01)
 C07D 417/14 (2006.01)

(21) International Application Number:

PCT/EP2006/066015

(22) International Filing Date:

5 September 2006 (05.09.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

05108395.4 13 September 2005 (13.09.2005) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **THURING, Johannes, Wilhelmus, John, F.** [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **MACDONALD, Gregor, James** [GB/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **GRANTHAM, Christopher, James** [GB/GB]; 'Te Kainga', 72 Guildford Road, Ash, Aldershot GU12 6BT (GB). **DINKLO, Theodorus** [NL/BE]; Merelstraat 7, B-2340 Beerse (BE). **LESAGE, Anne, Simone, Josephine** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

2 August 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES



(57) Abstract: This invention concerns the use of a compound of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is hydrogen, halo, C₁₋₆alkyl, Het¹, HO-C₁₋₆alkyl-, cyano-C₁₋₆alkyl-, amino-C(=O)-C₁₋₆alkyl-, formylamino-C₁₋₆alkyl-, C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl-, mono- or di(C₁₋₆alkyl)amino-C(=O)-C₁₋₆alkyl-, phenyl-C₁₋₆alkyl-, or He⁴-C₁₋₆alkyl-; Q is phenyl, pyridyl, benzofuranyl, 2,3-dihydro-benzofuranyl, pyrazolyl, isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted with up to three substituents each independently selected from halo, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkyl, Ar or polyhaloC₁₋₆alkyl; L is phenyl, pyridyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl or furanyl wherein each of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo, hydroxy, amino, cyano, C₁₋₆alkyl or C₁₋₆alkyl-O-; Het¹ represents morpholinyl; pyrazolyl or imidazolyl; Het⁴ represents morpholinyl, pyrazolyl or imidazolyl; Ar represents phenyl optionally substituted with halo, C₁₋₆alkyl, C₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl; for the manufacture of a medicament for the prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the α₇ nicotinic receptor is beneficial.

WO 2007/031440 A3

2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES

5 The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to positive modulators of nicotinic acetylcholine receptors, such positive modulator having the capability to increase the efficacy of nicotinic receptor agonists.

10 BACKGROUND OF THE INVENTION

Cholinergic receptors normally bind the endogenous neurotransmitter acetylcholine (ACh), thereby triggering the opening of ion channels. ACh receptors in the mammalian central nervous system can be divided into muscarinic (mAChR) and nicotinic (nAChR) subtypes based on the agonist activities of muscarine and nicotine,
15 respectively. The nicotinic acetylcholine receptors are ligand-gated ion-channels containing five subunits. Members of the nAChR subunit gene family have been divided into two groups based on their amino acid sequences; one group containing so-called (3 subunits, and a second group containing a subunits. Three kinds of a subunits, $\alpha 7$, $\alpha 8$ and $\alpha 9$, have been shown to form functional receptors when expressed alone
20 and thus are presumed to form homooligomeric pentameric receptors.

An allosteric transition state model of the nAChR has been developed that involves at least a resting state, an activated state and a "desensitized" closed channel state, a process by which receptors become insensitive to the agonist. Different nAChR ligands
25 can stabilize the conformational state of a receptor to which they preferentially bind. For example, the agonists ACh and (-) -nicotine respectively stabilize the active and desensitized states.

Changes of the activity of nicotinic receptors has been implicated in a number of
30 diseases. Some of these, for example myasthenia gravis and ADFLE (autosomal dominant nocturnal front lobe epilepsy) are associated with reductions in the activity of nicotinic transmission either because of a decrease in receptor number or increased desensitization.

35 Reductions in nicotinic receptors have also been hypothesized to mediate cognitive deficits seen in diseases such as Alzheimer's disease and schizophrenia.

2006290814 17 Sep 2010

The effects of nicotine from tobacco are also mediated by nicotinic receptors. and since the effect of nicotine is to stabilize receptors in a desensitized state, an increased activity of nicotinic receptors may reduce the desire to smoke.

- 5 Compounds which bind nAChRs have been suggested for the treatment of a range of clinical psychiatric and neurological disorders involving cognitive deficits in attention, alertness, and memory. These may include those that may benefit from selective enhancement in cholinergic transmission such as attention deficit, chronic psychotic disorders, jetlag, selected pain syndromes, and smoking cessation; and those thought to
10 involve reduced cholinergic function such as, neurodegenerative disorders, central inflammatory or autoimmune diseases, brain trauma and cerebral vascular disease. Modulation of $\alpha 7$ nicotinic receptor activity is expected to be beneficial in a number of diseases including Alzheimer's disease, Mild Cognitive Impairment (MCI) and related syndromes, Lewy Body Dementia, vascular dementia, Multiple Sclerosis, post-
15 encephalitic dementias, Parkinson's disease, Huntington's disease, Attention Deficit Hyperactivity Disorder (ADHD), schizophrenia, bipolar mood disorder, schizoaffective disorder, Tourette's syndrome, and brain trauma.

- 20 However, treatment with nicotinic receptor agonists which act at the same site as ACh is problematic because ACh not only activates, but also blocks receptor activity through processes which include desensitization and uncompetitive blockade. Furthermore, prolonged activation appears to induce a long-lasting inactivation. Therefore, agonists of ACh can be expected to reduce activity as well as enhance it.

- 25 At nicotinic receptors in general, and of particular note at the $\alpha 7$ -nicotinic receptor, desensitization limits the duration of action of an applied agonist.

- 30 Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.


It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.

35 DESCRIPTION OF THE INVENTION

We have surprisingly found that certain compounds can increase the efficacy of agonists at nicotinic acetylcholine receptors (nAChR). Compounds having this type of action (hereinafter referred to as "positive modulators") are likely to be particularly

useful for treatment of conditions associated with reductions in nicotinic transmission. In a therapeutic setting such compounds could restore normal interneuronal communication without affecting the temporal profile of activation. In addition, positive modulators are not expected to produce long-term inactivation of receptors as

5 may occur at prolonged application of agonists.



Positive nAChR modulators of the present invention useful for treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, in particular for the treatment of a range of disorders that may benefit from selective enhancement in cholinergic transmission such as learning deficit, cognition deficit, attention deficit, chronic psychotic disorders, jetlag, selected pain syndromes, smoking cessation or memory loss, more in particular for the treatment of diseases in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, including Mild Cognitive Impairment and related syndromes, vascular dementia, post-encephalitic dementia, Attention deficit Hyperactivity, anxiety, schizophrenia, mania, manic depression, jetlag, bipolar mood disorder and schizoaffective disorder.

The present invention concerns 2-aniline-4-aryl thiazole derivatives having positive modulator properties, in particular increasing the efficacy of agonists at the $\alpha 7$ nicotinic receptor. The invention further relates to methods for their preparation and pharmaceutical compositions comprising them. The invention also relates to the use of 2-amino-4,5-trisubstituted thiazole derivatives for the manufacture of a medicament for the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, in particular in the treatment of a range of disorders involving reduced cholinergic function that may benefit from selective enhancement in cholinergic transmission such as learning deficit, cognition deficit, attention deficit or memory loss. In particular in the treatment of Mild Cognitive Impairment, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, mania, manic depression or other neurological, degenerative disorders in which there is a loss of cholinergic function, including loss of cholinergic synapses, including jetlag, nicotine addiction and pain. More in particular for the treatment of diseases in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, including Mild Cognitive Impairment and related syndromes, vascular dementia, post-encephalitic dementia, Attention deficit Hyperactivity, anxiety, schizophrenia, mania, manic depression, jetlag, bipolar mood disorder and schizoaffective disorder.

WO 01/64674 describes 2,4-disubstituted thiazole derivatives as cytokine inhibitors, in particular as TNF- α and/or IL-12 inhibitors.

WO 03/015773 describes 2-amino-4,5-trisubstituted thiazole derivatives as cytokine inhibitors, in particular as TNF- α and/or IL-12 inhibitors.

US patents US 6,187,797; US 6,569,874; US patent application US 2004/073029 and PCT publication WO 98/28282 provide phenylthiazoles as factor Xa inhibitors useful as anticoagulant agents for treatment and prevention of thromboembolic disorders.

US patent application US 2004/0254236 provides aminoaryl substituted 5 membered heterocyclic compounds including thiazoles as cytokine inhibitors, in particular P38 inhibitors and their use as anti-inflammatory compounds.

European patent EP 0 267 986 provides 2-amino-4-phenyl-5-thiazoleethanols, as diuretics.


WO 96/03392 provides substituted thiazoles as anti-inflammatory agents that act by inhibiting enzymes in the arachidonic acid / prostaglandin pathway, in particular inhibiting the cyclooxygenase COX-2.

PCT publication WO99/21555 provides thiazoles as selective adenosine A3 receptor antagonists and their use as prophylactic and therapeutic agent for asthma, allergosis or inflammation.

PCT publication WO2004/110350 provides thiazoles with a phenyl substituted NH-group in position 2 as modulators of A β that act as BACE inhibitors, and which are accordingly useful in the treatment of amyloidoses.

The compounds of the present invention are distinguishable from the prior art because of their structure and their pharmacological activity as positive modulators of the $\alpha 7$ nicotinic acetylcholine receptor.

The present invention relates to the use of a compound for the manufacture of a medicament for the prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, wherein the compound is a compound of formula



a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof,

wherein

Z is hydrogen, halo; cyano; C₁₋₆alkyl; haloC₁₋₆alkyl; polyhaloC₁₋₆alkyl-;

C₃₋₆cycloalkyl-C(=O)-; C₁₋₆alkyl-C(=O)-; C₁₋₆alkyl-O-C(=O)-; Ar¹; Het¹;

R^uR^vN-C(=O)-; Ar²-C(=O)-NH-; Het²-C(=O)-NH-; C₃₋₆cycloalkyl-C(=O)-NH-;

5 C₁₋₆alkyl-C(=O)-NH-; HO-C₁₋₆alkyl-; cyano-C₁₋₆alkyl-; amino-C₁₋₆alkyl-;

formylamino-C₁₋₆alkyl-; mono -or di(C₁₋₆alkyl)amino-C₁₋₆alkyl-;

C₁₋₆alkyl-S(=O)₂-NH-C₁₋₆alkyl; C₁₋₆alkyl-O-C(=O)-NH-C₁₋₆alkyl;

R^xR^yN-C(=O)-C₁₋₆alkyl-; C₁₋₆alkyl-O-C(=O)-C₁₋₆alkyl-; C₁₋₆alkyl-S(=O)₂-C₁₋₆alkyl-;

Ar³-S(=O)₂-C₁₋₆alkyl-; Het³-S(=O)₂-C₁₋₆alkyl-; Ar⁴-C₁₋₆alkyl-;

10 Het⁴-C₁₋₆alkyl-; C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl-; Ar⁵-C(=O)-NH-C₁₋₆alkyl-;

Het⁵-C(=O)-NH-C₁₋₆alkyl-; C₃₋₆cycloalkyl-C(=O)-NH-C₁₋₆alkyl-;

C₁₋₆alkyl-O-C₁₋₆alkyl-; polyhaloC₁₋₆alkyl-O-C₁₋₆alkyl-; or amino-C₁₋₆alkyl-

substituted with C₁₋₄alkyl substituted piperidinyl;

Q is phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, thienyl, furanyl,

15 benzthiazolyl, 2,3-dihydro-benzofuranyl, benzofuranyl benzoxazolyl,

benzimidazolyl, indazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl,

oxadiazolyl, pyridazinyl, triazolyl, thiadiazolyl or pyrimidazolyl, each of said rings

optionally being substituted with up to three substituents each independently

selected from halo; hydroxy; cyano; C₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-

20 O-C(=O)-; polyhaloC₁₋₆alkyl; polyhaloC₁₋₆alkyl-O-, amino, mono -or

di(C₁₋₆alkyl)amino, formylamino, C₁₋₆alkyl-C(=O)-NH- or Ar;

L is phenyl, piperidinyl, pyrimidinyl, pyrazolyl, triazolyl, pyridyl, pyrimidazolyl,

8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl, benzodioxolyl, furanyl or

25 1,4-benzodioxanyl wherein each of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected

from halo; hydroxy; amino; cyano; mono-or di(C₁₋₆alkyl)amino; C₁₋₆alkyl; HO-

C₁₋₆alkyl-; amino-C₁₋₆alkyl-; HO-C(=O)-C₁₋₆alkyl-; polyhaloC₁₋₆alkyl;

polyhaloC₁₋₆alkyl-O-; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; amino-

C(=O)-;

30 phenyl-C₁₋₆alkyl-O-C(=O)-or C₁₋₆alkyl-C(=O)-NH-; or L represents C₁₋₆alkyl,

C₁₋₆alkyl-O-C₁₋₆alkyl or C₃₋₆cycloalkyl wherein said C₁₋₆alkyl, C₃₋₆cycloalkyl or

C₁₋₆alkyl-O-C₁₋₆alkyl is optionally substituted with one or where possible two or

more halo substituents;

Ar represents phenyl optionally substituted one or where possible two, three or more

35 substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl,

C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or

polyhaloC₁₋₆alkyl;

- Ar¹ represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- 5 Ar² represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- 10 Ar³ represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- 15 Ar⁴ represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- 20 Ar⁵ and Ar⁶ each independently represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- 25 Het¹ represents piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;
- 30 Het² represents piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;
- 35 Het³ represents piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;
- Het⁴ represents piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to

3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;


Het⁵ and Het⁶ each independently represents piperidinyl, piperazinyl, pyridyl, pyrrolidinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;

R^u and R^v each independently represent hydrogen, C₁₋₆alkyl, Ar⁶, Het⁶, C₃₋₆cycloalkyl, C₁₋₆alkyl-O-C₁₋₆alkyl or R^u and R^v taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, piperidinyl, thiomorpholinyl and morpholinyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;

R^x and R^y each independently represent hydrogen, C₁₋₆alkyl, Ar⁶, Het⁶, C₃₋₆cycloalkyl, C₁₋₆alkyl-O-C₁₋₆alkyl or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, piperidinyl, thiomorpholinyl and morpholinyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl.

In particular use is for the treatment of cognitive deficits seen in diseases such as Alzheimer's diseases and schizophrenia, more in particular in the treatment of MCI, ADHD, anxiety, schizophrenia, mania, manic depression or other neurological or psychiatric disorders in which there is loss of cholinergic function, including loss of cholinergic synapses, including jetlag, nicotine addiction and pain.

The present invention also relates to a compound of formula



a pharmaceutically acceptable addition salt, or a stereochemically isomeric form thereof, wherein

n is 0, 1, 2, 3 or 4;

m is 0, 1, 2, 3 or 4;


R¹ each independently represents halo; hydroxy; cyano; C₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl-;

- R² each independently represents halo; hydroxy; amino; cyano; mono-or di(C₁₋₆alkyl)amino; C₁₋₆alkyl; HO-C₁₋₆alkyl-; amino-C₁₋₆alkyl-; HO-C(=O) - C₁₋₆alkyl-; polyhaloC₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; amino-C(=O)-; polyhaloC₁₋₆alkyl-O- or C₁₋₆alkyl-C(=O)-NH-;
- 5 Z is Het¹; C₁₋₆alkoxy-C(=O)-; HO-C₁₋₄alkyl-, C₁₋₆alkyl-C(=O)-NH- C₁₋₄alkyl-; C₃₋₆cycloalkyl-C(=O)-NH-C₁₋₄alkyl-; cyano-C₁₋₄alkyl-; formylamino-C₁₋₄alkyl-; Het⁴-C₁₋₄alkyl-; Ar⁴-C₁₋₄alkyl-; R^xR^yN-C(=O)-C₁₋₄alkyl-; halo; R^uR^vN-C(=O)-; C₁₋₆alkyl-O-C₁₋₆alkyl or Z represents C₁₋₆alkoxy-C(=O)-C₂₋₄alkyl-;
- 10 Het¹ represents morpholinyl, thiomorpholinyl, imidazolyl, pyrrolidinyl or pyrazolyl; Het⁴ represents morpholinyl, thiomorpholinyl, imidazolyl, pyrrolidinyl or pyrazolyl; Het⁶ represents pyridyl; Ar⁴ represents phenyl optionally substituted with halo, C₁₋₆alkyl, C₁₋₆alkoxy, polyhaloC₁₋₆alkoxy or polyhaloC₁₋₆alkyl;
- 15 R^x and R^y each independently represent hydrogen, C₁₋₆alkyl or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, thiomorpholinyl, piperidinyl or morpholinyl; R^u and R^v each independently represent hydrogen, C₁₋₆alkyl or Het⁶ or R^u and R^v taken together with the N atom to which they are attached form a 5 or 6 membered
- 20 heterocycle selected from pyrrolidinyl, thiomorpholinyl, piperidinyl or morpholinyl; provided that ;
- Z is other than ethoxycarbonyl-;
 - the compound is other than 4-phenyl-2-(phenylamino)-5-thiazoleacetonitrile [406470-24-4]; 5-[2-(4-morpholinyl)ethyl]-N,4-diphenyl-2-Thiazolamine [754921-77-2]; 5-Thiazolepropanoic acid, 2-[(4-bromophenyl)amino]-4-(4-methoxyphenyl)-, methyl ester (9Cl) [571149-21-8]; 5-Thiazolepropanoic acid, 2-[(4-chlorophenyl)amino]-4-(4-methoxyphenyl)-, methyl ester (9Cl) [406471-23-6]; 5-Thiazolepropanoic acid, 4-(4-methoxyphenyl)-2-[(4-methoxyphenyl)amino]-, methyl ester (9Cl) [406469-54-3];
- 25 5-Thiazolepropanoic acid, 4-(4-methoxyphenyl)-2-[(2,3,4-trifluorophenyl)amino]-, methyl ester (9Cl) [402768-12-1]; 5-Thiazolepropanoic acid, 4-(4-methoxyphenyl)-2-(phenylamino)-, methyl ester (9Cl) [370840-06-5]; 5-Thiazoleethanol, 4-(4-chlorophenyl)-2-(phenylamino)- (9Cl) [117612-81-4] or 4-(4-fluorophenyl)-5-[2-(4-morpholinyl)ethyl]-N-phenyl-2-Thiazolamine [773792-81-7].
- 30
- 35

As well as to use of a compound of formula (I') for the manufacture of a medicament for the prevention or the treatment or prophylaxis of psychotic disorders, intellectual

impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, in particular in the treatment of cognitive deficits seen in diseases such as Alzheimer's disease and schizophrenia, more in particular in the treatment of Mild Cognitive Impairment, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, mania, manic depression or other neurological, degenerative disorders in which there is a loss of cholinergic function, including loss of cholinergic synapses, including jetlag, nicotine addiction and pain. Even more in particular for the treatment of diseases in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, including Mild Cognitive Impairment and related syndromes, vascular dementia, post-encephalitic dementia, Attention deficit Hyperactivity, anxiety, schizophrenia, mania, manic depression, jetlag, bipolar mood disorder and schizoaffective disorder.

This invention also provides the compounds of formula



a pharmaceutically acceptable addition salt, or a stereochemically isomeric form thereof, wherein

n is 0, 1, 2, 3 or 4;

m is 0, 1, 2, 3 or 4;

R^1 each independently represents halo; hydroxy; C_{1-6} alkyl; C_{1-6} alkyloxy; C_{1-6} alkylthio;

C_{1-6} alkyloxycarbonyl; polyhalo C_{1-6} alkyl-O- or polyhalo C_{1-6} alkyl;

R^2 each independently represents halo; hydroxy; amino; cyano; mono- or

di(C_{1-6} alkyl)amino; C_{1-6} alkyl; HO- C_{1-6} alkyl-; amino- C_{1-6} alkyl-; HO-C(=O)- C_{1-6} alkyl-; polyhalo C_{1-6} alkyl; C_{1-6} alkyl-O-; C_{1-6} alkylthio; C_{1-6} alkyl-O-C(=O)-; aminocarbonyl; polyhalo C_{1-6} alkyl-O- or C_{1-6} alkyl-C(=O)-NH-;

Z is Het^1 ; C_{1-6} alkyloxy-C(=O)-; HO- C_{1-4} alkyl-; C_{1-6} alkyl-C(=O)-NH- C_{1-4} alkyl-; C_{3-6} cycloalkyl-C(=O)-NH- C_{1-4} alkyl-; cyano- C_{1-4} alkyl-; formylamino- C_{1-4} alkyl-; Het^4 - C_{1-4} alkyl-; Ar^4 - C_{1-4} alkyl-; R^xR^yN -C(=O)- C_{1-4} alkyl-; halo; halo C_{1-6} alkyl; C_{1-6} alkyl; C_{1-6} alkyl-O- C_{1-6} alkyl; mono- or di(C_{1-4} alkyl)amino- C_{1-6} alkyl; C_{1-6} alkyl-O-C(=O)-NH- C_{1-6} alkyl; C_{1-6} alkyl-S(=O)₂-NH- C_{1-6} alkyl; Het^5 -C(=O)-NH- C_{1-6} alkyl; Ar^5 -C(=O)-NH- C_{1-6} alkyl or Z represents C_{1-6} alkyloxy-C(=O)- C_{2-4} alkyl-; in particular Z is Het^1 ;

C_{1-6} alkyl-C(=O)-NH- C_{1-4} alkyl-; C_{3-6} cycloalkyl-C(=O)-NH- C_{1-4} alkyl-; cyano- C_{1-4} alkyl-; formylamino- C_{1-4} alkyl-; Het^4 - C_{1-4} alkyl-; Ar^4 - C_{1-4} alkyl-; R^xR^yN -C(=O)- C_{1-4} alkyl-; C_{1-6} alkyl-O- C_{1-6} alkyl; C_{1-6} alkyl-O-C(=O)-NH- C_{1-6} alkyl;

$C_{1-6}alkyl-S(=O)_2-NH-C_{1-6}alkyl$; $Het^5-C(=O)-NH-C_{1-6}alkyl$;


$Ar^5-C(=O)-NH-C_{1-6}alkyl$ or Z represents $C_{1-6}alkyloxy-C(=O)-C_{2-4}alkyl$;

Het^1 represents morpholinyl, thiomorpholinyl, imidazolyl, pyrrolidinyl or pyrazolyl;

Het^4 represents morpholinyl, thiomorpholinyl, imidazolyl, pyrrolidinyl or pyrazolyl;

5

This invention also provides a compound of formula



a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein

10 m is 0, 1, 2, 3 or 4; in particular m is 0, 1 or 2;

R^1 each independently represents halo; hydroxy; $C_{1-6}alkyl$; $C_{1-6}alkyloxy$; $C_{1-6}alkylthio$; $C_{1-6}alkyloxycarbonyl$; polyhalo $C_{1-6}alkyl-O-$ or polyhalo $C_{1-6}alkyl$; in particular R^1 each independently represents halo; $C_{1-6}alkyloxy-$ or polyhalo $C_{1-6}alkyl$; more in particular R^1 each independently represents chloro, methoxy or

15 trifluoromethyl;

Z is $C_{1-6}alkyloxy-C(=O)-$; $HO-C_{1-4}alkyl$; $C_{1-6}alkyl-C(=O)-$; $C_{3-6}cycloalkyl-C(=O)-$ or $C_{1-6}alkyloxy-C(=O)-C_{1-6}alkyl$; in particular Z is $C_{1-6}alkyloxy-C(=O)-$; $HO-C_{1-4}alkyl$ or $C_{1-6}alkyl-C(=O)-$; more in particular Z is ethoxycarbonyl; methoxycarbonyl; $HO-methyl$; or $methyl-C(=O)-$; and

20 L is $C_{1-6}alkyl$; $C_{1-6}alkyl-O-C_{1-6}alkyl$ or $C_{3-6}cycloalkyl$ wherein said $C_{1-6}alkyl$; $C_{1-6}alkyl-O-C_{1-6}alkyl$ or $C_{3-6}cycloalkyl$ is optionally substituted with one or where possible two or more halo substituents; in particular L is methyl; propyl; isopropyl; methoxymethyl; methoxyethyl; difluoromethyl or trifluoromethyl provided that the compound is other than

- 25
- Ethyl 2-[*N*-(3,5-di-*tert*.butyl-4-hydroxyphenyl)amino]-4-methylthiazole-5-carboxylate
 - [2-(3,5-di-*tert*.butyl-4-hydroxyphenylamino)-4-methylthiazol-5-yl]methanol
 - [2-(2,4,6-trichlorophenylamino)-4-trifluoromethylthiazol-5-yl]methanol
- 30 Methyl 2-[*N*-(4-chlorophenyl)amino]-4-methylthiazole-5-carboxylate.

As well as to the use of a compound of formula (I''') for the manufacture of a medicament for the prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the

35 $\alpha 7$ nicotinic receptor is beneficial, in particular in the treatment of cognitive deficits

seen in diseases such as Alzheimer's diseases and schizophrenia, more in particular in the treatment of MCI, ADHD, anxiety, schizophrenia, mania, manic depression or other neurological or psychiatric disorders in which there is loss of cholinergic function, including loss of cholinergic synapses, including jetlag, nicotine addiction and pain.

Even more in particular for the treatment of diseases in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, including Mild Cognitive Impairment and related syndromes, vascular dementia, post-encephalitic dementia, Attention deficit Hyperactivity, anxiety, schizophrenia, mania, manic depression, jetlag, bipolar mood disorder and schizoaffective disorder.

The invention also relates to use of a compound for the manufacture of a medicament for the prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, wherein the compound is a compound of formula (I) wherein;

Z is hydrogen, halo, C_{1-6} alkyl, Het^1 , $HO-C_{1-6}$ alkyl-, cyano- C_{1-6} alkyl-, amino- $C(=O)-C_{1-6}$ alkyl-, formylamino- C_{1-6} alkyl-, C_{1-6} alkyl- $C(=O)-NH-C_{1-6}$ alkyl-, mono- or di(C_{1-6} alkyl)amino- $C(=O)-C_{1-6}$ alkyl-, phenyl- C_{1-6} alkyl-, or Het^4-C_{1-6} alkyl-;

Q is phenyl, pyridyl, benzofuranyl, 2,3-dihydro-benzofuranyl, pyrazolyl, isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted with up to three substituents each independently selected from halo, cyano, C_{1-6} alkyl, C_{1-6} alkyl-O-, C_{1-6} alkylthio, Ar or polyhalo C_{1-6} alkyl;

L is phenyl, pyridyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl or furanyl wherein each of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo, hydroxy, amino, cyano, C_{1-6} alkyl or C_{1-6} alkyl-O-;

Het^1 represents morpholinyl; pyrazolyl or imidazolyl;

Het^4 represents morpholinyl, pyrazolyl or imidazolyl;

Ar represents phenyl optionally substituted with halo, C_{1-6} alkyl, C_{1-6} alkyl-O- or polyhalo C_{1-6} alkyl.

Additionally the invention provides for a compound of formula (I') wherein;

m is 1, 2 or 3

n is 0, 1, 2 or 3

Z is hydrogen, halo, C_{1-6} alkyl-O- $C(=O)-$, $R^uR^vN-C(=O)-$, $HO-C_{1-6}$ alkyl-, cyano- C_{1-6} alkyl-, $R^xR^yN-C(=O)-C_{1-6}$ alkyl-, Het^4-C_{1-6} alkyl-, C_{1-6} alkyl- $C(=O)-NH-C_{1-6}$ alkyl-, $Het^5-C(=O)-NH-C_{1-6}$ alkyl-;

R¹ each independently represents halo, C₁₋₆alkyl, C₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
in particular R¹ each independently represents fluoro, chloro, methyl, methoxy or
trifluoromethyl;

5 R² each independently represents halo, C₁₋₆alkyl, C₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
in particular R² each independently represents fluoro, chloro, methyl, methoxy or
trifluoromethyl; even more particular R² each independently represents fluoro,
chloro, or methoxy;

Het⁴ represents morpholinyl

10 Het⁵ represents pyridyl or isoxazolyl wherein said isoxazolyl is optionally
substituted with C₁₋₆alkyl; in particular Het⁵ represents pyridyl or isoxazolyl
wherein said isoxazolyl is substituted with C₁₋₆alkyl, in particular methyl

R^u and R^v each independently represents hydrogen or C₁₋₆alkyl

R^x and R^y each independently represent hydrogen, C₁₋₆alkyl or C₁₋₆alkyl-O-
C₁₋₆alkyl.

15

Further the invention provides for a compound of formula (I'') wherein;

m is 1, 2 or 3

n is 0 or 1

20 Z is hydrogen, halo, C₁₋₆alkyl-O-C(=O)-, R^uR^vN-C(=O)-, HO-C₁₋₆alkyl-, cyano-
C₁₋₆alkyl-, R^xR^yN-C(=O)-C₁₋₆alkyl-, Het⁴-C₁₋₆alkyl-, C₁₋₆alkyl-C(=O)-NH-
C₁₋₆alkyl-, Het⁵-C(=O)-NH-C₁₋₆alkyl;

R¹ each independently represents halo, C₁₋₆alkyl, C₁₋₆alkyl-O- or polyhalo
C₁₋₆alkyl; in particular R¹ each independently represents fluoro, chloro, methyl,
methoxy or trifluoromethyl;

25 R² each independently represents halo or C₁₋₆alkyl; in particular R² each
independently represents fluoro, chloro or methyl; even more particular R² each
independently represents chloro, or methyl;

Het⁴ represents morpholinyl

30 Het⁵ represents pyridyl or isoxazolyl wherein said isoxazolyl is optionally
substituted with C₁₋₆alkyl; in particular Het⁵ represents pyridyl or isoxazolyl
wherein said isoxazolyl is substituted with C₁₋₆alkyl, in particular methyl

R^u and R^v each independently represents hydrogen or C₁₋₆alkyl

R^x and R^y each independently represent hydrogen, C₁₋₆alkyl or C₁₋₆alkyl-O-
C₁₋₆alkyl.

35

The invention also relates to a compound of formula (I) wherein Z is bromo,
hydroxymethyl, methyl-C(=O)-NH-methyl-, morpholino-methyl-, cyanomethyl-,
aminocarbonyl-methyl-,

methylaminocarbonyl-methyl-, dimethylaminocarbonyl-methyl-, benzyl, imidazolyl, pyrazolyl or pyrrolidinyl-carbonyl-methyl-.

5 The invention also provides for a compound according to the present invention for use as a medicine.


10 The invention further provides for use of a compound according to the invention for the manufacture of a medicament for the prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial.

15 The invention provides for a pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound according to the invention.

The invention relates to a process of preparing a pharmaceutical composition wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound according to the invention.

20 The invention also relates to a product containing (a) a compound of formula (I), (I'), (I'') or (I'''), and (b) a $\alpha 7$ nicotinic receptor agonist, as a combined preparation for simultaneous, separate or sequential use in preventing or treating diseases in which modulation of the $\alpha 7$ nicotinic receptor is beneficial. Further it relates to a product containing (a) a compound of formula (I), (I'), (I'') or (I'''), and (b) sedatives,
25 hypnotics, anxiolytics, antipsychotics, antianxiety agents, cyclopyrrolones, imidazopyridines, pyrazolopyrimidines, minor tranquilizers, melatonin agonists and antagonists, melatonergic agents, benzodiazepines, barbiturates, 5HT-2 antagonists, and the like, as a combined preparation for simultaneous, separate or sequential use in preventing or treating diseases in which modulation of the $\alpha 7$ nicotinic receptor is
30 beneficial. Additionally a product containing (a) a compound of formula (I), (I'), (I'') or (I'''), and (b) an anti-depressant or anti-anxiety agent, as a combined preparation for simultaneous, separate or sequential use in preventing or treating diseases in which modulation of the $\alpha 7$ nicotinic receptor is beneficial is provided.

35 The invention also relates to a method of prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial by administering to a patient in need thereof a therapeutically effective amount of a compound of formula



a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof,

wherein

- 5 Z is hydrogen, halo; cyano; C₁₋₆alkyl; haloC₁₋₆alkyl; polyhaloC₁₋₆alkyl-;
C₃₋₆cycloalkyl-C(=O)-; C₁₋₆alkyl-C(=O)-; C₁₋₆alkyl-O-C(=O)-; Ar¹; Het¹;
R^uR^vN-C(=O)-; Ar²-C(=O)-NH-; Het²-C(=O)-NH-; C₃₋₆cycloalkyl-C(=O)-NH-;
C₁₋₆alkyl-C(=O)-NH-; HO-C₁₋₆alkyl-; cyano-C₁₋₆alkyl-; amino-C₁₋₆alkyl-;
formylamino-C₁₋₆alkyl-; mono -or di(C₁₋₆alkyl)amino-C₁₋₆alkyl-;
10 C₁₋₆alkyl-S(=O)₂-NH-C₁₋₆alkyl; C₁₋₆alkyl-O-C(=O)-NH-C₁₋₆alkyl;
R^xR^yN-C(=O)-C₁₋₆alkyl-; C₁₋₆alkyl-O-C(=O)-C₁₋₆alkyl-; C₁₋₆alkyl-S(=O)₂-
C₁₋₆alkyl-; Ar³-S(=O)₂-C₁₋₆alkyl-; Het³-S(=O)₂-C₁₋₆alkyl-; Ar⁴-C₁₋₆alkyl-;
Het⁴-C₁₋₆alkyl-; C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl-; Ar⁵-C(=O)-NH-C₁₋₆alkyl-;
Het⁵-C(=O)-NH-C₁₋₆alkyl-; C₃₋₆cycloalkyl-C(=O)-NH-C₁₋₆alkyl-;
15 C₁₋₆alkyl-O-C₁₋₆alkyl-; polyhaloC₁₋₆alkyl-O-C₁₋₆alkyl-; or amino-C₁₋₆alkyl-
substituted with C₁₋₄alkyl substituted piperidinyl;
Q is phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, thienyl, furanyl,
benzthiazolyl, 2,3-dihydro-benzofuranyl, benzofuranyl benzoxazolyl,
benzimidazolyl, indazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl,
20 imidazolyl, oxadiazolyl, pyridazinyl, triazolyl, thiadiazolyl or pyrimidazolyl, each
of said rings optionally being substituted with up to three substituents each
independently selected from halo; hydroxy; cyano; C₁₋₆alkyl; C₁₋₆alkyl-O-;
C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; polyhaloC₁₋₆alkyl; polyhaloC₁₋₆alkyl-O-;
amino, mono -or di(C₁₋₆alkyl)amino, formylamino, C₁₋₆alkyl-C(=O)-NH- or Ar;
25 L is phenyl, piperidinyl, pyrimidinyl, pyrazolyl, triazolyl, pyridyl, pyrimidazolyl,
8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl, benzodioxolyl,
1,4-benzodioxanyl, or furanyl wherein each of said ring systems may optionally
be substituted with one or two or more substituents, each substituent
independently being selected from halo; hydroxy; amino; cyano; mono-or
30 di(C₁₋₆alkyl)amino; C₁₋₆alkyl; HO-C₁₋₆alkyl-; amino-C₁₋₆alkyl-; HO-C(=O)-
C₁₋₆alkyl-; polyhaloC₁₋₆alkyl; polyhaloC₁₋₆alkyl-O-; C₁₋₆alkyl-O-; C₁₋₆alkylthio;
C₁₋₆alkyl-O-C(=O)-; amino-C(=O)-;
phenyl-C₁₋₆alkyl-O-C(=O)-or C₁₋₆alkyl-C(=O)-NH-; or L represents C₁₋₆alkyl,
C₁₋₆alkyl-O-C₁₋₆alkyl or C₃₋₆cycloalkyl wherein said C₁₋₆alkyl, C₃₋₆cycloalkyl or
35 C₁₋₆alkyl-O-C₁₋₆alkyl is optionally substituted with one or where possible two or
more halo substituents;

Ar represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;

5 Ar¹ represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;

10 Ar² represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;

15 Ar³ represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;

20 Ar⁴ represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;

Ar⁵ and Ar⁶ each independently represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;

25 Het¹ represents piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;

30 Het² represents piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;

35 Het³ represents piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with

up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;

Het⁴ represents piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;

Het⁵ and Het⁶ each independently represents piperidinyl, piperazinyl, pyridyl, pyrrolidinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;

R^u and R^v each independently represent hydrogen, C₁₋₆alkyl, Ar⁶, Het⁶, C₃₋₆cycloalkyl, C₁₋₆alkyl-O-C₁₋₆alkyl or R^u and R^v taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, piperidinyl, thiomorpholinyl and morpholinyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;

R^x and R^y each independently represent hydrogen, C₁₋₆alkyl, Ar⁶, Het⁶, C₃₋₆cycloalkyl, C₁₋₆alkyl-O-C₁₋₆alkyl or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, piperidinyl, thiomorpholinyl and morpholinyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl.

Additionally the invention relates to a method of prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial by administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) wherein;

Z is hydrogen, halo, C₁₋₆alkyl, Het¹, HO-C₁₋₆alkyl-, cyano-C₁₋₆alkyl-, amino-C(=O)-C₁₋₆alkyl-, formylamino-C₁₋₆alkyl-, C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl-, mono- or di(C₁₋₆alkyl)amino-C(=O)-C₁₋₆alkyl-, phenyl-C₁₋₆alkyl-, or Het⁴-C₁₋₆alkyl-;

Q is phenyl, pyridyl, benzofuranyl, 2,3-dihydro-benzofuranyl, pyrazolyl, isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted

with up to three substituents each independently selected from halo, cyano,
C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, Ar or polyhaloC₁₋₆alkyl;
L is phenyl, pyridyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl,
imidazothiazolyl or furanyl wherein each of said ring systems may optionally be
5 substituted with one or two or more substituents, each substituent independently
being selected from halo, hydroxy, amino, cyano, C₁₋₆alkyl or C₁₋₆alkyl-O-;
Het¹ represents morpholinyl; pyrazolyl or imidazolyl;
Het⁴ represents morpholinyl, pyrazolyl or imidazolyl;
Ar represents phenyl optionally substituted with halo, C₁₋₆alkyl,
10 C₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl.

The invention further relates to a method of prevention or the treatment or prophylaxis
of psychotic disorders, intellectual impairment disorders or diseases or conditions in
which modulation of the $\alpha 7$ nicotinic receptor is beneficial by administering to a
15 patient in need thereof a therapeutically effective amount of a compound as herein
described.

Unless the context clearly requires otherwise, throughout the description and the
claims, the words "comprise", "comprising", and the like are to be construed in an
20 inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the
sense of "including, but not limited to".

As used hereinabove or hereinafter C₁₋₄alkyl as a group or part of a group defines
straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon
25

atoms such as methyl, ethyl, propyl, 1-methylethyl, butyl; C₁₋₆alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for C₁₋₄alkyl and pentyl, hexyl, 2-methylbutyl and the like; C₃₋₆cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The L or Q radical as described above for the compounds of formula (I) may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate. For example, when Q is pyridyl, it may be 2-pyridyl, 3-pyridyl or 4-pyridyl.

Lines drawn into ring systems indicate that the bond may be attached to any suitable ring atom. When the ring system is a bicyclic ring system, the bond may be attached to any suitable ring atom of either of the two rings.

As used herein before, the term (=O) forms a carbonyl moiety when attached to a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom.

The term halo is generic to fluoro, chloro, bromo and iodo. As used in the foregoing and hereinafter, polyhaloC₁₋₄alkyl or polyhaloC₁₋₆alkyl as a group or part of a group is defined as mono- or polyhalosubstituted C₁₋₄alkyl or C₁₋₆alkyl, for example methyl with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl, 1,1-difluoroethyl and the like. In case more than one halogen atoms are attached to an alkyl group within the definition of polyhaloC₁₋₄alkyl or polyhaloC₁₋₆alkyl, they may be the same or different.

The heterocycles as mentioned in the above definitions and hereinafter, are meant to include all possible isomeric forms thereof, for instance pyrrolyl also includes 2H-pyrrolyl; triazolyl includes 1,2,4-triazolyl and 1,3,4-triazolyl; oxadiazolyl includes 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl and 1,3,4-oxadiazolyl; thiadiazolyl includes 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl and 1,3,4-thiadiazolyl; pyranlyl includes 2H-pyranlyl and 4H-pyranlyl.

Further, the heterocycles as mentioned in the above definitions and hereinafter may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate. Thus, for example, when the heterocycle is imidazolyl, it may be a 1-imidazolyl, 2-imidazolyl, 3-imidazolyl, 4-imidazolyl and 5-imidazolyl;

when it is thiazolyl, it may be 2-thiazolyl, 4-thiazolyl and 5-thiazolyl; when it is triazolyl, it may be 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,3,4-triazol-1-yl and 1,3,4-triazol-2-yl; when it is benzothiazolyl, it may be 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl and 7-benzothiazolyl.

5

When any variable occurs more than one time in any constituent, each definition is independent.

It will be appreciated that some of the compounds of formula (I), (I') (I'') or (I''') and their *N*-oxides, addition salts, quaternary amines and stereochemically isomeric forms may contain one or more centers of chirality and exist as stereochemically isomeric forms.

The term "stereochemically isomeric forms" as used hereinbefore or hereinafter defines all the possible stereoisomeric forms which the compounds of formula (I), (I'), (I'') or (I''') and their *N*-oxides, addition salts, quaternary amines or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I), (I'), (I'') or (I''') and their *N*-oxides, salts, solvates, quaternary amines substantially free, *i.e.* associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. Stereochemically isomeric forms of the compounds of formula (I), (I'), (I'') or (I''') are obviously intended to be embraced within the scope of this invention.

For therapeutic use, salts of the compounds of formula (I), (I'), (I'') or (I''') are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.

The pharmaceutically acceptable acid and base addition salts as mentioned hereinabove or hereinafter are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of formula (I), (I'), (I'') or (I''') are able to form. The pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, *e.g.* hydrochloric or

hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, 5 salicylic, *p*-aminosalicylic, pantoic and the like acids.

Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

The compounds of formula (I), (I'), (I'') or (I''') containing an acidic proton may also 10 be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. 15 primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-*n*-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline; the benzathine, *N*-methyl-*D*-glucamine, hydrabamine salts, and salts with amino acids such as, for 20 example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.

The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I), (I'), (I'') or (I''') as well as the salts thereof, are able to 25 form. Such solvates are for example hydrates, alcoholates and the like.

The term "quaternary amine" as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (I), (I'), (I'') or (I''') are able to form by 30 reaction between a basic nitrogen of a compound of formula (I), (I'), (I'') or (I''') and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyl iodide or benzyl iodide. Other reactants with good leaving groups may also be used, such as alkyl 35 trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl *p*-toluenesulfonates. A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counterions include for example chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be made using ion exchange resin columns.

The *N*-oxide forms of the present compounds are meant to comprise the compounds of formula (I), (I'), (I'') or (I''') wherein one or several tertiary nitrogen atoms are oxidized to the so-called *N*-oxide.

- 5 Some of the compounds of formula (I), (I'), (I'') or (I''') may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

A first group of compounds are those compounds of formula (I) wherein one or more of
10 the following restrictions apply;

- (i) Z is hydrogen, halo; C₁₋₆alkyl; polyhaloC₁₋₆alkyl-; C₃₋₆cycloalkyl-C(=O)-; C₁₋₆alkyl-C(=O)-; amino-C(=O)-; cyano; C₁₋₆alkyl-O-C(=O)-; Ar¹; Het¹; HO-C₁₋₆alkyl-; cyano-C₁₋₆alkyl-; amino-C₁₋₆alkyl-; mono -or
15 di(C₁₋₆alkyl)amino-C₁₋₆alkyl-; R^xR^yN-C(=O)-C₁₋₆alkyl-; formylamino-C₁₋₆alkyl-; C₁₋₆alkyl-O-C(=O)-C₁₋₆alkyl-; C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl-; Ar³-C(=O)-NH-; Het³-C(=O)-NH-; C₃₋₆cycloalkyl-C(=O)-NH-C₁₋₆alkyl-; C₁₋₆alkyl-O-C₁₋₆alkyl-; Ar⁴-C₁₋₆alkyl-; Het⁴-C₁₋₆alkyl-; polyhaloC₁₋₆alkyl-O-C₁₋₆alkyl-; or amino-C₁₋₆alkyl- substituted with C₁₋₄alkyl substituted
20 piperidiny; in particular Z is halo; polyhaloC₁₋₆alkyl-; C₃₋₆cycloalkyl-C(=O)-; C₁₋₆alkyl-C(=O)-; amino-C(=O)-; cyano; C₁₋₆alkyl-O-C(=O)-; Ar¹; Het¹; HO-C₁₋₆alkyl-; cyano-C₁₋₆alkyl-; amino-C₁₋₆alkyl-; mono -or
25 di(C₁₋₆alkyl)amino-C₁₋₆alkyl-; R^xR^yN-C(=O)-C₁₋₆alkyl-; formylamino-C₁₋₆alkyl-; C₁₋₆alkyl-O-C(=O)-C₁₋₆alkyl-; C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl-; Ar³-C(=O)-NH-; Het³-C(=O)-NH-; C₃₋₆cycloalkyl-C(=O)-NH-C₁₋₆alkyl-; C₁₋₆alkyl-O-C₁₋₆alkyl-; Ar⁴-C₁₋₆alkyl-; Het⁴-C₁₋₆alkyl-; polyhaloC₁₋₆alkyl-O-C₁₋₆alkyl-; or amino-C₁₋₆alkyl- substituted with C₁₋₄alkyl substituted
30 piperidiny;
- (ii) Q is phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, thienyl, furanyl, benzthiazolyl, 2,3-dihydro-benzofuranyl, benzofuranyl
35 benzoxazolyl, benzimidazolyl, indazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, pyridazinyl, triazolyl, thiadiazolyl or pyrimidazolyl, each of said rings optionally being substituted with up to three substituents each independently selected from halo; hydroxy; cyano; C₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; polyhaloC₁₋₆alkyl-O-; polyhaloC₁₋₆alkyl or Ar;
- (iii) L is phenyl, pyrimidinyl, pyrazolyl, triazolyl, pyridyl, pyrimidazolyl, piperidinyl, 8-Azaprimidazolyl, pyridazinyl, imidazothiazolyl, benzodioxolyl, 1,4-benzodioxanyl, or furanyl wherein each of said ring

- systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo; hydroxy; amino; cyano; mono- or di(C₁₋₆alkyl)amino; C₁₋₆alkyl; HO-C₁₋₆alkyl-; amino-C₁₋₆alkyl-; HO-C(=O)-C₁₋₆alkyl-; polyhaloC₁₋₆alkyl; polyhaloC₁₋₆alkyl-O-; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; amino-C(=O) or C₁₋₆alkyl-C(=O)-NH-;
- 5
- (iv) Ar represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)-, polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- 10
- (v) Ar¹ represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)- or polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- 15
- (vi) Ar³ represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)- or polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- 20
- (vii) Ar⁴ represents phenyl optionally substituted one or where possible two, three or more substituents each independently selected from halo, hydroxy, cyano, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkylthio, C₁₋₆alkyl-O-C(=O)- or polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- 25
- (viii) Het¹ represents piperidinyl, piperazinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;
- 30
- (ix) Het³ represents piperidinyl, piperazinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;
- 35
- (x) Het⁴ represents piperidinyl, piperazinyl, morpholinyl, imidazolyl, oxazolyl, oxadiazolyl, thiazolyl, isoxazolyl, isothiazolyl, thiomorpholinyl or pyrazolyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C₁₋₆alkyl;

- (xi) R^x and R^y each independently represent hydrogen, C_{1-6} alkyl or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, thiomorpholinyl and morpholinyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo, hydroxy, amino, cyano or C_{1-6} alkyl.

An interesting embodiment of the present invention concerns those compounds of formula (I) wherein one or more of the following restrictions apply :

- (i) Z is hydrogen, halo, C_{1-6} alkyl, C_{1-6} alkyl-C(=O)-, C_{1-6} alkyl-O-C(=O)-, Ar^1 , Het^1 , $R^uR^vN-C(=O)-$, $HO-C_{1-6}$ alkyl-, cyano- C_{1-6} alkyl-, halo- C_{1-6} alkyl-, amino- C_{1-6} alkyl-, $Het^2-C(=O)-NH-$, formylamino- C_{1-6} alkyl-, mono- or di(C_{1-6} alkyl)amino- C_{1-6} alkyl-, $R^xR^yN-C(=O)-C_{1-6}$ alkyl-, C_{1-6} alkyl-O-C(=O)- C_{1-6} alkyl-, Ar^4-C_{1-6} alkyl-, Het^4-C_{1-6} alkyl-, C_{1-6} alkyl-C(=O)-NH- C_{1-6} alkyl-, $Ar^5-C(=O)-NH-C_{1-6}$ alkyl-, $Het^5-C(=O)-NH-C_{1-6}$ alkyl-, C_{1-6} alkyl-S(=O)₂-NH- C_{1-6} alkyl-, C_{1-6} alkyl-O-C(=O)-NH- C_{1-6} alkyl or C_{1-6} alkyl-O- C_{1-6} alkyl-; in particular Z is hydrogen, halo, C_{1-6} alkyl, Het^1 , $HO-C_{1-6}$ alkyl-, cyano- C_{1-6} alkyl-, amino-C(=O)- C_{1-6} alkyl-, formylamino- C_{1-6} alkyl-, C_{1-6} alkyl-C(=O)-NH- C_{1-6} alkyl-, mono- or di(C_{1-6} alkyl)amino-C(=O)- C_{1-6} alkyl-, phenyl- C_{1-6} alkyl-, or Het^4-C_{1-6} alkyl-; more in particular Z is halo, Het^1 , $HO-C_{1-6}$ alkyl-, cyano- C_{1-6} alkyl-, amino-C(=O)- C_{1-6} alkyl-, formylamino- C_{1-6} alkyl-, C_{1-6} alkyl-C(=O)-NH- C_{1-6} alkyl-, mono- or di(C_{1-6} alkyl)amino-C(=O)- C_{1-6} alkyl-, phenyl- C_{1-6} alkyl-, or Het^4-C_{1-6} alkyl-
- (ii) Q is phenyl; pyridyl; benzofuranyl; 2,3-dihydro-benzofuranyl; pyrazolyl; benzimidazolyl; isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted with up to three substituents each independently selected from halo, cyano, C_{1-6} alkyl, C_{1-6} alkyl-O-, C_{1-6} alkylthio, C_{1-6} alkyl-O-C(=O)-, Ar or polyhalo- C_{1-6} alkyl; in particular Q is phenyl; pyridyl; benzofuranyl; 2,3-dihydro-benzofuranyl; pyrazolyl; isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted with up to three substituents each independently selected from halo, cyano, C_{1-6} alkyl, C_{1-6} alkyl-O-, C_{1-6} alkylthio, Ar or polyhalo- C_{1-6} alkyl;
- (iii) L represents C_{1-6} alkyl, C_{1-6} alkyl-O- C_{1-6} alkyl or C_{3-6} cycloalkyl, wherein said C_{1-6} alkyl, C_{1-6} alkyl-O- C_{1-6} alkyl or C_{3-6} cycloalkyl is optionally substituted with one or where possible two or more halo substituents; or L is phenyl, pyridyl, piperidinyl, pyrimidinyl, 1,4-benzodioxanyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl or furanyl wherein each

- of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo, hydroxy, amino, cyano, C₁₋₆alkyl, phenyl-C₁₋₆alkyl-O-C(=O)- or C₁₋₆alkyl-O-; in particular L is phenyl, pyridyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl or furanyl wherein each of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo, hydroxy, amino, cyano, C₁₋₆alkyl or C₁₋₆alkyl-O-;
- (iv) Het¹ represents morpholinyl; pyrazolyl or imidazolyl;
- (v) Het² represents isoxazolyl or pyridyl wherein each of said ring systems may optionally be substituted with up to 3 C₁₋₆alkyl substituents;
- (vi) Het⁴ represents morpholinyl, pyrazolyl or imidazolyl;
- (vii) Het⁵ represents isoxazolyl or pyridyl wherein each of said ring systems may optionally be substituted with up to 3 C₁₋₆alkyl substituents;
- (viii) Ar represents phenyl optionally substituted with halo, C₁₋₆alkyl, C₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- (ix) Ar¹ represents phenyl optionally substituted with one or where possible two, three or more halo substituents;
- (x) Ar⁴ represents phenyl;
- (xi) R^u and R^v each independently represent hydrogen, C₁₋₆alkyl, phenyl or pyridyl wherein said phenyl or pyridyl or optionally substituted with one or where possible two, three or more substituents selected from halo or C₁₋₆alkyloxy-;
- (xii) R^x and R^y each independently represent hydrogen, C₁₋₆alkyl-O-C₁₋₆alkyl, C₁₋₆alkyl, or R^x and R^y taken together with the N atom to which are attached form pyrrolidinyl

An even further interesting embodiment of the present invention concerns those compounds of formula (I) wherein one or more of the following restrictions apply:

- (i) Z is hydrogen, halo, C₁₋₆alkyl-O-C(=O)-, HO-C₁₋₆alkyl-, cyano-C₁₋₆alkyl-, pyridylaminocarbonyl-, aminocarbonyl-C₁₋₆alkyl-, Het⁴-C₁₋₆alkyl-, C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl-; in particular embodiment Z represents hydrogen, CH₃-C(=O)-NH-CH₂-, ethoxycarbonyl, aminocarbonylmethyl-, pyridylaminocarbonyl-, morpholinomethyl-, hydroxymethyl, cyanomethyl, bromo, chloro or fluoro; in a more particular embodiment Z is halo, C₁₋₆alkyl-O-C(=O)-, HO-C₁₋₆alkyl-, cyano-C₁₋₆alkyl-, aminocarbonyl-C₁₋₆alkyl-, Het⁴-C₁₋₆alkyl-, C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl-; in an even more particular embodiment Z represents CH₃-C(=O)-NH-CH₂-, ethoxycarbonyl,

- pyridylaminocarbonyl-, aminocarbonylmethyl-, morpholinomethyl-, hydroxymethyl, cyanomethyl, chloro, bromo or fluoro; in an even further embodiment Z represents hydrogen, halo, C₁₋₆alkyl-O-C(=O)-, HO-C₁₋₆alkyl-, cyano-C₁₋₆alkyl-, pyridylaminocarbonyl- or aminocarbonyl- C₁₋₆alkyl-; also of interest are those compounds of formula (I) wherein Z represents hydrogen, methyl, hydroxymethyl, ethoxycarbonyl, methoxycarbonyl or pyridylaminocarbonyl; more in particular those compounds of formula (I) wherein Z represents hydrogen;
- (ii) Q is phenyl, 2,3-dihydro-benzofuranyl, pyridyl or benzofuranyl each of said rings optionally being substituted with up to three substituents each independently selected from halo; C₁₋₆alkyl-; C₁₋₆alkyl-O- or polyhalo C₁₋₆alkyl; in particular Q represents benzofuranyl, 2,3-dihydro-benzofuranyl or phenyl substituted with one or two substituents selected from halo, C₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl; even more particular Q represents benzofuranyl, 2,3-dihydro-benzofuranyl, pyridyl or phenyl wherein said pyridyl or phenyl are optionally substituted with one or two substituents selected from methyl, trifluoromethyl, fluoro, chloro or methoxy; in an even further embodiment Q represents phenyl or pyridyl wherein said pyridyl or phenyl are optionally substituted with one or two substituents selected from methyl, trifluoromethyl, fluoro, chloro or methoxy; in another particular embodiment Q represents phenyl or pyridyl wherein said phenyl is optionally substituted with one or two substituents selected from methyl, trifluoromethyl, fluoro, chloro or methoxy;
- (iii) L is phenyl, pyridyl, piperidinyl, 8-Azapyrimidazolyl, 1,4-benzodioxanyl or pyrimidazolyl each of said rings optionally being substituted with up to three substituents each independently being selected from halo; hydroxy or C₁₋₆alkyl; in particular L is pyridyl; pyridyl substituted with halo, hydroxy or C₁₋₆alkyl; phenyl; phenyl substituted with halo, hydroxy or C₁₋₆alkyl-O-, in particular chloro, methoxy or hydroxy substituents; piperidinyl substituted with phenylmethoxycarbonyl; 1,4-benzodioxanyl or L is pyrimidazolyl;
- (iv) Het⁴ represents pyrrolidinyl, piperidinyl, thiomorpholinyl or morpholinyl; in particular Het⁴ represents pyrrolidinyl, piperidinyl, thiomorpholinyl or morpholinyl wherein said pyrrolidinyl, piperidinyl, thiomorpholinyl or morpholinyl are attached to the remainder of the molecule via the N-atom.

Another particular embodiment of the present invention concerns those compounds of formula (I') wherein one of the following restrictions apply :

n is 0, 1, 2, 3 or 4; in particular n is 0, 1 or 2;

m is 0, 1, 2, 3 or 4; in particular m is 0, 1, 2, or 3;

- 5 R^1 each independently represents halo; hydroxy; cyano; C_{1-6} alkyl; C_{1-6} alkyl-O-; C_{1-6} alkylthio; C_{1-6} alkyl-O-C(=O)- or polyhalo C_{1-6} alkyl; in particular R^1 represents halo, C_{1-6} alkyl or C_{1-6} alkyl-O-;
- R^2 each independently represents halo; hydroxy; amino; cyano; mono-or di(C_{1-6} alkyl)amino; C_{1-6} alkyl; HO- C_{1-6} alkyl-; amino- C_{1-6} alkyl-;
- 10 HO-C(=O)- C_{1-6} alkyl-; polyhalo C_{1-6} alkyl; C_{1-6} alkyloxy; C_{1-6} alkylthio; C_{1-6} alkyl-O-C(=O)-; aminocarbonyl; or C_{1-6} alkyl-C(=O)-NH-; in particular R^2 represents halo; hydroxy; polyhalo C_{1-6} alkyl or C_{1-6} alkyloxy;
- Z is Het¹; HO- C_{1-4} alkyl-; C_{1-6} alkyl-C(=O)-NH- C_{1-4} alkyl-; cyano- C_{1-4} alkyl-; C_{1-6} alkyl-O-C(=O)-; halo; $R^u R^v N-C(=O)-$; C_{1-6} alkyl-O- C_{1-6} alkyl-; formylamino- C_{1-4} alkyl-;
- 15 Het⁴- C_{1-4} alkyl-; $R^x R^y N-C(=O)-C_{1-4}$ alkyl-; phenyl-; or Z represents C_{1-6} alkyloxy-C(=O)- C_{2-4} alkyl-, provided however that Z is other than ethoxycarbonyl ; in particular Z is Het¹; HO- C_{1-4} alkyl-; C_{1-6} alkyl-C(=O)-NH- C_{1-4} alkyl-; cyano- C_{1-4} alkyl-; formylamino- C_{1-4} alkyl-; Het⁴- C_{1-4} alkyl-; $R^x R^y N-C(=O)-C_{1-4}$ alkyl-; phenyl-; or Z represents C_{1-6} alkyloxy-C(=O)- C_{2-4} alkyl-; in an even further
- 20 embodiment Z represents HO- C_{1-4} alkyl-; halo; pyridylaminocarbonyl; C_{1-6} alkyl-O- C_{1-6} alkyl or Z represents C_{1-6} alkyloxy-C(=O)- C_{2-4} alkyl-;
- Het¹ represents morpholinyl, imidazolyl or pyrazolyl;
- Het⁴ represents morpholinyl, imidazolyl or pyrazolyl; in particular Het⁴ represents morpholinyl;
- 25 Het⁶ represents pyridyl
- R^x and R^y each independently represent hydrogen, C_{1-6} alkyl or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, thiomorpholinyl, piperidinyl or morpholinyl; in particular
- R^x and R^y each independently represent hydrogen, C_{1-6} alkyl or R^x and R^y taken
- 30 together with the N atom to which they are attached form pyrrolidinyl;
- R^u and R^v each independently represent hydrogen, C_{1-6} alkyl, Het⁶ or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, thiomorpholinyl, piperidinyl or morpholinyl.

35

Also an interesting embodiment of the present invention concerns those compounds of formula (I'') wherein one or more of the following restrictions apply;

n is 0, 1, 2, 3 or 4; in particular N is 0 or 1;

- m is 0, 1, 2, 3 or 4; in particular m is 0, 1, 2 or 3;
- R¹ each independently represents halo; hydroxy; C₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)- or polyhaloC₁₋₆alkyl; in particular R¹ represents halo; C₁₋₆alkyl; C₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- 5 R² each independently represents halo; hydroxy; amino; cyano; mono- or di(C₁₋₆alkyl)amino; C₁₋₆alkyl; HO-C₁₋₆alkyl-; amino-C₁₋₆alkyl-; carboxyl-C₁₋₆alkyl-; polyhaloC₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; aminocarbonyl; or C₁₋₆alkyl-C(=O)-NH-; in particular R² represents halo; amino, C₁₋₆alkyl-O- or C₁₋₆alkyl;
- 10 Z is halo; C₁₋₆alkyl; haloC₁₋₆alkyl; C₁₋₆alkyl-O-C₁₋₆alkyl; Het¹; HO-C₁₋₄alkyl-; C₁₋₆alkyl-C(=O)-NH-C₁₋₄alkyl-; cyano-C₁₋₄alkyl-; C₁₋₆alkyloxy-C(=O)-NH-C₁₋₆alkyl; C₁₋₆alkyl-S(=O)₂-NH-C₁₋₆alkyl; formylamino-C₁₋₄alkyl-; mono- or di(C₁₋₆alkyl)amino-C₁₋₆alkyl-; Het⁴-C₁₋₄alkyl-; R^xR^yN-C(=O)-C₁₋₄alkyl-; phenyl-; Het⁵-C(=O)-NH-C₁₋₆alkyl; Ar⁵-C(=O)-NH-C₁₋₆alkyl or C₁₋₆alkyloxy-C(=O)-
- 15 C₂₋₄alkyl-; in particular Z is Het¹; HO-C₁₋₄alkyl-; C₁₋₆alkyl-C(=O)-NH-C₁₋₄alkyl-; cyano-C₁₋₄alkyl-; formylamino-C₁₋₄alkyl-; Het⁴-C₁₋₄alkyl-; R^xR^yN-C(=O)-C₁₋₄alkyl-; phenyl-; or Z represents C₁₋₆alkyloxy-C(=O)-C₂₋₄alkyl-; in a further embodiment Z represents halo, C₁₋₆alkyl; haloC₁₋₆alkyl; C₁₋₆alkyl-O-C₁₋₆alkyl; HO-C₁₋₄alkyl-; C₁₋₆alkyl-C(=O)-NH-C₁₋₄alkyl-; cyano-C₁₋₄alkyl-; C₁₋₆alkyloxy-C(=O)-NH-C₁₋₆alkyl;
- 20 C₁₋₆alkyl-S(=O)₂-NH-C₁₋₆alkyl; mono- or di(C₁₋₆alkyl)amino-C₁₋₆alkyl-; Het⁴-C₁₋₄alkyl-; R^xR^yN-C(=O)-C₁₋₄alkyl-; Het⁵-C(=O)-NH-C₁₋₆alkyl or Ar⁵-C(=O)-NH-C₁₋₆alkyl;
- Het¹ represents morpholinyl, imidazolyl, pyrrolidinyl or pyrazolyl; in particular Het¹ represents morpholinyl, imidazolyl or pyrazolyl;
- 25 Het⁴ represents morpholinyl, imidazolyl, pyrrolidinyl or pyrazolyl; in particular Het⁴ represents morpholinyl, imidazolyl or pyrazolyl; in particular Het⁴ represents morpholinyl or pyrrolidinyl;
- Het⁵ represents isoxazolyl or pyridyl wherein each of said ring systems may optionally be substituted with up to three C₁₋₆alkyl substituents;
- 30 Ar⁵ represents phenyl optionally substituted with hydroxy, halo or polyhaloC₁₋₆alkyl; in particular Ar⁵ represents phenyl;
- R^x and R^y each independently represent hydrogen, C₁₋₆alkyl, C₁₋₆alkyl-O-C₁₋₆alkyl or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, thiomorpholinyl, piperidinyl or morpholinyl; in particular R^x and R^y each independently represent hydrogen,
- 35 C₁₋₆alkyl or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, thiomorpholinyl, piperidinyl or morpholinyl;

provided that Z is other than hydroxyl-C₁₋₂alkyl, halo, methyl, ethoxycarbonyl-, methoxycarbonyl-, dimethylaminomethyl-, dimethylaminoethyl-, ethylaminomethyl- or morpholinyl-C₁₋₂alkyl; when in the compound of formula (I'') the pyridyl ring is attached at positions 3 or 4 to the thiazole ring.

5

Another interesting embodiment of the present invention concerns those compounds of formula (I), (I'), (I'') or (I''') wherein Z is bromo, hydroxymethyl, methyl-C(=O)-NH-methyl-, morpholino-methyl-, cyanomethyl-, aminocarbonyl-methyl-,
 10 methylaminocarbonyl-methyl-, dimethylaminocarbonyl-methyl-, benzyl, imidazolyl, pyrazolyl or pyrrolidinyl-carbonyl-methyl-.

In a further embodiment the present invention provides the compounds of formula (I') wherein one or more of the following restrictions apply;

- 15 (i) m is 1, 2 or 3
- (ii) n is 0, 1, 2 or 3; in particular n is 0 or 2
- (iii) Z is hydrogen, halo, C₁₋₆alkyl-O-C(=O)-, R^uR^vN-C(=O)-, HO-C₁₋₆alkyl-, cyano-C₁₋₆alkyl-, R^xR^yN-C(=O)-C₁₋₆alkyl-, Het⁴-C₁₋₆alkyl-, C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl-, Het⁵-C(=O)-NH-C₁₋₆alkyl; in particular Z is
 20 bromo, fluoro, hydroxymethyl, methyl-C(=O)-NH-methyl, morpholino-methyl-, cyanomethyl-, ethoxycarbonyl-, aminocarbonyl-methyl-, methylaminocarbonyl-methyl-, dimethylaminocarbonyl-methyl-, methylaminocarbonyl-, benzyl, imidazolyl, pyrazolyl or pyrrolidinyl-carbonyl-methyl-; more in particular Z is bromo,
 25 hydroxymethyl, methyl-C(=O)-NH-methyl, morpholino-methyl-, cyanomethyl-, aminocarbonyl-methyl-, methylaminocarbonyl-methyl-, dimethylaminocarbonyl-methyl-, benzyl, imidazolyl, pyrazolyl or pyrrolidinyl-carbonyl-methyl-;
- (iv) R¹ each independently represents halo, C₁₋₆alkyl, C₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl; in particular R¹ each independently represents fluoro, chloro, methyl, methoxy or trifluoromethyl;
- (v) R² each independently represents halo, C₁₋₆alkyl, C₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl; in particular R² each independently represents fluoro, chloro, methyl, methoxy or trifluoromethyl; even more particular R²
 35 each independently represents fluoro, chloro, or methoxy.
- (vi) Het⁴ represents morpholinyl
- (vii) Het⁵ represents pyridyl or isoxazolyl wherein said isoxazolyl is optionally substituted with C₁₋₆alkyl; in particular Het⁵ represents

pyridyl or isoxazolyl wherein said isoxazolyl is substituted with C₁₋₆alkyl, in particular methyl

- (viii) R^u and R^v each independently represents hydrogen or C₁₋₆alkyl
- (ix) R^x and R^y each independently represent hydrogen, C₁₋₆alkyl or C₁₋₆alkyl-O-C₁₋₆alkyl.

5

In a further embodiment the present invention provides the compounds of formula (I') wherein one or more of the following restrictions apply;

- (i) m is 1, 2 or 3
- 10 (ii) n is 0 or 1
- (iii) Z is hydrogen, halo, C₁₋₆alkyl-O-C(=O)-, R^uR^vN-C(=O)-, HO-C₁₋₆alkyl-, cyano-C₁₋₆alkyl-, R^xR^yN-C(=O)-C₁₋₆alkyl-, Het⁴-C₁₋₆alkyl-, C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl-, Het⁵-C(=O)-NH-C₁₋₆alkyl; in particular Z is bromo, fluoro, hydroxymethyl, methyl-C(=O)-NH-methyl-,
15 pyridyl-C(=O)-NH-methyl-, morpholino-methyl-, cyanomethyl-, aminocarbonyl-methyl-, methoxyethyl-aminocarbonyl-methyl-, isopropyl-aminocarbonyl-methyl-, methylaminocarbonyl-methyl-, dimethylaminocarbonyl-methyl-, benzyl, imidazolyl, pyrazolyl or pyrrolidinyl-carbonyl-methyl-; more in particular Z is bromo,
20 hydroxymethyl, methyl-C(=O)-NH-methyl-, morpholino-methyl-, cyanomethyl-, aminocarbonyl-methyl-, pyrrolidinyl-carbonyl-methyl-methylaminocarbonyl-methyl-, dimethylaminocarbonyl-methyl-, benzyl, imidazolyl, pyrazolyl or isoxazolyl-C(=O)-NH-methyl- wherein said isoxazolyl is substituted with methyl;
- 25 (iv) R¹ each independently represents halo, C₁₋₆alkyl, C₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl; in particular R¹ each independently represents fluoro, chloro, methyl, methoxy or trifluoromethyl;
- (v) R² each independently represents halo or C₁₋₆alkyl; in particular R² each independently represents fluoro, chloro or methyl; even more particular
30 R² each independently represents chloro, or methyl;
- (x) Het⁴ represents morpholinyl
- (xi) Het⁵ represents pyridyl or isoxazolyl wherein said isoxazolyl is optionally substituted with C₁₋₆alkyl; in particular Het⁵ represents pyridyl or isoxazolyl wherein said isoxazolyl is substituted with
35 C₁₋₆alkyl, in particular methyl
- (xii) R^u and R^v each independently represents hydrogen or C₁₋₆alkyl
- (xiii) R^x and R^y each independently represent hydrogen, C₁₋₆alkyl or C₁₋₆alkyl-O-C₁₋₆alkyl.

In a further embodiment the present invention provides the compounds of formula (I) wherein one or more of the following restrictions apply;

- (i) Z is hydrogen, halo, C₁₋₆alkyl-O-C(=O)-, R^uR^vN-C(=O)-, HO-C₁₋₆alkyl-, cyano-C₁₋₆alkyl-, R^xR^yN-C(=O)-C₁₋₆alkyl-, Het⁴-C₁₋₆alkyl-, C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl-, Het⁵-C(=O)-NH-C₁₋₆alkyl;
- (ii) Q is phenyl or 2,3-dihydro-benzofuranyl, each of said rings optionally being substituted with up to three substituents selected from halo, C₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- (iii) L is phenyl, pyridyl, pyrimidazolyl or 1,4-benzodioxanyl, each of said rings optionally being substituted with up to three substituents selected from halo, hydroxy or C₁₋₆alkyl;
- (iv) Het⁴ represents morpholinyl
- (v) Het⁵ represents pyridyl or isoxazolyl wherein said isoxazolyl is optionally substituted with C₁₋₆alkyl; in particular Het⁵ represents pyridyl or isoxazolyl wherein said isoxazolyl is substituted with C₁₋₆alkyl, in particular methyl
- (vi) R^u and R^v each independently represents hydrogen or C₁₋₆alkyl
- (vii) R^x and R^y each independently represent hydrogen, C₁₋₆alkyl or C₁₋₆alkyl-O-C₁₋₆alkyl.

In a further interesting embodiment of the present invention the compounds are selected from;

<i>N</i> -[4-Pyridin-3-yl-2-(3-trifluoromethyl-phenylamino)-thiazol-5-ylmethyl]-acetamide
2-(2,4-Dichloro-phenylamino)-4-phenyl-thiazole-5-carboxylic acid ethyl ester
2-[4-Phenyl-2-(3-trifluoromethyl-phenylamino)-thiazol-5-yl]-acetamide
2-[4-(2,4-Dichloro-phenyl)-2-(3-trifluoromethyl-phenylamino)-thiazol-5-yl]-acetamide
(4-Fluoro-3-trifluoromethyl-phenyl)-(5-morpholin-4-ylmethyl-4-pyridin-3-yl-thiazol-2-yl)-amine
[2-(4-Fluoro-3-trifluoromethyl-phenylamino)-4-pyridin-4-yl-thiazol-5-yl]-methanol
[4-(2,4-Dichloro-phenyl)-2-(3-trifluoromethyl-phenylamino)-thiazol-5-yl]-acetonitrile
[4-(2,4-Dichloro-phenyl)-2-(3-trifluoromethyl-phenylamino)-thiazol-5-yl]-methanol
4-[2-(2,5-Dichloro-phenylamino)-thiazol-4-yl]-benzene-1,2-diol
(2,3-Dihydro-benzofuran-5-yl)-(4-imidazo[1,2- <i>a</i>]pyridin-3-yl-thiazol-2-yl)-amine
(2,4-Dimethoxy-phenyl)-(4-imidazo[1,2- <i>a</i>]pyridin-3-yl-thiazol-2-yl)-amine
[2-(4-Fluoro-3-trifluoromethyl-phenylamino)-4-pyridin-3-yl-thiazol-5-yl]-methanol
(4-Imidazo[1,2- <i>a</i>]pyridin-3-yl-thiazol-2-yl)-(4-methoxy-phenyl)-amine
(5-Fluoro-4-pyridin-3-yl-thiazol-2-yl)-(3-trifluoromethyl-phenyl)-amine
[4-Phenyl-2-(3-trifluoromethyl-phenylamino)-thiazol-5-yl]-acetonitrile
[4-(6-Methyl-pyridin-3-yl)-thiazol-2-yl]-(3-trifluoromethyl-phenyl)-amine
<i>N</i> -[[4-(3-pyridinyl)-2-[[3-(trifluoromethyl)phenyl]amino]-5-thiazolyl]methyl]-4-

pyridinecarboxamide
2-[(4-methoxyphenyl)amino]-4-(4-pyridinyl)-5-thiazolemethanol
2-[(2,5-dichlorophenyl)amino]-4-(4-pyridinyl)-5-thiazoleacetamide
5-methyl-N-[[4-(3-pyridinyl)-2-[[3-(trifluoromethyl)phenyl]amino]-5-thiazolyl]methyl]-3-isoxazolecarboxamide
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(2,4-dimethoxyphenyl)amino]-5-thiazolemethanol
2-[(5-chloro-2,4-dimethoxyphenyl)amino]-4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-thiazolemethanol
2-[(5-chloro-2,4-dimethoxyphenyl)amino]-4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-thiazoleacetamide
2-[(5-chloro-2,4-dimethoxyphenyl)amino]-4-(3,4-difluorophenyl)-N-methyl-5-thiazolecarboxamide
2-[(5-chloro-2,4-dimethoxyphenyl)amino]-4-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-methyl-5-thiazoleacetamide
2-[(2,5-dichlorophenyl)amino]-N-(2-methoxyethyl)-4-(4-pyridinyl)-5-thiazoleacetamide
2-[(2,5-dichlorophenyl)amino]-N-(1-methylethyl)-4-(4-pyridinyl)-5-thiazoleacetamide


or a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof.

- The compounds of this invention can be prepared by any of several standard synthetic processes commonly used by those skilled in the art of organic chemistry and described for instance in the following references; "Heterocyclic Compounds" – Vol.24 (part4) p 261-304 Fused pyrimidines, Wiley – Interscience ; Chem. Pharm. Bull., Vol 41(2) 362-368 (1993); J.Chem.Soc., Perkin Trans. 1, 2001, 130-137. In particular the synthesis of compounds of formula (I) wherein Z is halo, substituted C₁₋₆alkyl, C₁₋₆alkyloxycarbonyl or C₁₋₆alkylcarbonyl, or wherein Z is C₁₋₆alkyl or cyano, is described in WO 03/015773.

- Compounds of formula (I) wherein Z is hydrogen and Arⁱ represents an aromatic residue, including an optionally substituted phenyl or an optionally substituted pyridyl, hereinafter referred to as the compounds of formula (I-a), are generally prepared by heating an excess of a compound of formula (II) with a substituted thiourea of formula (III) in a protic solvent such as ethanol or a higher alkanol or a aprotic solvent such as DMF. Excess compound of formula (II) is scavenged by a nucleophile that is immobilized on a solid support such as polystyrene. A suitable nucleophile comprises a reactive amine such as TRIS. Optionally, the acid that is generated during the reaction

can be quenched with an immobilized inorganic base, such as bicarbonate on polystyrene. The quenching step can be carried out in the same solvent as the thiazole ring formation and can be performed at room temperature or at elevated temperature (50°C) for several hours, in particular 15 hours. The purification typically involves removing the polymer supported reagents and products by filtration, washing with a suitable solvent such as DMF or an alcohol and concentrating the filtrates by applying vacuum. In some cases further purification using chromatographic techniques might be appropriate, in particular reversed phase HPLC and further work-up known by people skilled in the art.


10



wherein Q is defined as for the compounds of formula (I) hereinbefore.

In addition to the compounds of formula (I) wherein Z represents substituted C₁₋₆alkyl as described in WO 03/015773, those compounds of formula (I) wherein Z represents C₁₋₆alkyl substituted with hydroxy, cyano or aminocarbonyl, hereinafter referred to as the compounds of formula (I-b₁₋₃), are generally prepared by heating the compounds of formula (I-a) as the free base or a salt such as the hydrochloride or hydrobromide with formaldehyde (IV) in a water miscible organic co-solvent such as THF, in the presence of a base, such as for example triethylamine.


20




The subsequent transformation of the primary alcohol (I-b₁) into the cyanomethyl (I-b₂) consists of a two step reaction with in the first step a conversion of the alcohol into a suitable leaving group, in particular a halide (X in scheme hereinafter) using art known reaction conditions, i.e. using strongly acidic conditions, such as for example 30% HBr in acetic acid or HCl in 1,4-dioxane, followed by the nucleophilic displacement of the halide with an inorganic cyanide, such as for example sodium cyanide, in an aprotic solvent such as DMF. The reaction is most preferably carried out by suspending the cyanide in DMF, to which the halide is added in the solid state.

30


-27-



Hydrolysis of the cyano substituted C_{1-6} alkyl (I-b₂) yields the aminocarbonyl substituted compounds of formula (I-b₃). This reaction is typically performed by reaction in a mixture of $\text{H}_2\text{SO}_4/\text{H}_2\text{O}$. Alternatively this reaction is performed using urea-hydroperoxide in a two solvent system consisting of water and a water miscible organic co-solvent such as acetone in the presence of an inorganic base, such as for example K_2CO_3 .




Alternatively, those compounds of formula (I-b₁) can be prepared by reduction of the appropriate ethylester (V) with a hydride reductant, in particular using lithium borohydride in an aprotic solvent such as THF at an elevated temperature, such as 60°C



Conversion into the cyano-alkyl and reduction into the aminocarbonyl as described for the cyanomethyl hereinbefore, provides those compounds of formula (I) wherein Z represents C_{1-6} alkyl substituted with cyano or aminocarbonyl.


Compounds of formula (I) wherein Z is C_{1-6} alkyl substituted with amino, mono -or di(C_{1-6} alkyl)amino, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, said Z being represented by $\text{Z}_c\text{-C}_{1-6}$ alkyl, and said compounds being represented by formula (I-c), can be prepared by reacting an intermediate of formula (VI) wherein W_3 represents a suitable leaving group, such as for example halo, e.g. chloro, with an intermediate of formula (VII) in the presence of a suitable base, such as for example NaHCO_3 , and a suitable solvent, such as for example acetonitrile.

-28-




Further C₁₋₆alkyl-carbonyl substituted aminoalkyl derivatives are prepared departing from the known cyanide (I-d). Reduction of said cyanide using art known conditions, such as for example using hydrogen in the presence of a suitable catalyst such as Raney nickel in a solvent system like methanol-ammonia and THF, provides the amine of formula (I-c₁).

Acylation of the amine of formula (I-c₁) with an acylating agent, such as for example an acylhalide including acetylchloride, arylcarbonylhalide or heteroarylcarbonylhalide; in the presence of an amine base, such as triethyl amine in a suitable solvent, such as for instance THF, provides the acylamines of formula (I-e)




Sulfonylation of the amine of formula (I-c₁) with an sulfonylating agent, such as for example methanesulfonyl chloride when R represents methyl; in the presence of an amine base, such as triethyl amine in a suitable solvent, such as for instance THF, provides the sulfonamides of formula (I-e₁)




For those compounds of formula (I) wherein Z represents Het³ are generally prepared using art known metal-catalyzed coupling reactions such as Buchwald/Hartwig, Suzuki, and Stille coupling reactions. Briefly, for those compounds of formula (I) wherein the Het³ is linked through a carbon atom with the thiazole ring, hereinafter referred to as the compounds of formula (I-f₁), said compounds can be obtained by reacting a 5-halo aminothiazole of formula (XI), such as for example a 5-bromo aminothiazole, with a metallated heterocycle Het³. M as used herein, can be a boronic acid (M=BOH₂) or the corresponding ester, such as a pinacolo borane. Alternatively, M can be an

organostannane, such as $\text{Sn}(n\text{-Bu})_3$. The reaction is best performed in an aprotic organic solvent such as toluene, 1,4-dioxane, DMF and the like, at an elevated temperature, typically in the range of 80 to 150°C. The reaction is advantageously carried out in the presence of a metal catalyst, such as palladium, and a ligand, such as triphenyl phosphine and also typically requires a base such as potassium phosphate, cesium carbonate and the like, or an amine base, such as triethyl amine.




For those compounds of formula (I) wherein the Het^3 is linked through a nitrogen atom with the thiazole ring, hereinafter referred to as the compounds of formula (I-f₂), said compounds can be obtained by reacting a 5-halo aminothiazole, such as for example a 5-bromo aminothiazole, with an aromatic or saturated Het^3 having a free NH. The reaction can be performed in the presence of a copper catalyst, such as Cu(I) iodide in the presence of a ligand such as ethylene diamine and the like and may require an inorganic base such as cesium carbonate and the like. This transformation typically requires a high-boiling aprotic solvent such as dimethyl acetamide or *N*-methyl pyrrolidinone and the like and can best be performed at elevated temperatures, typically between 80 to 150°C. Alternatively, the copper catalyst can be replaced by a palladium catalyst. In this case the reaction requires a ligand such as BINAP, and a strong inorganic base, such as sodium *tert*-butoxide and the like. A suitable solvent is an aprotic solvent such as toluene, 1,4-dioxane, DMF and the like and the reaction is performed at an elevated temperature in the range of 80 to 150°C.




As already mentioned hereinbefore, the synthesis of the 5-halo aminothiazole (XI) has been described in PCT publication WO 03/015773. Briefly, said compounds can be prepared by reacting a compound of formula (I-a) with an halo-introducing agent of formula (XII) wherein R represents the remainder of the halo-introducing agent, in the presence of a suitable solvent, such as for example *N,N*-dimethylformamide, optionally in the presence of a suitable base, such as for example 2,6-lutidine. Suitable halo-

-30-

introducing agents are for example 1-chloro-pyrrolidinedione, 1-bromo-pyrrolidinedione or Selectfluor® (1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane, bis[tetrafluoroborate(1-)]).




The thioureas of formula (III') as used hereinbefore, and in particular the thioureas wherein Q represents an optionally substituted phenyl group, are generally prepared by reaction in a first step an appropriate aniline derivative of formula (VIII) with benzoyl isothiocyanate in the presence of an amine base, such as for example triethyl amine in a suitable solvent such as THF; followed by a base catalysed hydrolysis with a suitable base, such as for instance sodium hydroxide, in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol at reflux temperature.



wherein R¹ and m are defined as for the compounds of formula (I') hereinbefore.

Synthesis of the arylcarbonyl derivatives of formula (II) is described in WO 03/015773, briefly, an intermediate of formula (IX) is halogenated with a bromine transferring agent under art known conditions, for example with *N,N,N*-trimethylbenzenaminium tribromide in the presence of a suitable solvent, such as for example tetrahydrofuran and an alcohol, e.g. methanol.




For those compounds of formula (I) wherein L represents an amino substituted pyridyl, the intermediates of formula (IX) are prepared departing from the appropriate acetyl-nicotinic acid by a Curtius rearrangement involving the heating of said carboxylic acid


-31-

in an alcohol, e.g. tert-butyl alcohol in the presence of DPPA and an amine base, such as triethyl amine, yielding the Boc-protected amine derivative of formula (X).

Deprotection under acidic conditions, such as heating said intermediate of formula (X) in aqueous hydrochloric acid and a suitable solvent such as ethanol, yields the amino substituted intermediate of formula (IX-a).




For those compounds of formula (I) wherein L represents a fluoro substituted pyridyl, the intermediates of formula (IX) are prepared departing from the appropriate fluoro-nicotinoyl chloride by methylation using a methyl anion equivalent, in particular dimethyl malonate and subsequent decarboxylation. The addition of dimethyl malonate can be performed in the presence of a Lewis acid, such as magnesium chloride and an amine base such as triethyl amine in a suitable solvent, e.g. toluene. The decarboxylation leading to the intermediate of formula (IX-b) can be carried out under aqueous conditions in the presence of a high boiling organic co-solvent, such as DMSO, at an elevated temperature, such as 160°C.



As shown hereinbefore, the 4-substituted 2-amino-thiazoles are generally prepared by heating an excess of an appropriate ketone (II) with a substituted thiourea (III) in a protic solvent such as ethanol or a higher alcohol or a protic solvent such as DMF. The 5-substituents of the thiazoles of the present invention subsequently being introduced. In an alternative method, the 5-substituted 4-aryl substituted 2-amino-thiazoles are obtained through a similar reaction from the alternative ketones of general formula (XIII).

-32-



wherein z represents a cyano, cyano- C_{1-4} alkyl; the different amides as defined for the compounds of formula (I) hereinbefore; C_{1-6} alkyl-O-C(=O)- or C_{1-6} alkyl-S(=O)₂-.


- 5 Those compounds of formula (I-g) wherein z represents represents cyano or cyano- C_{1-4} alkyl can be converted in compounds of formula (I-g) wherein z represents amino- C_{2-5} alkyl by reaction with a suitable reducing agent, such as for example H_2 , in the presence of a suitable catalyst, such as for example Raney Nickel, and as suitable solvent, such as for example tetrahydrofuran, or an alcohol, e.g. EtOH, preferentially in
10 the presence of NH_3 .

Those compounds of formula (I-g) wherein z represents cyano- C_{1-4} alkyl can also be converted in;

- 15 - those compounds of formula (I-g) wherein z represents aminocarbonyl- C_{1-4} alkyl by reaction in a mixture of H_2SO_4/H_2O .
- those compounds of formula (I-g) wherein z represents carboxyl- C_{1-4} alkyl by reaction with a suitable acid, such as concentrated hydrochloric acid, in the presence of a suitable solvent, e.g. water, optionally in the presence of a
20 water miscible co-solvent such as for example 1,4-dioxane, THF or the like.

- In the presence of a suitable reducing agent, such as for example $LiBH_4$ or $LiAlH_4$, and a suitable solvent, such as for example tetrahydrofuran or diethyl ether, those compounds of formula (I-g) wherein z represents C_{1-6} alkyl-O-C(=O)- C_{1-4} alkyl can be
25 converted in those compounds of formula (I-g) wherein z represents HO- C_{2-5} alkyl. The ester function can also be converted in either the free carboxylic acid through hydrolysis of the ester, i.e. at an elevated temperature (40-100°C) under either aqueous acid or saponification reaction conditions, or into an amide under art known conditions, i.e. at room temperature or slightly above (30-60°C) by the use of a coupling agent such
30 as for example O-Benzotriazole- N,N,N',N' -tetramethyl-uronium-hexafluoro-phosphate; N,N' -carbonyldiimidazole; dicyclohexylcarbodiimide; $POCl_3$; $TiCl_4$; sulfuryl chloride fluoride or chlorosulfonyl isocyanate, in a solvent such as dichloromethane, DMF or the like.

Said alternative ketones are the result of a nucleophilic acylation reaction of activated double bonds followed by a subsequent halogenation reaction.



5

The nucleophilic acylation reaction of the α,β -unsaturated compound (XV), also known as the Stetter Reaction, is done under art known conditions, comprising the use of an umpoling reagent such as a cyanide ion or a heterazolium carbene, to change the normal carbonyl charge affinity (Stetter H. and Kuhlmann H. in *Organic Reactions*; Paquette L.A., Ed.; Wiley: New York, 1991; Vol 40, p.407-496).


10

The subsequent halogenation reaction is done using standard conditions including, in the presence of a halogenating agent such as Br_2 , SO_2Cl_2 or another halogenating reagent such as *N*-chlorosuccinimide (NCS).

15

As provided in more detail in the examples hereinafter, this alternative synthesis approach has been useful to;

- directly introduce an ester or amide linked via an alkyl linker at C5 of the aminothiazoles of the present invention. Alternatively, this can be achieved using a keto-ester of general formula (XXIII) below.




20

As already outlined hereinbefore, the ester can be converted in either the free carboxylic acid or into an amide under art known conditions.

- directly introduce a nitrile via an alkyl linker at C5 of the aminothiazoles of the present invention.

25

-34-




As already outlined hereinbefore, this nitrile can be converted into other functional groups, including free carboxylic acids, amines and amides following art-known procedures.

5


For a direct introduction of an ester or amide at C5 of the aminothiazoles of the present invention one would have to depart from a β -keto ester of the general formula (XX). The subsequent halogenation reaction, and thiazole formation is done using the general procedures described hereinbefore.

10



The preparation of the beta keto ester of the formula XX involves a 2 steps process. The carboxylic acid function in XVII is first converted into a suitable leaving group. When said leaving group is alkoxy, said transformation can be achieved by treating XVII with a protic acid, such as HCl, in an alcoholic solvent, such as ethanol and the like at a temperature range of 0°C – 80°C, typically at room temperature. When said leaving group is chloro, said transformation can be achieved by treating XVII with thionyl chloride as a solvent or oxalyl chloride in methylene chloride as the solvent or the like. A catalytic amount of dimethyl formamide accelerates said transformation significantly. A typical temperature range to effect said transformation is between 0°C – 50°C. When said leaving group is imidazole, said transformation can be achieved by treating XVII with carbonyl diimidazole in a polar aprotic solvent like acetonitrile or the like. Said transformation can be effected at a temperature range 0°C – 80°C, typically at room temperature. In a second step the carboxylic acid derivative XVIIa is treated with a malonic acid derivative, such as XVIII, in a polar aprotic solvent, such as


acetonitrile or the like. Said transformation can be effected at a temperature range 0°C – 80°C, typically at room temperature.



5


Alternatively to the above, an alkyl linked ester or amide can be introduced at C5 of the aminothiazoles of the present invention when departing from a keto ester of the general formula (XXIII). The subsequent halogenation reaction, and thiazole formation is done using the general procedures described hereinbefore.

10



A keto ester of the general formula XXIII can be prepared in 3 steps starting from a beta keto ester of the general formula XX. The first step involves treating the keto ester with a halo carboxylic ester derivative XXI in an alcoholic solvent such as ethanol and the like, in the presence of the corresponding alcoholate base, such as NaOEt when the solvent is ethanol. Said transformation can be carried out at a temperature range of 20°C – 100°C, typically at 80°C. In the second step of this process, the di-ester XXII is treated with strong acid, such as concentrated hydrochloric acid at elevated temperature, typically at reflux temperature, resulting in hydrolysis of said diester and in situ decarboxylation. The intermediate mono carboxylic acid can optionally be converted into the corresponding carboxylic ester derivative of the general formula XXIII via an analogous process as described hereinbefore. It should be recognized by somebody skilled in the art, that other carboxylic acid derivatives, such as amides, can be prepared as well in an analogous fashion as described hereinbefore.

-36-



More specific examples for the synthesis of compounds of formula (I) are provided in the examples hereinafter.

5

Where necessary or desired, any one or more of the following further steps in any order may be performed :

- (i) removing any remaining protecting group(s);
- (ii) converting a compound of formula (I) or a protected form thereof into a further
10 compound of formula (I) or a protected form thereof;
- (iii) converting a compound of formula (I) or a protected form thereof into a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof;
- (iv) converting a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of
15 formula (I) or a protected form thereof into a compound of formula (I) or a protected form thereof;
- (v) converting a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof into another *N*-oxide, a pharmaceutically acceptable addition salt a quaternary amine or a solvate of a compound of formula
20 (I) or a protected form thereof;
- (vi) where the compound of formula (I) is obtained as a mixture of (R) and (S) enantiomers resolving the mixture to obtain the desired enantiomer.

Compounds of formula (I), *N*-oxides, addition salts, quaternary amines and
25 stereochemically isomeric forms thereof can be converted into further compounds according to the invention using procedures known in the art.

It will be appreciated by those skilled in the art that in the processes described above the functional groups of intermediate compounds may need to be blocked by protecting
30 groups.

Functional groups, which are desirable to protect, include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl groups (e.g. *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl or trimethylsilyl), benzyl and

tetrahydropyranyl. Suitable protecting groups for amino include *tert*-butoxycarbonyl or benzyloxycarbonyl. Suitable protecting groups for carboxylic acid include C₍₁₋₆₎alkyl or benzyl esters.

- 5 The compounds of formula (I) may be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth
- 10 alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboxyloxy acid or halo substituted benzenecarboxyloxy acid, e.g. 3-chlorobenzenecarboxyloxy acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. *t*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alcohols, e.g.
- 15 ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

- Compounds of formula (I) wherein L is substituted with amino may be converted into a compound of formula (I) wherein L is substituted with C₁₋₆alkylformylamino by
- 20 reaction with a C₁₋₆alkylcarbonyl chloride in a suitable solvent, such as for example pyridine.

- Compounds of formula (I) wherein Q is substituted with cyano may be converted into a compound of formula (I), wherein Q is substituted with carboxyl by reaction with a
- 25 suitable acid, such as concentrated hydrochloric acid, in the presence of a suitable solvent, e.g. water.

- Compounds of formula (I), wherein L is substituted with C₁₋₆alkyl-C(=O)-NH-, may be converted into a compound of formula (I), wherein L is substituted with amino, by
- 30 reaction with a suitable acid, such as for example hydrobromic acid and the like, in the presence of a suitable solvent, such as water.

- Compounds of formula (I) wherein Z is cyano may be converted into a compound of formula (I) wherein Z is aminocarbonyl by reaction in a mixture of H₂SO₄/H₂O.

- 35 Compounds of formula (I) wherein Z is cyano may also be converted into a compound of formula (I) wherein Z is -CH₂-NH₂ by reaction with a suitable reducing agent, such as for example H₂, in the presence of a suitable catalyst, such as for example Raney

Nickel, and a suitable solvent, such as for example tetrahydrofuran, or an alcohol, e.g. CH₃OH, preferentially in the presence of NH₃

5 Compounds of formula (I) wherein Z is C₁₋₆alkyloxycarbonyl may be converted into a compound of formula (I) wherein Z is -CH₂-OH in the presence of a suitable reducing agent, such as for example LiBH₄ or diisobutylaluminiumhydride (DIBAL), and a suitable solvent, such as for example tetrahydrofuran.

10 Compounds of formula (I) wherein Z is C₁₋₆alkylcarbonyl can be converted into a compound of formula (I) wherein Z is C₁₋₅alkyl-CHOH- in the presence of a suitable reducing agent, such as for example NaBH₄ or diisobutylaluminiumhydride (DIBAL), and a suitable solvent, such as for example tetrahydrofuran or diethyl ether.

15 Compounds of formula (I) wherein Z is C₁₋₆alkyl substituted with amino, can be converted into a compound of formula (I) wherein Z is C₁₋₆alkyl substituted with amino which is substituted with piperidinyl or C₁₋₄alkyl substituted piperidinyl, by reaction with piperidine or C₁₋₄alkyl substituted piperidine in the presence of H₂, a suitable catalyst, such as for example palladium on charcoal, a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example an alcohol, e.g. methanol and the like.

20 Compounds of formula (I) wherein Z is C₁₋₆alkyl substituted with amino, can also be converted into a compound of formula (I) wherein Z is C₁₋₆alkyl substituted with dimethylamino, by reaction with paraform in the presence of H₂, a suitable catalyst, such as for example palladium on charcoal, a suitable catalyst poison, such as for
25 example a thiophene solution, and a suitable solvent, such as for example an alcohol, e.g. methanol and the like.

The compounds of the present invention were found to be positive modulators of the $\alpha 7$ nicotinic receptor. The $\alpha 7$ nicotinic receptor ($\alpha 7$ nAChR) belongs to the
30 superfamily of cys-loop, ionotropic ligand-gated ion channels which includes the 5-HT₃, GABA_A and glycine receptor families. It is activated by acetylcholine and its breakdown product choline and a major feature of the $\alpha 7$ nAChR is its rapid desensitisation in the persistent presence of agonist. It is the second most abundant nicotinic receptor subtype in the brain and is an important regulator of release of many
35 neurotransmitters. It has a discrete distribution in several brain structures with relevance to attentional and cognitive processes, such as the hippocampus and pre-frontal cortex and has been implicated in a variety of psychiatric and neurological disorders in humans.

Genetic evidence for its association with schizophrenia is seen in the form of strong linkage between a schizophrenia marker (sensory gating deficit) and the $\alpha 7$ locus on 15q13-14 (Freedman et al. 1997. PNAS 94, 587-592) and polymorphisms in core promoter region of the $\alpha 7$ gene (Leonard et al. 2002).

5

Pathological evidence points to a loss of $\alpha 7$ immunoreactivity and α -Btx-binding in the hippocampus, frontal and cingulate cortex of schizophrenic brains (Freedman et al. 1995; Guan et al. 1999; Marutle et al. 2001), in Parkinson's and Alzheimer's disease (Banerjee et al. 2000; Burghaus et al. 2000) and paraventricular nucleus and nucleus reuniens in autism (Ray et al. 2005).

10

Pharmacological evidence such as the marked smoking habits of schizophrenics compared to normals have been interpreted as an attempt by the patients to self-medicate to make up for a deficit in $\alpha 7$ nicotinic transmission (Dalack et al. 1998).

15

Transient normalization of defects in sensory gating (PPI) in both animal models and man upon nicotine administration (Adler et al. 1982; Bickford and Wear, 1995) and temporary restoration of normal sensory gating in schizophrenics when forebrain cholinergic activity low (e.g. stage 2 sleep) (Griffith et al. 1998) have both been interpreted to be the result of transient activation of the $\alpha 7$ nicotinic receptor followed by desensitisation.

20

Thus there is good reason to suppose that activating the $\alpha 7$ nAChR will have therapeutically beneficial effects for a number of CNS (psychiatric and neurological) disorders.

25

As already mentioned the $\alpha 7$ nAChR rapidly desensitises in the persistent presence of the natural transmitter acetylcholine as well as exogenous ligands such as nicotine. In the desensitised state the receptor remains ligand-bound but functionally inactive. This is not so much a problem for natural transmitters such as acetylcholine and choline since these are substrates for very powerful breakdown (acetylcholinesterase) and clearance (choline transporter) mechanisms. These transmitter breakdown/clearance mechanisms are likely to maintain the balance between activatable and desensitised $\alpha 7$ nAChRs in a physiologically useful range (Dani et al. 2000). However, synthetic agonists, which are not substrates for the natural breakdown and clearance mechanisms are perceived to have a potential liability both for over-stimulation and also to push the $\alpha 7$ nAChR population equilibrium towards a persistently desensitised state, which is undesirable in disorders in which deficiencies in $\alpha 7$ nAChR expression or function play a role. Agonists by their nature must target the ACh binding pocket which is highly

30

35

conserved across the different nicotinic receptor subtypes leading to the potential for adverse reactions by non-specific activation of other nicotinic receptor subtypes. Therefore, to avoid these potential liabilities an alternative therapeutic strategy to $\alpha 7$ agonism is to enhance receptor responsiveness to the natural agonists with a positive allosteric modulator (PAM). A PAM is defined as an agent which binds to a site distinct from the agonist binding site, and therefore is not expected to have agonist or desensitisation properties, but enhances the responsiveness of the $\alpha 7$ nAChR to the natural transmitter. The value of this strategy is that for a given amount of transmitter the magnitude of $\alpha 7$ nAChR response is increased in the presence of the PAM relative to the level of transmission possible in its absence. So for disorders in which there is a deficit in $\alpha 7$ nAChR protein the PAM-induced increase in $\alpha 7$ nicotinic transmission can be beneficial. As a PAM relies on the presence of the natural transmitter the potential for over-stimulation is limited by the breakdown/clearance mechanisms for the natural transmitter.

It is accordingly an object of the present invention to provide methods of treatment that include administering either a positive modulator as the only active substance, thus modulating the activity of endogenous nicotinic receptor agonists such as acetylcholine or choline, or administering a positive modulator together with a nicotinic receptor agonist. In a particular form of this aspect of the invention, the method of treatment comprises treatment with a positive modulator of the $\alpha 7$ nicotinic receptor as described herein and an $\alpha 7$ nicotinic receptor agonist or partial agonist. Examples of suitable compounds with $\alpha 7$ nicotinic receptor agonistic activity include 1,4-Diazabicyclo[3.2.2]nonane-4-carboxylic acid, 4-bromophenyl ester, monohydrochloride (a.k.a SSR180711A); (-)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one; 3-[(2,4-Dimethoxy)Benzylidene]-Anabaseine Dihydrochloride (a.k.a GTS-21); [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide Hydrochloride] a.k.a PNU-282987)

Positive nAChR modulators of the present invention are useful for treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of $\alpha 7$ nicotinic receptor activity is beneficial. A particular aspect of the method of the invention is a method of treatment for learning deficit, cognition deficit, attention deficit or memory loss, modulation of $\alpha 7$ nicotinic receptor activity is expected to be beneficial in a number of diseases including Alzheimer's disease, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, mania, manic depression, Parkinson's disease, Huntington's

disease, Tourette's syndrome, brain trauma or other neurological, degenerative or psychiatric disorders in which there is loss of cholinergic function, including loss of cholinergic synapses, including jetlag, nicotine addiction, pain.

- 5 In view of the above described pharmacological properties, the compounds of formula (I), (I'), (I'') or (I''') or any subgroup thereof, their *N*-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms, may be used as a medicine. In particular, the present compounds can be used for the manufacture of a medicament for treatment or prophylaxis of psychotic disorders,
10 intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial.

- In view of the utility of the compounds of formula (I), (I'), (I'') or (I'''), there is provided a method of treating warm-blooded animals, including humans, suffering
15 from or a method of preventing warm-blooded animals, including humans, to suffer from diseases in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, such as schizophrenia, mania, and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Mild Cognitive Impairment, Attention Deficit Hyperactivity Disorder, Parkinson's disease,
20 Huntington's disease, Tourette's syndrome, brain trauma, jetlag, nicotine addiction and pain. More especially the compounds are suitable for use as a medicine in the treatment or prevention of schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic
25 disorder, psychotic disorder not otherwise specified; psychosis associated with dementia; major depressive disorder, dysthymic disorder, depressive disorder not otherwise specified, Bipolar I disorder, bipolar II disorder, cyclothymic disorder, bipolar disorder not otherwise specified, mood disorder due to a general medical condition, substance-induced mood disorder, mood disorder not otherwise specified;
30 anxiety disorders; mental retardation; pervasive developmental disorders; attention deficit disorders, disruptive behaviour disorders; tic disorders; substance dependence; substance abuse; substance withdrawal. Even more in particular for the treatment of diseases in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, including Mild Cognitive Impairment and related syndromes, vascular dementia, post-encephalitic
35 dementia, Mild Cognitive Impairment, Attention deficit Hyperactivity, anxiety, schizophrenia, mania, manic depression, jetlag, bipolar mood disorder and schizoaffective disorder. In an even further embodiment for the treatment of diseases in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, including Mild

Cognitive Impairment and related syndromes, vascular dementia, post-encephalitic dementia, Attention deficit Hyperactivity, anxiety, schizophrenia, mania, manic depression, jetlag, bipolar mood disorder and schizoaffective disorder.

- 5 Said methods comprise the administration, i.e. the systemic or topical administration, preferably oral administration, of an effective amount of a compound of formula (I), (I'), (I'') or (I'''), a *N*-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine or a possible stereoisomeric form thereof, to warm-blooded animals, including humans.

10

- One skilled in the art will recognize that a therapeutically effective amount of the PAM's of the present invention is the amount sufficient to modulate the activity of the $\alpha 7$ nicotinic receptor and that this amount varies *inter alia*, depending on the type of disease, the concentration of the compound in the therapeutic formulation, and the condition of the patient. Generally, an amount of PAM to be administered as a therapeutic agent for treating diseases in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, such as schizophrenia, mania, and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Mild Cognitive Impairment, Attention Deficit Hyperactivity Disorder, 15 Parkinson's disease, Huntington's disease, Tourette's syndrome, brain trauma, jetlag, nicotine addiction and pain will be determined on a case by case by an attending physician.

20

- Generally, a suitable dose is one that results in a concentration of the PAM at the treatment site in the range of 0.5 nM to 200 μ M, and more usually 5 nM to 20 μ M. To obtain these treatment concentrations, a patient in need of treatment likely will be administered between 0.01 mg/kg to 250 mg/kg body weight, in particular from 0.1 mg/kg to 50 mg/kg body weight. The amount of a compound according to the present invention, also referred to here as the active ingredient, which is required to achieve a therapeutically effect will be, of course vary on case-by-case basis, vary with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated. A method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day. In these methods of treatment the compounds according to the invention are preferably formulated prior to admission. As described herein below, suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.
- 25
- 30
- 35

- The present invention also provides compositions for preventing or treating diseases in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, such as schizophrenia, mania, and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Mild Cognitive
- 5 Impairment, Attention Deficit Hyperactivity Disorder, Parkinson's disease, Huntington's disease, Tourette's syndrome, brain trauma, jetlag, nicotine addiction and pain. Said compositions comprising a therapeutically effective amount of a compound of formula (I), (I'), (I'') or (I''') and a pharmaceutically acceptable carrier or diluent.
- 10 While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition. Accordingly, the present invention further provides a pharmaceutical composition comprising a compound according to the present invention, together with a pharmaceutically acceptable carrier or diluent. The carrier or diluent must be "acceptable" in the sense of being compatible with the other
- 15 ingredients of the composition and not deleterious to the recipients thereof. The pharmaceutical compositions of this invention may be prepared by any methods well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al. Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Company, 1990, see especially Part 8 : Pharmaceutical preparations and their
- 20 Manufacture). A therapeutically effective amount of the particular compound, in base form or addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for systemic
- 25 administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as
- 30 suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will
- 35 usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case

- appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause
5 any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment.
- 10 It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity
15 of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
- 20 The present compounds can be used for systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. The compounds are preferably orally administered. The exact dosage and frequency of
25 administration depends on the particular compound of formula (I), (I'), (I'') or (I''') used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may
30 be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
- The compounds of the present invention may be used in combination with one or more other drugs in the treatment, prevention, control, amelioration, or reduction of risk of
35 diseases or conditions for which compounds of the present invention or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone. Such other drug(s) may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a

- compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of the present invention is preferred. However, the combination therapy may also include therapies in which the compound of the present invention and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of the present invention and the other active ingredients may be used in lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of the present invention. The above combinations include combinations of a compound of the present invention not only with one other active compound, but also with two or more other active compounds. Likewise, compounds of the present invention may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which compounds of the present invention are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention.
- 25 The weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with another agent, the weight ratio of the compound of the present invention to the other agent will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
- 35 In such combinations the compound of the present invention and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).

Accordingly, the subject compounds may be used alone or in combination with other agents which are known to be beneficial in the subject indications or other drugs that affect receptors or enzymes that either increase the efficacy, safety, convenience, or reduce unwanted side effects or toxicity of the compounds of the present invention. The
5 subject compound and the other agent may be coadministered, either in concomitant therapy or in a fixed combination.

In one embodiment, the compounds of formula (I), (I'), (I'') or (I''') may also be used in combination with other conventional $\alpha 7$ nicotinic receptor agonists, such as for
10 example 1,4-Diazabicyclo[3.2.2]nonane-4-carboxylic acid, 4-bromophenyl ester, monohydrochloride (a.k.a SSR180711A); (-)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidine]-2'-one; 3-[(2,4-Dimethoxy)Benzylidene]-Anabaseine Dihydrochloride (a.k.a GTS-21); or [*N*-[(3*R*)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide Hydrochloride] a.k.a PNU-282987). Thus, the present invention also relates to the
15 combination of a compound of formula (I), (I'), (I'') or (I''') and a $\alpha 7$ nicotinic receptor agonist. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I), (I'), (I'') or (I'''), and (b) a $\alpha 7$ nicotinic receptor agonist, as a combined preparation for simultaneous, separate or sequential use in the treatment of diseases wherein modulation of the $\alpha 7$
20 nicotinic receptor is beneficial, in particular in for the treatment of a range of disorders involving reduced cholinergic function such as learning deficit, cognition deficit, attention deficit or memory loss. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.

25 In a second embodiment, the compounds of formula (I), (I'), (I'') or (I''') may also be used in combination with sedatives, hypnotics, anxiolytics, antipsychotics, antianxiety agents, cyclopyrrolones, imidazopyridines, pyrazolopyrimidines, minor tranquilizers, melatonin agonists and antagonists, melatonergic agents, benzodiazepines, barbiturates, 5HT-2 antagonists, and the like, such as: adinazolam, allobarbitol, alonimid,
30 alprazolam, amisulpride, amitriptyline, amobarbital, amoxapine, aripiprazole, bentazepam, benzocetamine, brotizolam, bupropion, busprione, butabarbital, butalbital, capuride, carbocloral, chloral betaine, chloral hydrate, clomipramine, clonazepam, cloperidone, clorazepate, chlordiazepoxide, clorethate, chlorpromazine, clozapine, cyprazepam, desipramine, dexclamol, diazepam, dichloralphenazone, divalproex,
35 diphenhydramine, doxepin, estazolam, ethchlorvynol, etomidate, fenobam, flunitrazepam, flupentixol, fluphenazine, flurazepam, fluvoxamine, fluoxetine, fosazepam, glutethimide, halazepam, haloperidol, hydroxyzine, imipramine, lithium, lorazepam, lormetazepam, maprotiline, mecloqualone, melatonin, mephobarbital,

meprobamate, methaqualone, midaflur, midazolam, nefazodone, nisobamate, nitrazepam, nortriptyline, olanzapine, oxazepam, paraldehyde, paroxetine, pentobarbital, perlapine, perphenazine, phenelzine, phenobarbital, prazepam, promethazine, propofol, protriptyline, quazepam, quetiapine, reclazepam, risperidone, roletamide, secobarbital, sertraline, suproclonidine, temazepam, thioridazine, thiothixene, trazodone, triazolam, trepipam, triclofos, trifluoperazine, trimetozine, trimipramine, uldazepam, venlafaxine, zaleplon, ziprasidone, zolazepam, Zolpidem, and salts thereof, and combinations thereof, and the like, or the subject compound may be administered in conjunction with the use of physical methods such as with light therapy or electrical stimulation.

In a third embodiment, the compounds of formula (I), (I'), (I'') or (I''') may also be used in combination with anti-depressant or anti-anxiety agent, including norepinephrine reuptake inhibitors (including tertiary amine tricyclics and secondary amine tricyclics), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists, [alpha]-adrenoreceptor antagonists, neurokinin-1 receptor antagonists, atypical anti-depressants, benzodiazepines, 5-HT_{1A} agonists or antagonists, especially 5-HT_{1A} partial agonists, and corticotropin releasing factor (CRF) antagonists. Specific agents include: amitriptyline, clomipramine, doxepin, imipramine and trimipramine; amoxapine, desipramine, maprotiline, nortriptyline and protriptyline; fluoxetine, fluvoxamine, paroxetine and sertraline; isocarboxazid, phenelzine, tranylcypromine and selegiline; moclobemide; venlafaxine; duloxetine; agomelatine; bupropion, lithium, nefazodone, trazodone and viloxazine; alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam and prazepam; buspirone, flesinoxan, gepirone and ipsapirone, and pharmaceutically acceptable salts thereof.

References

- Adler et al. 1982. Biol Psych 44, 98-106
Banerjee et al. 2000, Neurobiol of Disease, 10, 666-672
Bickford and Wear, 1995. Brain Res 705, 235-240
Burghaus et al. 2000, Mol Brain Res, 76, 385-388
Dalack et al. 1998. Am J Psych 11, 1490-1501
Dani et al. 2002, Eur. J Pharmacology, 393 31-38
Freedman et al. 1995, Biol Psychiatry, 38, 22-33
Freedman et al. 1997, PNAS, 94, 587-592
Hamill et al. 1981, Pflugers Archs 391, 85-100

- Guan et al. 1999, Neuroreport, 10, 1779-1782
Griffith et al. 1998, Biol Psych 44, 98-106
Leonard et al. 2002, Arch Gen Psychiatry, 59, 1085-1095
Marutle et al. 2001, J Chemical Neuroanatomy, 22, 115-126
5 Ray et al. 2005, Neurobiol of Disease, 19, 366-377
Ridley et al. 2001, Br J Pharmacol, 133, 1286-1295
Virginio et al. 2002, Eur J Pharmacol 445, 153-161


Experimental part

- 10 Hereinafter, the term 'MP' stands for melting point, the term 'c.p.' stands for chemically pure, the term 'p.a.' stands for pro analyse, 'q.s.' means sufficient quantity, 'THF' means tetrahydrofuran, 'CH₂Cl₂' means dichloromethane, 'MgSO₄' means magnesium sulphate, 'Et₃N' means triethylamine, 'EtOAc' means ethyl acetate, 'DMF' means *N,N*-dimethylformamide, 'DIPE' means diisopropyl ether, 'CH₃CN' means
15 acetonitrile, 'DMSO' means dimethylsulfoxide, 'LiBH₄' means lithium tetrahydroborate, 'DPPA' means phosphorazidic acid diphenyl ester, 'EtOH' means ethanol, 'NaHCO₃' means carbonic acid monosodium salt, 'Na₂SO₄' means sulfuric acid disodium salt, 'NaCl' means sodium chloride, 'HOAc' means acetic acid, 'Et₂O' means diethyl ether, 'K₂CO₃' means potassium carbonate, 'HBTU' means 1-
20 [bis(dimethylamino)methylene]-1H-Benzotriazoliumhexafluorophosphate(1-)-3-oxide, 'NaCN' means sodium cyanide, 'HCl' means hydrochloric acid. 'MeOH' means methanol.

A. Preparation of the intermediates


25 Example A1

a) Preparation of intermediate 1




- A mixture of 2-bromo-1-phenylethanone (0.0402 mol) and [3-(trifluoromethyl)phenyl]-thiourea (0.0402 mol) in EtOH (q.s.) was stirred 4 hours at 70°C. The solvent was evaporated. The residue was triturated under EtOH, filtered off, treated with diluted ammonium hydroxide, then extracted twice with CH₂Cl₂. The
30 separated organic layer was dried (MgSO₄), filtered and the solvent evaporated, yielding 6.75 g (52%) of intermediate 1.

b) Preparation of intermediate 2



A mixture of intermediate 1 (0.0062 mol), a 40% aqueous formaldehyde solution (20 ml) and Et₃N (5 ml) in THF (20 ml) was reacted for 30 minutes at 140°C in a microwave oven, then cooled. Diluted ammonia was added and extracted with EtOAc (2 x) and dried. The residue was triturated from a small amount of CH₂Cl₂, filtered off and dried, yielding 1.36 g of intermediate 2 (analytically pure material).


c) Preparation of intermediate 3



Intermediate 2 (0.00143 mol) was stirred in a 30% HBr/HOAc solution (20 ml) for 25 minutes. Toluene (\pm 100 ml) was added to the reaction mixture and the solvent was evaporated. Toluene (100 ml) was added and azeotroped on the rotary evaporator. A solution of NaCN (0.00285 mol) in DMF (15 ml; previously stirred for 10 minutes) was added to the residue and rinsed with DMF (5 ml). The reaction mixture was stirred for 10 minutes at room temperature. The reaction was quenched by addition of a saturated aqueous Na₂CO₃ solution (\pm 75 ml). This mixture was extracted with Et₂O/DIPE, then DIPE. The combined organic layers were washed with water, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by flash column chromatography over a Biotage 25 cartridge (eluent: 20%, 30% EtOAc/hexane). The pure product fractions were collected and the solvent was evaporated. The residue (amber oil) crystallised upon standing. The solid was stirred in cyclohexane, filtered off and dried, yielding 0.128 g of intermediate 3 (MP: 121-122°C).


Example A2

a) Preparation of intermediate 4



A solution of benzoyl isothiocyanate (0.068 mol) in THF (50ml) was added dropwise to a solution of 4-fluoro-3-methylbenzenamine (0.068 mol) in THF (150ml). The reaction mixture was stirred overnight at room temperature. The solvent was evaporated. The residue was suspended in DIPE, filtered off, washed and dried (vacuum) yielding intermediate 4.


b) Preparation of intermediate 5



A mixture of intermediate 4 (0.055 mol) and a 1M NaOH solution (0.06 mol) in EtOH (500ml) was stirred and refluxed for 1 hour. The reaction mixture was cooled and the solvent was evaporated. The residue was suspended in H₂O, filtered off, washed and dried (vacuum), yielding 9.8g (97%) of intermediate 5.

5 Example A3


a) Preparation of intermediate 6



N,N,N-trimethylbenzenaminium tribromide (0.01 mol) was added to a solution of β -oxo-benzenepropanoic acid ethyl ester (0.01 mol) in THF (50 ml), then the mixture was stirred for 4 hours at room temperature, filtered and the filtrate was evaporated. The obtained residue was dissolved in EtOH (50 ml) and (2,4-dichlorophenyl)-thiourea (0.01 mol) was added. The reaction mixture was warmed and then was stirred and refluxed overnight. The solvent was evaporated and the residue was purified by column chromatography (eluent: CH₂Cl₂). The purest product fractions were collected and the solvent was evaporated. The residue was crystallised from DIPE, then the resulting precipitate was filtered off and dried, yielding 0.050 g (1%) of intermediate 6 (MP: 150°C).

Example A4


a) Preparation of intermediate 7



A mixture of α -bromo- β -oxo-3-pyridinepropanenitrile (0.0045 mol) and [3-(trifluoromethyl)phenyl]-thiourea (0.0045 mol) in EtOH (40ml) was stirred and refluxed for 4 hours; then stirred overnight. The solvent was evaporated. The residue was dissolved in 2-propanone. The solvent was evaporated. The residue was taken up in CH₂Cl₂ and alkalized with a concentrated ammonium hydroxide solution. The separated organic layer was dried, filtered and the solvent was evaporated. This fraction (0.8g) was dissolved in 2-propanol and acidified with HCl/2-propanol. The precipitate was filtered off and dried. This fraction (0.2g, 11%) was crystallised from 2-

propanol/EtOH. The precipitate was filtered off and dried, yielding 0.15g of intermediate 7 as a hydrochloride salt (.HCl).


b) Preparation of intermediate 8



A mixture of intermediate 7 (0.0137 mol), NH₃/MeOH (7N) (100 ml) and THF (p.a.) (50 ml) was hydrogenated at 14°C with Raney Nickel (1 g) as a catalyst. After uptake of H₂ (2 equiv.), the catalyst was filtered off and the filtrate was evaporated. The residue was stirred in CH₃CN (25 ml), filtered off, washed with CH₃CN and with DIPE, then dried at 50°C (vac.), yielding 1.86 g (38.7 %) of intermediate 8.


Example A5

a) Preparation of intermediate 9



Et₃N (0.22 mol) and dimethyl malonate (14 g) were added to a slurry of magnesium chloride (0.06 mol) in toluene (90 ml) (exothermic). The reaction mixture was stirred at room temperature for 2 hours. Then, a solution of 5-fluoro-3-pyridinecarbonyl chloride (0.09 mol) in a small amount of toluene was added within 30 minutes. The reaction mixture was stirred at room temperature overnight. The solution was acidified with 1N HCl and this mixture was extracted with DIPE. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was taken up into DMSO/H₂O 200/10 and this mixture was stirred at 160°C for 2 hours. The reaction mixture was cooled, stirred overnight at room temperature, then diluted with water. This mixture was extracted with EtOAc. The separated organic layer was dried (MgSO₄), filtered and the solvent evaporated. The residue was taken up into DIPE and then acidified with HBr/ HOAc. A small amount of 2-propanone was added. The solvent was evaporated. The residue was suspended in CH₃CN. A solid was formed, then filtered off (direct decomposition into oil), and the filtrate was evaporated, yielding intermediate 9 as a hydrobromide salt (.HBr).

b) Preparation of intermediate 10




Intermediate 9 (0.016 mol) was dissolved in a 48% HBr solution (40 ml), giving Solution (I). Bromine (0.016 mol) was dissolved in a small amount of a 48% HBr solution, giving solution (II). Solution (II) was added dropwise to solution (I) at room


temperature. The reaction mixture was stirred for 2 hours at 70°C, then stirred at room temperature overnight. The solvent was evaporated, yielding intermediate 10 as a hydrobromide salt (.HBr).

Example A6

a) Preparation of intermediates 11 and 12



intermediate 11




intermediate 12

- 5 A mixture of 2-bromo-1-(3-fluorophenyl)ethanone (0.004 mol) and [3-(trifluoromethyl)phenyl]-thiourea (0.004 mol) in EtOH (40ml) was stirred and refluxed for 16 hours. The solvent was evaporated and the mixture was dissolved in CH₂Cl₂ and an aqueous Na₂CO₃-solution. The aqueous layer was extracted with CH₂Cl₂. The combined separated organic layers were dried (MgSO₄) and the solvent was
- 10 evaporated. The residue was purified by column chromatography on a biotage system (eluent : CH₂Cl₂/hexane 30/70). The product fractions were collected and the solvent was evaporated. The obtained intermediate 11 was dissolved in CH₃CN and a mixture of 2-propanol/HCl was added until pH1. This mixture was stirred for 20 minutes and then filtered, washed with DIPE and dried (60°C, 72 hours, vacuum), yielding 0.57g
- 15 (38%; white powder) of intermediate 12 as a hydrochloride salt (.HCl).


Example A7

a) Preparation of intermediate 13




- A mixture of 5-acetyl-3-pyridinecarboxylic acid (0.02 mol) in 2-butyl-2-propanol (100ml) was stirred and heated to 60°C. Et₃N (0.06 mol) was added dropwise and the reaction mixture was further heated until 90°C. Then DPPA (0.02 mol) was slowly
- 20 added dropwise at 90°C. The reaction mixture was stirred at 90°C overnight. The reaction mixture was then cooled and the solvent was evaporated. The residue was taken up in H₂O and extracted with CH₂Cl₂. The separated organic layer was dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/MeOH 98/2). The product fractions were collected
- 25 and the solvent was evaporated, yielding 1.8g of intermediate 13.

b) Preparation of intermediate 14



To a mixture of intermediate 13 (0.006 mol) in EtOH (40ml), a 36% HCl solution (c.p.) (1.6ml) was added dropwise. The reaction mixture was stirred and refluxed for 4 hours and then stirred at room temperature overnight. The mixture was diluted with H₂O and made alkaline with Na₂CO₃. The aqueous layer was extracted with CH₂Cl₂ and the separated organic layer was dried (MgSO₄), filtered and the solvent was evaporated. The residue was taken up in 2-propanone/HBr and HOAc. The formed solid was filtered off, washed and dried (vacuum), yielding 0.35g of intermediate 14.


c) Preparation of intermediate 15



A mixture of intermediate 14 (0.0016 mol) in a 48% HBr solution (20ml) was stirred and heated to 60°C. Then a solution of bromine (0.0016 mol) in a little bit of a 48% HBr solution was added dropwise. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated, yielding intermediate 15 as a hydrobromide salt (.2HBr).

Example A8


a) Preparation of intermediate 16



A mixture of (4-methoxyphenyl)-thiourea (0.0615 mol) and 2-bromo-1-phenylethanone (0.0615 mol) in EtOH (615 ml) was stirred and refluxed for one hour. The resulting precipitate was filtered off and dried, yielding 15.3 g (68%) of intermediate 16 as a hydrobromide salt (.HBr).

Example A9

a) Preparation of intermediate 17




2-Bromo-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-ethanone (0.0169 mol) and (2,4-dimethoxyphenyl)-thiourea (0.0169 mol) were dissolved in EtOH (80 ml). The

-54-

resultant reaction solution was stirred and refluxed for 4 hours, then cooled to room temperature. The resulting precipitate was filtered off, washed with EtOH (40 ml) and with EtOAc (80 ml), then stirred in a saturated aqueous NaHCO₃ solution (100 ml) for 30 minutes. The mixture was filtered. The filter residue was washed with water (100 ml), with EtOAc (40 ml), then dried, yielding 3.25 g (51%) of intermediate 17.


Example A10

a) Preparation of intermediate 18



2-Bromo-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-ethanone (0.0337 mol) and (5-chloro-2,4-dimethoxyphenyl)-thiourea (0.0337 mol) were dissolved in EtOH (160 ml). The resultant reaction solution was stirred and refluxed for 4 hours, then cooled to room temperature. The resulting precipitate was filtered off, washed with EtOH (100 ml) and with EtOAc (200 ml), then stirred in a saturated aqueous NaHCO₃ solution (200 ml) for 30 minutes. The mixture was filtered. The filter residue was washed with water (200 ml), with EtOAc (100 ml), then dried, yielding 13.0 g (96%) of intermediate 18.


b) Preparation of intermediate 19



Intermediate 18 (0.00124 mol), Et₃N (1.2 ml), formaldehyde (6 ml, 40%) and THF (6 ml) were transferred into a microwave tube. The reaction mixture was heated for 3 minutes at 120 °C in a microwave oven. The reaction was quenched by adding aqueous ammonia. The layers were separated. The aqueous phase was extracted with EtOAc. The organic layer was separated, washed with brine, dried (Na₂SO₄), filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography over silica gel. The product fractions were collected and the solvent was evaporated, yielding 4 g (75%) of intermediate 19.

-55-


c) Preparation of intermediate 20



Intermediate 19 (0.001 mol) was co-evaporated with dry THF (10 ml) in vacuo. The residue was dissolved in dry CH₂Cl₂ (10 ml). The mixture was cooled on a dry-ice/2-propanone bath. Trimethylsilanecarbonitrile (0.012 mol) was added. BF₃Et₂O (0.0032 mol) was added dropwise over 15 minutes. The reaction mixture was stirred for 30 minutes on the dry ice/2-propanone bath, then warmed to room temperature and stirred for another 2 hours at room temperature. A saturated aqueous NaHCO₃ solution (20 ml) was added. CH₂Cl₂ (30 ml) was added and shaken. The organic layer was separated, washed with a saturated aqueous NaCl solution (20 ml), dried (anh. Na₂SO₄), filtered and the solvent was evaporated in vacuo. The residue was purified by column chromatography over silica gel (eluent: dilution system of CH₂Cl₂). The product fractions were collected and the solvent was evaporated, yielding 0.09 g (20%) of intermediate 20.

Example A11


a) Preparation of intermediate 21



Intermediate 20 (0.0014 mol) was dissolved in a mixture of HOAc (30 ml), H₂O (15 ml) and concentrated HCl (15 ml). The resultant reaction mixture was stirred and refluxed for 1 hour. The solvent was evaporated in vacuo, yielding intermediate 21 (used in next reaction step, without further purification).

Example A12


a) Preparation of intermediate 22



A mixture of (2,5-dichlorophenyl)-thiourea and 2-bromo-1-phenylethanone (0.023 mol) in EtOH was stirred and refluxed for 2 hours. The reaction mixture was allowed to cool, then the precipitate was filtered off and dried, yielding 6.43 g (87 %, MP:

5 221.4°C to 225.3°C) of intermediate 22 as a hydrobromide salt (.HBr).


b) Preparation of intermediate 23



A mixture of intermediate 22 (0.0156 mol) in a 40% aqueous formaldehyde solution (20 ml), Et₃N (5 ml) and THF (20 ml) was heated in a microwave to 100 °C and stirred for 1 hour. Then the solvent was evaporated. The residue was taken up with H₂O and extracted with CH₂Cl₂. The separated organic layer was dried, filtered and the solvent
10 was evaporated. The residue was purified over silica gel by glass filter (eluent: CH₂Cl₂/MeOH 99/1, 98/2, 96/4 and 94/6). The product fractions were collected and the solvent was evaporated. The residue was taken up in EtOH. The precipitate was filtered off and dried, yielding 1.79 g (33%; MP: from 172.8 °C to 175.0 °C) of intermediate 23.

15 Example A13


a) Preparation of intermediate 24



A mixture of 2-bromo-1-(4-pyridinyl)-ethanone, hydrobromide (0.02 mol) and (5-chloro-2,4-dimethoxyphenyl)-thiourea (0.02 mol) in EtOH (200 ml) was stirred and refluxed for 4 hours, then cooled to room temperature. The resulting precipitate was filtered off, washed with EtOH and dried, yielding 6.0 g (60%) of intermediate 24 as a
20 hydrobromide salt (.HBr).

-57-


b) Preparation of intermediate 25



A mixture of intermediate 24 (0.00098 mol), Et₃N (1.2 ml), formaldehyde (6 ml) and THF (6 ml) was introduced into a 40-ml microwave-tube. The reaction mixture was heated for 30 minutes at 130 °C in a microwave oven. The reaction mixtures were combined, then quenched by adding aqueous ammonia (20 ml), then stirred. The layers
5 were separated. The aqueous phase was extracted with EtOAc (2 x 20 ml). The organic layers were combined, washed with brine (2 x 10 ml), dried (MgSO₄), filtered and the solvent was evaporated in vacuo. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/MeOH 30/1). The product fractions were collected and the solvent was evaporated, yielding 2.45 g (65%) of intermediate 25.

10 Example A14


a) Preparation of intermediate 26



Intermediate 25 (0.00053 mol) was suspended in 4N HCl/dioxane (20 ml). The suspension was stirred overnight. The solvent was evaporated in vacuo, yielding intermediate 26.

Example A15


a) Preparation of intermediate 27



15 A mixture of β-oxo-4-pyridinepropanoic acid, ethyl ester (0.006 mol) and methanamine (q.s.) was stirred and refluxed (100 °C) for 30 minutes in a microwave oven. This mixture was cooled, then extracted with CH₂Cl₂. The organic layer was separated, dried (Na₂SO₄), filtered and the solvent was evaporated in vacuo, yielding (crude, used in next reaction step, without further purification) intermediate 27.


Example A16

a) Preparation of intermediate 28




- 4-Pyridinecarboxaldehyde (0.44 mol) in DMF (150 ml) was added drop wise in 5 minutes to a mixture of NaCN (0.106 mol) in DMF (200 ml). The reaction mixture was stirred for 5 minutes. Then 1,1-dimethylethyl ester 2-propenoic acid (0.423 mol) in DMF (350 ml) was added drop wise in 10 minutes. The reaction mixture was refluxed for 4 hours. Then H₂O was added. The mixture was extracted with Et₂O. The separated organic layer was washed with saturated NaHCO₃ aqueous solution. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/MeOH 99/1, 98.5/1.5 and 98/2). The product fractions were collected and the solvent was evaporated, yielding 69 g (70%) of intermediate 28.

b) Preparation of intermediate 29




A mixture of intermediate 28 (0.0213 mol) and bromine (4 eq) in EtOH (100 ml) was stirred for 2 hours at room temperature and for 5 hours at reflux. The solvent was evaporated, yielding 5 g (75%) of intermediate 29.

c) Preparation of intermediate 30



- A mixture of intermediate 29 (0.003 mol) and (2,5-dichlorophenyl)-thiourea (0.003 mol) in EtOH (100 ml) was stirred at reflux for 2 hours. The precipitate (4.75 g) was filtered off and dried. The mother liquor was left to stand and resulted in new product crystallization. This precipitate was filtered off and dried, yielding 2.22 g (80%; MP: 156.8 °C - 163.5 °C) of intermediate 30.


d) Preparation of intermediate 31



A mixture of intermediate 30 (0.0025 mol) in HCl/Dioxane (25 ml) and H₂O (25 ml) was stirred overnight at 50 °C. The solvent was evaporated. The residue was dried, yielding 1 g (100%) of intermediate 31 as a hydrochloride salt (.HCl).

Example A17


a) Preparation of intermediate 32



- 5 Sulfuryl chloride (0.0007 mol) was added to 3,4-difluoro-β-oxo-benzenepropanoic acid, ethyl ester (0.00066 mol) in CH₂Cl₂ (5 ml). The mixture was stirred for 2 hours at room temperature. The solvent was evaporated in vacuo. (5-Chloro-2,4-dimethoxyphenyl)-thiourea (0.0006 mol) was added to the residue, followed by addition of EtOH (5 ml). The resultant reaction mixture was stirred and refluxed for 2
- 10 hours, then cooled to room temperature. The resulting precipitate was filtered off, washed with EtOH, and dried, yielding 0.200 g of intermediate 32.

Example A18


a) Preparation of intermediate 33



- 2-Chloro-4-pyridinecarboxylic acid (0.0635 mol) was dissolved in THF (25 ml) and CH₃CN (25 ml). 1,1'-Carbonylbis-1H-Imidazole (0.0698 mol) was added to the
- 15 solution and stirred for 2.5 hours at room temperature to result in reaction mixture (A). Magnesium chloride (0.095 mol) and Et₃N (0.1905 mol) were added to a solution of monoethyl ester propanedioic acid, potassium salt (0.0667 mol) in CH₃CN (50ml) while ice-cooling. The reaction mixture was stirred for 5 hours at room temperature. Then reaction mixture (A) was added to the reaction mixture and stirred for 15 hours at
- 20 room temperature. The mixture was poured in ice-water. This mixture was acidified with HCl (concentrated) to pH=5 to pH=6. This mixture was extracted with EtOAc. The separated organic layer was dried (Na₂SO₄), filtered and the solvent was


evaporated. The residue was purified by column chromatography. The product fractions were collected and the solvent was evaporated, yielding 10 g (69%) of intermediate 33.

b) Preparation of intermediate 34




- 5 A mixture of intermediate 33 (0.04393 mol) and EtOH, sodium salt (0.08786 mol) in EtOH (100 ml) was heated for 3 hours at 80 °C. The reaction mixture was cooled. 3-Bromopropanoic acid methyl ester (0.04393 mol) was added drop wise to the reaction mixture and stirred overnight at 50 °C. The residue was purified by column chromatography. The product fractions were collected and the solvent was evaporated, yielding 9.6 g (72%) of intermediate 34.

c) Preparation of intermediate 35




- 10 A mixture of intermediate 34 (0.02913 mol) in concentrated HCl (50 ml) was heated at reflux for 3 hours. The solvent was evaporated (vacuo) and the residue was dried, yielding 5.5 g (71%) of intermediate 35 as a hydrochloride salt (.HCl).

d) Preparation of intermediate 36



- 15 A mixture of intermediate (0.02083 mol) in HCl/EtOH (100 ml) was stirred overnight. The solvent was evaporated (vacuo), yielding 6 g (98%) of intermediate 36 as a hydrochloride salt (.HCl).

e) Preparation of intermediate 37




- 20 A mixture of intermediate 36 (0.00018 mol) and *N,N,N*-tributyl-1-butanaminium (tribromide) (0.00078 mol) in THF (20 ml) was refluxed for 2 hours. The solvent was evaporated. (4-Methoxyphenyl)-thiourea (0.00117 mol) and EtOH (20 ml) were added to the residue and then refluxed for 2 hours. The solvent was evaporated. The residue was partitioned between NaHCO₃ saturated aqueous solution and EtOAc. The

separated organic layer's solvent was evaporated. The residue was purified by TLC (eluens: petroleum ether/EtOAc 2:1), yielding 0.080 g (24%) of intermediate 37.

B. Preparation of the compounds

5 Example B1

Preparation of compound 1



















Intermediate 3 (0.00017 mol) was dissolved in 2-propanone (2 ml). H₂O (2 ml) was added, followed by addition of urea-hydrogen peroxide (CAS no.: [124-43-6]) (0.00068 mol), then K₂CO₃ (0.00009 mol). The reaction mixture was stirred overnight at room temperature. Then, more K₂CO₃ (0.006 g) was added and the reaction mixture was stirred overnight at room temperature. The reaction was quenched with EtOAc. The organic layer was filtered through an Extrelut cartridge, then purified over a Biotage 12 cartridge (eluent: CH₂Cl₂/MeOH 98/2). The product fractions were collected and the solvent was evaporated. The residue was crystallised from CH₂Cl₂. The precipitate was filtered off and dried. The crystallization filtrate was purified by flash column chromatography over a Biotage 12 cartridge (eluent: CH₂Cl₂/MeOH 98/2). The product fractions were collected and the solvent was evaporated. The residue (0.035 g, 57%, off-white solid) was triturated under DIPE, filtered off and dried, yielding 0.023 g of compound 1 (MP: 186-187°C).



20 *Table F-1* lists the compounds that were prepared according to Examples A1a, A1b, A1c or B1 described earlier. The following abbreviations were used in the table :
'HBr' stands for the hydrobromide salt, 'HCl' stands for hydrochloride salt, 'MP' stands for melting point.

Table F-1

25


<p>.HBr; Co. No. 11; according to A1a; MP: 194°C</p>	<p>.HCl; Co. No. 21; according to A1a</p>
--	---

	
Co. No. 13; according to A1a	.HBr; Co. No. 22; according to A1a
	
.HBr; Co. No. 14; according to A1a	Co. No. 23; according to A1c; MP:167-168°C
	
Co. No. 15; according to A1a	.2HBr; Co. No. 24; according to A1a
	
.2HBr; Co. No. 16; according to A1a	.HBr; Co. No. 25; according to A1a
	
.HCl; Co. No. 17; according to A1a	Co. No. 26; according to A1a
	
Co. No. 18; according to B1; MP: 209-211°C	Co. No. 28 according to A1a
	
.HBr; Co. No. 19; according to A1a	Co. No. 31; according to A1b
	
.HBr; Co. No. 112; according to A1c	Co. No. 114; according to A1c

	
Co. No. 113; according to B1	Co. No. 115; according to B1; MP: 189.5-192.7°C

Example B2



Preparation of compound 2






- 1-(6-Chloro-3-pyridinyl)ethanone (0.005 mol) in THF (p.a.) (100 ml) was stirred at room temperature. *N,N,N*-trimethylbenzenaminium tribromide (0.005 mol) was added portionwise over 1 hour. The mixture was stirred for 1 hour at room temperature. The precipitate was filtered off and washed with THF (p.a.) (50 ml). Intermediate 5 (0.005 mol) was added portionwise to the filtrate. The reaction mixture was stirred overnight at room temperature. The solvent was evaporated. The residue was stirred in 2-propanone (p.a.). The precipitate was filtered off and dried. The residue (0.96g) was taken up in H₂O, alkalized and extracted with CH₂Cl₂. The separated organic layer was dried, filtered and the solvent was evaporated. The crude product was purified by column chromatography over silica gel (eluent : CH₂Cl₂/(MeOH/NH₃) 98/2), then purified by column chromatography over silica gel (eluent: CH₂Cl₂/(MeOH/NH₃) 99/1) and finally recrystallised from CH₃CN, yielding 0.35g (22%) of compound 2 (MP: 175°C).

Table F-2 lists the compounds that were prepared according to Example B2 described above. The following abbreviations were used in the table : ‘.HCl’ stands for hydrochloride salt, ‘.HBr’ stands for hydrobromide salt, ‘MP’ stands for melting point.


20 Table F-2

	
.HCl; Co. No. 29; MP: 154°C	.HCl; Co. No. 30; MP: 162°C

 <p>.HBr; Co. No. 20</p>	 <p>.HBr; Co. No 12</p>
 <p>.HBr; Co. No. 27; MP: >260°C</p>	

Example B3

Preparation of compound 3







LiBH₄, 2M in THF (5 equiv, 0.00331 mol) was added to intermediate 6 (0.000661 mol) in dry THF (15 ml), stirred at room temperature under N₂ atmosphere. The reaction mixture was stirred for 6 days at 60°C. The reaction was quenched with 1N NaOH and the mixture was stirred for 2 days. This mixture was extracted with EtOAc (2 x). The separated organic layer was dried (MgSO₄), filtered and the solvent evaporated. The residue was purified by flash column chromatography over a Biotage 25M cartridge (eluent: EtOAc/hexane 3/7). The product fractions were collected and the solvent was evaporated, yielding 0.059 g (25%) of compound 3.

Table F-3 lists the compounds that were prepared according to Example B3 described above.


Table F-3

15

 <p>Co. No. 116;</p>	 <p>Co. No. 118;</p>
 <p>Co. No. 117;</p>	 <p>Co. No. 119;</p>

Example B4

Preparation of compound 4



5 A mixture of intermediate 8 (0.000856 mol), Et₃N (0.0011 mol) and THF (p.a., dried on molecular sieves) (7.5ml) was stirred on an ice-bath under N₂ and a solution of acetyl chloride (0.0011 mol) in THF (p.a., dried on molecular sieves) (2.5 ml) was added dropwise. After addition, the reaction mixture was stirred on an ice-bath for 1.5 hour, poured out into water (30 ml) and then stirred for 15 minutes. The formed solids were filtered off, washed with water and with DIPE. These solids were recrystallised from CH₃CN, washed with CH₃CN and with DIPE, then dried at 50°C (vacuum), yielding 0.136 g (40.5%) of compound 4.

10


Table F-4 lists the compound that was prepared according to Example B4 described above.

Table F-4

Co. No. 32

Example B5


Preparation of compound 5



A mixture of intermediate 10 (0.005 mol) and [4-fluoro-3-(trifluoromethyl)phenyl]-thiourea (0.005 mol) in EtOH (50ml) was stirred and refluxed for 3 hours, then stirred at room temperature overnight. The solvent was evaporated. The residue was
5 suspended in 2-propanone. The precipitate was filtered off, washed and dried in vacuo, yielding 0.8g of compound 5.

Example B6


Preparation of compound 6



A mixture of intermediate 11 (0.005 mol) in *N,N*-dimethylformamide (15 ml) was stirred at 0 °C and 1-bromo-2,5-pyrrolidinedione (0.005 mol) was added. The reaction
10 mixture was stirred for 3 hours at room temperature and the solvent was evaporated. The residue was stirred in a Na₂CO₃ solution and the mixture was extracted with CH₂Cl₂. The solvent was evaporated and the residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂). The product fractions were collected and the solvent was evaporated. The residue (free base) was then converted into the
15 hydrochloric acid salt (1:1), the resulting precipitate was filtered off and dried, yielding 0.7 g of compound 6 as a hydrochloride salt (.HCl).

Example B7

Preparation of compound 7




A mixture of intermediate 11 (0.01 mol) and 2,6-dimethylpyridine (0.01 mol) in *N,N*-dimethylformamide (50 ml) was stirred at 0°C and Selectfluor® (0.02 mol) was added
20 portionwise in 1 hour. The reaction mixture was stirred overnight and the solvent was evaporated. The residue was dissolved in H₂O and the mixture was extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄) and the solvent was

-67-

evaporated. The residue was purified by column chromatography over silica gel. The product fractions were collected and the solvent was evaporated. The residue converted into the hydrochloric acid salt (1:1) with HCl/2-propanol. The resulting precipitate was filtered off and dried, yielding 1.2g of compound 7 as a hydrochloride salt (.HCl).

5


Table F-5 lists the compound that was prepared according to Example B7 described above.

Table F-5

10

Example B8

Preparation of compound 8











A mixture of (2,3-dichlorophenyl)-thiourea (0.000067 mol) and 2-bromo-1-(2,4-dimethoxyphenyl)ethanone (0.000080 mol) in DMF (6 ml) was placed in a shaker overnight at 70°C. Unreacted reagents were scavenged with TRIS resin (0.084 g, 0.00027 mol) and bicarbonate resin (0.073 g, 0.00027 mol) over the weekend. The resins were removed by filtration and the filtrates concentrated in vacuo. Impure compounds (LC/MS purity < 90%) were purified by reversed phase high-performance liquid chromatography using an ammonium bicarbonate buffer. The product fractions were collected and the organic solvent was evaporated. The aqueous concentrate was extracted. The extract was dried, filtered and the solvent evaporated, yielding 0.012 g (47.0%) of compound 8.

15




20

Table F-6 lists the compounds that were prepared according to Example B8 described above.

Table F-6


	
Co. No. 33	Co. No. 39
	
Co. No. 34	Co. No. 40
	
Co. No. 35	Co. No. 41
	
Co. No. 36	Co. No. 42

-69-

 <p>Co. No. 37</p>	 <p>Co. No. 43</p>
 <p>Co. No. 38</p>	


Example B9

Preparation of compound 9




- A mixture of 2-chloro-1-imidazo[1,2-a]pyridin-3-yl-ethanone monohydrochloride (0.017 mol) and [4-fluoro-3-(trifluoromethyl)phenyl]-thiourea (0.017 mol) in EtOH (150ml) was stirred and refluxed for 6 hours; then stirred overnight at room temperature. The precipitate was filtered off. The residue was taken up in EtOH. This mixture was stirred overnight. The precipitate was filtered off, washed and dried (vacuum), yielding compound 9 as a hydrochloride salt (.HCl; MP: 248°C).
- 10 *Table F-7* lists the compounds that were prepared according to Example B9 described above. The following abbreviations were used in the table : '.HCl' stands for hydrochloride salt.

Table F-7

 <p>.HCl; Co. No. 44</p>

Example B10


Preparation of compound 10



- A mixture of intermediate 15 (0.003 mol) and [4-fluoro-3-(trifluoromethyl)phenyl]-thiourea (0.003 mol) in EtOH (30 ml) was stirred and refluxed for 3 hours, then stirred at room temperature for 2 hours. The solvent was evaporated. The residue was taken up
 5 into water/EtOH, then alkalized with Na₂CO₃, and extracted with CH₂Cl₂. The separated organic layer was dried (MgSO₄), filtered, and the solvent was evaporated, yielding 1.08 g of residue. Part (0.2 g) of this residue was suspended in DIPE, filtered off, washed and dried in vacuo, yielding 0.2 g of compound 10.

Example B11

Preparation of compound 93




- 10 A mixture of intermediate 16 (0.0083 mol) and 1-bromo-2,5-pyrrolidinedione (0.0083 mol) in DMF (30 ml) was stirred for one hour at room temperature. Ice was added. The supernatant was decanted off. The solid residue was stirred in EtOH, filtered off and dried, yielding 1.61 g (54%) of compound 93.
- 15 *Table F-8* lists the compounds that were prepared according to Example B11 described above. The following abbreviation was used in the table : '.HCl' stands for hydrochloride salt.

Table F-8

Co. No. 121; .HCl

Example B12


Preparation of compound 94



- N*-(3-methylphenyl)-4-(3-pyridinyl)-2-thiazolamine (0.00232 mol) was dissolved in DMF (p.a.) (12ml) and the mixture was cooled with ice-bath. After 30 minutes, 1-chloro-2,5-pyrrolidinedione (0.00233 mol) was added and the reaction mixture was stirred for 1 hour at 0 °C. The mixture was allowed to warm to room temperature and was stirred overnight and then concentrated. The residue was triturated under NaOH (1M; 10ml) and was stirred vigorously for 3 hours and filtered. The precipitate was crystallized from EtOH and was then purified by column chromatography over Hyperprep C18 HS BDS (eluent : (0.5%NH₄Ac in H₂O/CH₃CN 90/10)/MeOH/CH₃CN 75/25/0;0/50/50;0/0/100). The product fractions were collected and the solvent was evaporated. The residue was stirred in DIPE. The precipitate was filtered off and dried, yielding 0.042g of compound 94.

Example B13

Preparation of compound 95











- A mixture of intermediate 17 (0.000676 mol) in a 40% formaldehyde solution (3 ml), THF (3 ml) and Et₃N (1 ml) was stirred for 6 minutes at 100 °C in a microwave oven. The reaction was quenched by adding aqueous ammonia (20 ml), then stirred for 30 minutes. The mixture was extracted with EtOAc. The organic layer was separated, dried (Na₂SO₄), filtered and the solvent was evaporated in vacuo. The residue was purified by flash column chromatography over silica gel. The product fractions were collected and the solvent was evaporated, yielding compound 95.

Table F-9 lists the compounds that were prepared according to Example B13 described above. The following abbreviation was used in the table : 'MP' stands for melting point.


Table F-9

5

	
Co. No. 122; MP: 126.2-126.8°C	Co. No. 126;
	
Co. No. 123;	Co. No. 127;
	
Co. No. 124;	Co. No. 128;
	
Co. No. 125;	Co. No. 129;


Example B14

Preparation of compound 96




- Hydrogen peroxide (2 ml) was added to a mixture of intermediate 20 (0.000341 mol) and NaOH (0.0025 mol) in DMSO (4 ml). The reaction mixture was stirred for 30 minutes at room temperature. The precipitate was filtered off and the filter residue was
- 5 purified by high-performance liquid chromatography. The product fractions were collected and the solvent was evaporated, yielding 0.100 g of compound 96.

Table F-10 lists the compound that was prepared according to Example B14 described above.

10 Table F-10Example B15

Preparation of compound 97








- A mixture of intermediate 21 (0.000433 mol), methanamine, hydrochloride (0.0024
- 15 mol), *N*-(ethylcarbonimidoyl)-*N,N*-dimethyl-1,3-propanediamine, monohydrochloride

- (0.000645 mol), 1-hydroxy-1H-benzotriazole (0.000433 mol) and K_2CO_3 (0.0020 mol) in CH_3CN (10 ml) was stirred and refluxed for 2 hours. The reaction mixture was cooled to room temperature. The precipitate was filtered off and the filtrate's solvent was evaporated in vacuo. The residue was purified by preparative high-performance liquid chromatography. The product fractions were collected and the solvent was evaporated, yielding compound 97.


Table F-II lists the compounds that were prepared according to Example B15 described above. The following abbreviation was used in the table : 'MP' stands for melting point.

Table F-II

	
Co. No. 131;	Co. No. 134;
	
Co. No. 132;	Co. No. 135;
	
Co. No. 133;	

Example B16

Preparation of compound 98



A mixture of intermediate 23 (0.00057 mol), paraform (200 mg) and Pt/C 5% (10 mg) in thiophene solution (0.1 ml) and MeOH (50 ml) was hydrogenated at 50 °C. Then the solvent was evaporated. The residue was purified by high-performance liquid chromatography (standard gradient elution with NH_4HCO_3). The product fractions were collected and the solvent was evaporated. Then the residue was dried, yielding 0.034 g (16%; MP: 105.1 °C to 105.5 °C) of compound 98.


Table F-12 lists the compound that was prepared according to Example B16 described above. The following abbreviation was used in the table : 'MP' stands for melting point.

Table F-12

Co. No. 136; MP: 205.3-205.8°C

15 Example B17

Preparation of compound 99




Intermediate 25 (0.00053 mol) was suspended in 4N HI/Dioxane (20 ml). The suspension was stirred overnight. The solvent was evaporated in vacuo. Pyrrolidine (0.048 mol) was added. The reaction mixture was stirred for 4 hours. A 5% aqueous NaOH solution (10 ml) was added. This mixture was extracted with CH_2Cl_2 (2 x 10

-76-

ml). The organic layer was separated, washed with water (10 ml) and with brine (10 ml), dried (Na_2SO_4 , anhydrous), filtered and the filter residue was washed with CH_2Cl_2 (5 ml). The filtrate's solvent was evaporated in vacuo. The residue was purified by high-performance liquid chromatography. The product fractions were collected and the solvent was evaporated, yielding 0.100 g (43.9%) of compound 99.

Example B18


Preparation of compound 100



Morpholine (0.023 mol) was added to intermediate 25. The reaction mixture was stirred for 4 hours. A 5% aqueous NaOH solution (10 ml) was added. This mixture was extracted with CH_2Cl_2 (2 x 10 ml). The organic layer was separated, washed with water (10 ml) and with brine (10 ml), dried (Na_2SO_4 , anhydrous), filtered and the filter residue was washed with CH_2Cl_2 (5 ml). The filtrate's solvent was evaporated in vacuo. The residue was purified by high-performance liquid chromatography. The product fractions were collected and the solvent was evaporated, yielding 0.060 g (26.8%) of compound 100.

Example B19







Preparation of compound 101



A mixture of 2-bromo-1-(3-pyridinyl)-1-propanone, hydrobromide (0.003 mol) and [3-(trifluoromethyl)phenyl]-thiourea (0.003 mol) in EtOH (150ml) was stirred and refluxed overnight. The solvent was evaporated. The residue was stirred in 2-propanone and a small amount of EtOH. The precipitate was filtered off and dried in vacuo at 50 °C, yielding 0.952g of compound 101 as a hydrobromide salt (.2HBr).

Table F-13 lists the compounds that were prepared according to Example B19 described above.


Table F-13

	
Co. No. 137;	Co. No. 140;
	
Co. No. 138;	Co. No. 141
	
Co. No. 139;	Co. No. 142

5

Example B20

Preparation of compound 102



Sulfonyl chloride (0.0055 mol) was added dropwise to a solution of 3-oxo-hexanoic acid, ethyl ester (0.0055 mol) in CH₂Cl₂ (q.s.). The reaction mixture was stirred for 2 hours at room temperature. The solvent was evaporated. A solution of (4-methoxyphenyl)-thiourea (0.0055 mol) in EtOH (100 ml) was added to the residue. The resultant reaction mixture was stirred and refluxed for 4 hours. A saturated aqueous NaHCO₃ solution was added. This mixture was extracted with EtOAc. The separated organic layer was purified by column chromatography over silica gel. The product fractions were collected and the solvent was evaporated, yielding compound 102.















10

15

-78-


Table F-14 lists the compounds that were prepared according to Example B20 described above.

Table F-14

	
Co. No. 143	Co. No. 150
	
Co. No. 144	Co. No. 151
	
Co. No. 145	Co. No. 152
	
Co. No. 146	Co. No. 153
	
Co. No. 147	Co. No. 154
	
Co. No. 148	Co. No. 155
	
Co. No. 149	Co. No. 156

Example B21

Preparation of compound 103



- 5 A mixture of 2-chloro-4-methoxy-3-oxo-butanoic acid, methyl ester (0.0069 mol) and [3-(trifluoromethyl)phenyl]-thiourea (0.0069 mol) in EtOH (20 ml) was stirred and refluxed for 4 hours. The solvent was evaporated. The residue was stirred in a saturated aqueous NaHCO₃ solution, then extracted with EtOAc. The separated organic layer was purified by column chromatography. The product fractions were collected and the solvent was evaporated, yielding compound 103.


- 10 *Table F-15* lists the compounds that were prepared according to Example B21 described above.

Table F-15

Co. No. 157	Co. No. 159
Co. No. 158	

Example B22

Preparation of compound 104




- 15 β -Oxo-1-[(phenylmethoxy)carbonyl]-3-piperidinepropanoic acid, ethyl ester (0.0033 mol) and sulfonyl chloride (0.0036 mol) were dissolved in CH₂Cl₂ (10 ml). The reaction mixture was stirred for 2 hours. The solvent was evaporated in vacuo. This residue and (4-methoxyphenyl)-thiourea (0.0030 mol) were dissolved in EtOH (10 ml) and the resultant reaction mixture was stirred and refluxed for 4 hours, then cooled to room

temperature. The mixture was filtered and the filter residue was washed with EtOH (10 ml), then stirred in a saturated aqueous NaHCO_3 solution, then filtered off and dried in vacuo, yielding 0.8 g (54%) of compound 104.


- 5 *Table F-16* lists the compounds that were prepared according to Example B22 described above.

Table F-16



10 **Example B23**


Preparation of compound 105



- 15 Sulfuryl chloride (0.0017 mol) was added to a mixture of intermediate 27 (0.00168 mol) in CH_2Cl_2 (10 ml). The reaction mixture was stirred for 2 hours. The solvent was evaporated. (5-Chloro-2,4-dimethoxyphenyl)-thiourea (0.0015 mol) was added to the residue, followed by the addition of EtOH (10 ml). The reaction mixture was stirred and refluxed for 4 hours. NaHCO_3 (0.3 g) was added and the mixture was stirred for 30 minutes. The resulting precipitate was filtered off and the filtrate's solvent was evaporated. The residue was purified by preparative high-performance liquid chromatography. The product fractions were collected and the solvent was evaporated, yielding compound 105.

Example B24

Preparation of compound 106



A mixture of intermediate 31 (0.00026 mol) and HBTU (0.00039 mol) in DMF (5 ml) was stirred for 1 hour. 2-Methoxyethanamine (0.00078 mol) was added to the reaction mixture and then stirred for 3 hours at room temperature. The solvent was evaporated.

- 5 The residue was purified by high-performance liquid chromatography (standard gradient elution with NH_4HCO_3 buffer). The product fractions were collected and the solvent was evaporated. The residue was dried, yielding 0.045 g (40%; MP: 218.0 °C to 224.2 °C) of compound 106.


- 10 *Table F-17* lists the compounds that were prepared according to Example B24 described above. The following abbreviation was used in the table : 'MP' stands for melting point.

Table F-17

Co. No. 161; MP: 256.1-263.7°C	Co. No. 163; MP: 237.2-244.0°C
Co. No. 162; MP: 146.7-156.9°C	

Example B25


Preparation of compound 107



- Reaction in microwave oven. A mixture of intermediate 32 (0.00066 mol) in $\text{CH}_3\text{NH}_2/\text{H}_2\text{O}$ (20 ml) was heated for one hour at 100 °C. The reaction mixture was cooled to room temperature. This mixture was extracted with CH_2Cl_2 . The separated organic layer was dried (Na_2SO_4), filtered and the solvent evaporated. The residue was purified by high-performance liquid chromatography. The product fractions were collected and the solvent was evaporated, yielding compound 107.

Example B26






Preparation of compound 108



- A mixture of intermediate 8 (0.000285 mol) and 5-methyl-3-isoxazolecarbonyl chloride (0.000285 mol) in Et_3N (0.00057 mol) and CH_2Cl_2 (5 ml) was stirred at room temperature for 30 minutes. Then an aqueous solution of Na_2CO_3 (1 ml) was added to the reaction mixture and the reaction mixture was filtered through an extrelute filter. Then the filtrate's solvent was evaporated and the residue was purified by high-performance liquid chromatography (standard gradient elution with NH_4HCO_3). The product fractions were collected and the solvent was evaporated. The residue was dried, yielding 0.044 g (34%; MP: 222.5 °C to 223.4 °C) of compound 108.

Table F-18 lists the compounds that were prepared according to Example B26 described above.


Table F-18

 <p>Co. No. 164</p>	 <p>Co. No. 167</p>
 <p>Co. No. 165</p>	 <p>Co. No. 168</p>
 <p>Co. No. 166</p>	

5

Example B27

Preparation of compound 109



A mixture of intermediate 8 (0.000285 mol), methanesulfonyl chloride (0.000285 mol) and Et₃N (0.00057 mol) in CH₂Cl₂ (50 ml) was stirred for 30 minutes at room temperature. Upon reaction completion, the reaction mixture was washed with an aqueous Na₂CO₃ solution. The organic phase was dried, filtered and the solvent evaporated. The residue was purified by reversed-phase high-performance liquid chromatography (standard gradient elution with NH₄HCO₃ buffer). The product


10

-84-

fractions were collected and the solvent was evaporated, yielding 0.013 g (11%) of compound 109.

Example B28


Preparation of compound 110



- 5 3-Chloro-2,4-pentanedione (0.0238 mol) and (2,5-dichlorophenyl)-thiourea (0.0238 mol) were treated with pyridine (2.1 ml). MeOH (38 ml) was added and the reaction mixture was refluxed. Extra MeOH (30 ml) was added and after 3 hours, the mixture was cooled to room temperature. The product was filtered off and washed 3 times with Et₂O, then dried in the vacuum oven, yielding 9.6 g of compound 110.

Example B29

Preparation of compound 111



- 10 A mixture of intermediate 37 (0.00019 mol) in methanamine (10 ml; 27-32% CH₃NH₂ alcohol solution) was heated overnight at 85 °C in a sealed tube. The solvent was evaporated. The residue was purified by reversed phase high performance liquid chromatography. The desired fractions were collected and the solvent was evaporated, yielding 0.022 g (28.7%) of compound 111.

15

Table F-*Ia* lists the compounds that were prepared as described in Patent Publication No. WO 01/64674, according to Example B1 a) in said Patent Publication No., the Table No. is retrievable in said Patent Publication.

The following abbreviations were used in the table : ‘.HBr’ stands for the hydrobromide acid salt, ‘.HCl’ stands for hydrochloride acid salt, ‘.C₂H₅O’ stands for ethanolate, ‘MP’ stands for melting point.

Table F-*Ia*

.HCl; Co. No. 45	Table No. 10
.HCl; Co. No. 46; MP: 271.0-274.1°C	Table No. 10
.HCl; Co. No. 47; MP: >260°C	Table No. 10
.HCl; Co. No. 48; MP: >260°C	Table No. 10
.HCl; Co. No. 49; MP: 238°C	Table No. 10
	.HCl; Co. No. 59; MP: 170-172°C
	Table No. 9




















	
.HCl; Co. No. 50; MP: 158°C	.HCl; Co. No. 60 Table No. 9
	
.HCl; Co. No. 51; MP: 218-220°C	.HCl; Co. No. 61 Table No. 9
	
.HCl; Co. No. 52; MP: 220°C	.HCl; Co. No. 62 Table No. 9
	
.HCl .C ₂ H ₆ O; Co. No. 53	.HCl; Co. No. 63; MP: 242°C
	
.HCl; Co. No. 54	Table No.2

Table F-**1b** lists the compounds that were prepared as described in Patent Publication No. WO 01/64674, according to Example B1 b) in said Patent Publication No., the Table No. is retrievable in said Patent Publication.

The following abbreviations were used in the table : '.HBr' stands for the
5 hydrobromide acid salt, '.HCl' stands for hydrochloride acid salt, 'MP' stands for melting point.

Table F-1b

	Table No. 11		Table No. 2
.HBr . H ₂ O; Co. No. 64		.HBr; Co. No. 71; MP: 260-262°C	
	Table No. 11		Table No. 2
.2HBr; Co. No. 65; MP: >250°C		.HCl; Co. No. 72	
	Table No. 11		Table No. 3
.2HBr; Co. No. 66		Co. No. 73; MP: 214°C	
	Table No. 11		Table No. 3
.HBr; Co. No. 67		.HCl; Co. No. 74; MP: 146-148°C	
	Table No. 11		Table No. 5
.HBr; Co. No. 68		.HBr; Co. No. 75	













			
.HCl; Int. 12	Table No. 12	.HBr; Co. No. 76	Table No. 7
			
.HBr; Co. No. 69	Table No. 2	.2HBr; Co. No. 77	Table No. 7
			
.HBr; Co. No. 70; MP: 254°C	Table No. 2	.HBr; Co. No. 78; MP: 242-244°C	Table No. 7

Table F-II lists the compounds that were prepared as described in Patent Publication No. WO 03/015773, according to the mentioned Example No. as described in said Patent Publication No. and retrievable in Table No. 1.

- 5 The following abbreviations were used in the table: 'MP' stands for melting point.

Table F-II

			
Co. No. 79	Ex. No. B1a	Co. No. 86	Ex. No. B2b
			
Co. No. 80	Ex. No. B1a	Co. No. 87	Ex. No. B2b
			
Co. No. 81; MP: 226°C	Ex. No. B1a	Co. No. 88	Ex. No. B2b









			
Co. No. 82	Ex. No. B1a	Co. No. 89; MP: 240-247°C	Ex. No. B6
			
Co. No. 83; MP: 176-178°C	Ex. No. B1b	Co. No. 90	Ex. No. B9
			
Co. No. 84	Ex. No. B2b	Co. No. 91	Ex. No. B9
			
Co. No. 85	Ex. No. B2b	Co. No. 92	Ex. No. B1a

Table F-III lists the known compounds that were found to be positive modulators of the $\alpha 7$ nicotinic acetylcholine receptor, and accordingly useful in the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, in particular in the treatment of cognitive deficits seen in diseases such as Alzheimer's disease and schizophrenia, more in particular in the treatment of ADHD, anxiety, schizophrenia, mania, manic depression or other neurological or psychiatric disorders in which there is loss of cholinergic function, including loss of cholinergic synapses, including jetlag, nicotine addiction and pain.

Table F-III

Registry Number	Co. No.	CA Index Name
315679-10-8	169	5-Thiazolecarboxamide, 2-[(4-fluorophenyl)amino]-4-phenyl-N-3-pyridinyl-
356569-19-2	170	5-Thiazolecarboxamide, 2-[(2,4-dimethylphenyl)amino]-4-phenyl-N-3-pyridinyl-
307513-68-4	171	5-Thiazolecarboxamide, 4-phenyl-2-(phenylamino)-N-3-pyridinyl-

356569-17-0	172	5-Thiazolecarboxamide, 2-[(2-methylphenyl)amino]-4-phenyl-N-3-pyridinyl-
406469-54-3	173	5-Thiazolepropanoic acid, 4-(4-methoxyphenyl)-2-[(4-methoxyphenyl)amino]-, methyl ester
311791-26-1	174	5-Thiazolecarboxylic acid, 2-[(2,5-dichlorophenyl)amino]-4-phenyl-, ethyl ester

- It is accordingly an object of the invention to provide the use of the compounds enlisted in any one of tables F-Ia, F-Ib, F-II or F-III in the manufacture of a medicament for the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial, in particular in the treatment of cognitive deficits seen in diseases such as Alzheimer's disease and schizophrenia, more in particular in the treatment of ADHD, anxiety, schizophrenia, mania, manic depression or other neurological or psychiatric disorders in which there is loss of cholinergic function, including loss of cholinergic synapses, including jetlag, nicotine addiction and pain.

Compound identification

LCMS-methods:5 General procedure A

The HPLC gradient was supplied by a Waters Alliance HT 2790 system with a column heater set at 40°C. Flow from the column was split to a Waters 996 photodiode array (PDA) detector and a Waters-Micromass ZQ mass spectrometer with an electrospray ionization source operated in positive and negative ionization mode. Mass spectra were acquired by scanning from 100 to 1000 in 1 second using a dwell time of 0.1 second. The capillary needle voltage was 3 kV and the source temperature was maintained at 140 °C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.

15 General procedure B

The HPLC gradient was supplied by an Agilent 1100 module consisting of a pump and DAD detector (wavelength used 220 nm) and column heater. Flow from the column was split to the Agilent MSD Series G1946C and G1956A. MS detector was configured with API-ES. Mass spectra were acquired by scanning from 100 to 1000. The capillary needle voltage was 2500 V for positive ionization mode and 3000 V for negative ionization mode. Fragmentation voltage was 50 V. Drying gas temperature was maintained at 350 °C at a flow of 10 l/min.

General procedure C

25 The HPLC gradient was supplied by an Alliance HT 2795 (Waters) system consisting of a quaternary pump with degasser, an autosampler, a column oven (set at 40 °C) and DAD detector. Flow from the column was split to the MS detector. MS detectors were configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1500 in 1 second using a dwell time of 0.1 second. The capillary needle voltage was 3.5 kV and the source temperature was maintained at 100 °C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.

Method 1

35 In addition to general procedure A: Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 mm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient

condition from 100 % A to 50 % B and 50 % C in 6.5 minutes, to 100 % B in 1 minute, 100 % B for 1 minute and reequilibrate with 100 % A for 1.5 minutes. An injection volume of 10 µl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.

5

Method 2

In addition to general procedure A: Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 mm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 1 % A, 49 % B and 50 % C in 6.5 minutes, to 1 % A and 99 % B in 1 minute and hold these conditions for 1 minute and reequilibrate with 100 % A for 1.5 minutes. An injection volume of 10 µl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.

15

Method 3

In addition to general procedure A: Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 mm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Two mobile phases (mobile phase A: 70 % methanol + 30 % H₂O; mobile phase B: 0.1 % formic acid in H₂O/methanol 95/5) were employed to run a gradient condition from 100 % B to 5 % B + 95 % A in 12 minutes. An injection volume of 10 µl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.

Method 4

In addition to general procedure A: Reversed phase HPLC was carried out on a Chromolith (4.6 x 25 mm) with a flow rate of 3 ml/min. Three mobile phases (mobile phase A: 95 % 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 96 % A, 2 % B and 2 % C, to 49 % B and 49 % C in 0.9 minutes, to 100 % B in 0.3 minutes and hold for 0.2 minutes. An injection volume of 2 µl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.

30

Method 5

In addition to general procedure A: Column heater was set at 60 °C. Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 mm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50 % B and 50 % C in 6.5 minutes, to 100 % B in 0.5 minute and hold these conditions for 1 minute and reequilibrate with 100 % A for 1.5 minutes. An injection volume of 10 µl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.

Method 6

In addition to general procedure A: Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 mm, 4.6 x 100 mm) with a flow rate of 1.2 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 2 % A, 49 % B and 49 % C in 10 minutes, to 1 % A and 99 % B in 1 minute and hold these conditions for 3 minutes and reequilibrate with 100 % A for 2.5 minutes. An injection volume of 10 µl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode. Column temperature was 45 °C.

Method 7

In addition to general procedure B: Reversed phase HPLC was carried out on a YMC ODS-AQ S-5 µm, 12 nm column (2.0 x 50 mm) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: water with 0.1 % TFA; mobile phase B: acetonitrile with 0.05 % TFA) were used to run a gradient condition from 95 % A and 5 % B to 100 % B in 3.5 minutes. Typical injection volumes of 2 µl were used. Column temperature was 50 °C.

Method 8

In addition to general procedure B: Reversed phase HPLC was carried out on a YMC ODS-AQ S-5 μm , 12 nm column (2.0 x 50 mm) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: water with 0.1 % TFA; mobile phase B: acetonitrile with 0.05 % TFA) were used to run a gradient condition from 90 % A and 10 % B to 100 % B in 3.4 minutes and hold for 0.1 minutes. Typical injection volumes of 2 μl were used. Column temperature was 50 °C.

Method 9

In addition to general procedure B: Reversed phase HPLC was carried out on a YMC ODS-AQ S-5 μm , 12 nm column (2.0 x 50 mm) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: water with 0.1 % TFA; mobile phase B: acetonitrile with 0.05 % TFA) were used to run a gradient condition from 80 % A and 20 % B to 100 % B in 3.3 minutes and hold for 0.2 minutes. Typical injection volumes of 2 μl were used. Column temperature was 50 °C.

Method 10

In addition to general procedure B: Reversed phase HPLC was carried out on a YMC ODS-AQ S-5 μm , 12 nm column (2.0 x 50 mm) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: water with 0.1 % TFA; mobile phase B: acetonitrile with 0.05 % TFA) were used to run a gradient condition from 70 % A and 30 % B to 100 % B in 3.2 minutes and hold for 0.3 minutes. Typical injection volumes of 2 μl were used. Column temperature was 50 °C.

Method 11

In addition to general procedure B: Reversed phase HPLC was carried out on a YMC ODS-AQ S-5 μm , 12 nm column (2.0 x 50 mm) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: water with 0.1 % TFA; mobile phase B: acetonitrile with 0.05 % TFA) were used to run a gradient condition from 60 % A and 40 % B to 100 % B in 3 minutes and hold for 0.5 minutes. Typical injection volumes of 2 μl were used. Column temperature was 50 °C.

Method 12

- In addition to general procedure B: Reversed phase HPLC was carried out on a YMC ODS-AQ S-5 μm , 12 nm column (2.0 x 50 mm) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase C: 10 mmol/L NH_4HCO_3 ; mobile phase D: acetonitrile) were used to run a gradient condition from 90 % C and 10 % D to 100 % D in 3.4 minutes and hold for 0.1 minutes. Typical injection volumes of 2 μl were used. Column temperature was 50 °C.

Method 13

- In addition to general procedure B: Reversed phase HPLC was carried out on a YMC ODS-AQ S-5 μm , 12 nm column (2.0 x 50 mm) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: water with 0.1 % TFA; mobile phase B: acetonitrile with 0.05 % TFA) were used to run a gradient condition from 90 % A and 10 % B to 100 % B in 3.4 minutes and hold for 0.1 minutes. Typical injection volumes of 2 μl were used. Column temperature was 50 °C.

Method 14

- In addition to general procedure B: Reversed phase HPLC was carried out on a YMC ODS-AQ S-5 μm , 12 nm column (2.0 x 50 mm) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: water with 0.1 % TFA; mobile phase B: acetonitrile with 0.05 % TFA) were used to run a gradient condition from 70 % A and 30 % B to 100 % B in 3.2 minutes and hold for 0.3 minutes. Typical injection volumes of 2 μl were used. Column temperature was 50 °C.

Method 15

- In addition to general procedure A: Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 mm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95 % 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 30 % A, 35 % B; 35 % C in 3 minutes to 50 % B and 50 % C in 3.5 minutes, to 100 % B in 0.5 minutes. An injection volume of 10 μl was used. Cone voltage was 10 V for positive ionization mode.

Method 16

In addition to general procedure C: Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 mm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50 % B and 50 % C in 7.5 minutes, to 100 % B in 1 minute, 100 % B for 2 minutes and reequilibrate with 100 % A for 2 minutes. An injection volume of 10 µl was used. Cone voltage was 30 V for positive ionization mode and 30 V for negative ionization mode.

10

Method 17

In addition to general procedure B: Reversed phase HPLC was carried out on a YMC ODS-AQ S-5 µm, 12 nm column (2.0 x 50 mm) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: water with 0.1 % TFA; mobile phase B: acetonitrile with 0.05 % TFA) were used. First, 100 % A was hold for 1 minute. Then a gradient was applied to 40 % A and 60 % B in 4 minutes and hold for 2.5 minutes. Typical injection volumes of 2 µl were used. Oven temperature was 50 °C.

15

Table: Analytical data

20

Comp. Nr.	R _t	(MH) ⁺	Procedure	Physico-chemical data
1	6.07	378	1	186-187 °C
18	6.46	446	1	209-211 °C
64	5.37	333	1	HBr-salt
60	6.03	313	1	HCl-salt
80	4.36	379	1	
88	5.45	303	1	
91	5.76	370	1	
17	6.04	353	1	HCl-salt
61	5.51	341	1	HCl-salt
62	6.31	367	1	HCl-salt
29	7.12	375	1	154 °C HCl-salt
26	6.34	347	1	

Comp. Nr.	R _t	(MH) ⁺	Procedure	Physico-chemical data
47	5.87	362	1	> 260 °C HCl-salt
int. 12	6.94	339	1	HCl-salt
55	5.32	353	1	HCl-salt
44	6.38	385	1	HCl-salt
10	5.67	355	1	
5	6.59	358	1	
52	6.21	339	1	220 °C HCl-salt
58	6.46	371	1	HCl-salt
51	6.16	307	1	218-220 °C HCl-salt
71	6.47	361	1	260-262 °C HBr-salt
56	6.46	361	1	HCl-salt
74	6.54	311	1	146-148 °C HCl-salt
11	7.08	375	1	194 °C HBr-salt
20	7.02	357	1	HBr-salt
12	7.18	355	1	HBr-salt
25	6.22	322	1	HBr-salt
16	6.53	340	1	HBr-salt
63	5.71	368	1	242 °C HCl-salt
93	6.87	361	2	114.1-115.0 °C
115	1.07	378	4	189.5-192.7 °C
162	1	433	4	146.7-156.9 °C
106	0.92	437	4	218.0-224.2 °C
161	6.13	421	2	256.1-263.7 °C
85	6.59	375	1	
27	5.94	323	1	> 260 °C HBr-salt
53	6.34	327	1	HCl-salt
2	6.54	320	1	175 °C

Comp. Nr.	R _t	(MH) ⁺	Procedure	Physico-chemical data
15	5.83	347	1	
30	6.3	275	1	162 °C HCl-salt
19	6.18	332	1	HBr-salt
40	7.21	381	1	
42	6.84	317	1	
14	6.3	340	1	HBr-salt
66	4.74	269	1	HBr-salt
90	6.31	439	1	
13	6.96	339	1	
76	5.86	268	1	HBr-salt
87	6.36	336	1	
86	6.37	336	1	HBr-salt
24	6.32	303	1	HBr-salt
int. 1	6.89	321	1	
70	5.68	323	1	254 °C HBr-salt
79	7	356	1	HBr-salt
101	6.33	336	2	HBr-salt
6	7.32	417	1	HCl-salt
int. 5	3.7	185	1	
int. 6	7.18	393	1	150 °C
72	5.89	311	1	HCl-salt
int. 7	6.31	347	1	HCl-salt
int. 2	6.36	351	1	
3	6.62	351	1	
23	6.26	428	1	167-168 °C
150	3.33	331	9	
int. 25	2.27	378	7	206.8-208.7 °C
112	3.41	422	8	204.1-205.5 °C
132	2.48	494.1	10	170.2-177.0 °C
123	2.08	344.1	7	104.5-106.6 °C

Comp. Nr.	R _t	(MH) ⁺	Procedure	Physico-chemical data
134	2.91	454	8	177.9-181.6 °C
126	2.35	437	8	160.1-169.5 °C
99	1.92	431.1	8	199.3-201.7 °C
100	2.13	447.1	13	183.4-187.2 °C
114	2.36	387	7	decomposed at 181.2 °C
130	2.89	440	8	
116	3.37	317.1	12	
143	3.19	331.1	9	
155	3.49	359.1	9	
96	2.68	462	13	
119	3.53	343	12	
160	3.21	534.2	11	
145	3.26	357.1	10	
103	2.84	347	9	
97	2.9	476.1	13	
140	3.08	347	8	
135	2.28	459.1	8	
95	3.06	401.1	12	
105	2.22	405.1	7	
117	3.31	317.1	12	
int. 19	3.22	435.1	12	
144	2.9	293.1	8	
104	3.15	496.2	10	
148	3.4	345.1	9	
151	3.09	307.1	8	
159	3.17	361.1	8	
int. 20	3.05	444.1	8	
118	2.68	305.1	12	
154	3.13	347.1	8	
147	3.34	385	14	
107	3.14	440	8	
152	3.47	357	10	

Comp. Nr.	R _t	(MH) ⁺	Procedure	Physico-chemical data
149	3.6	345	9	
156	3.52	359	10	
153	3.23	367	9	
158	2.78	323.1	8	
146	3.3	319.1	8	
102	2.88	321.1	9	
157	3.33	361	8	
133	2.5	516	9	
174	10.69	393	6	
129	1.04	366	4	
128	1.07	366	4	
125	0.92	377	4	196.2-198.9 °C
65	5.62	323	1	>250 °C HBr-salt
73	5.93	323	1	214 °C
59	6.34	367	1	170-172 °C HCl-salt
49	5.61	340	1	238 °C HCl-salt
45	5.65	372	1	HCl-salt
54	6.8	395	1	HCl-salt
69	5.54	318	1	HBr-salt
78	5.97	286	1	242-244 °C HBr-salt
48	5.82	362	1	>260 °C HCl-salt
68	6.45	336	1	HBr-salt
50	5.85	353	1	158 °C HCl-salt
34	6.65	343	1	
75	5.84	328	1	HBr-salt
77	5.87	268	1	HBr-salt
22	5.89	355	1	HBr-salt
67	6.67	336	1	HBr-salt

Comp. Nr.	R _t	(MH) ⁺	Procedure	Physico-chemical data
83	6.4	304	1	176-178 °C
9	6.5	379	1	248 °C HCl-salt
84	6.74	418	1	
7	7.26	357	1	HCl-salt
127	4.72	313	5	179.9-182.4 °C
89	5.75	370	1	240-247 °C
46				271.0-274.1 °C HCl-salt
81				226 °C
int. 3				121-122 °C
28	7.45	389	2	
8	8.11	381	15	
31	6.09	419	1	
35	6.72	353	15	
36	8.09	381	15	
37	6.69	353	15	
38	7.56	345	15	
39	8.24	381	15	
41	1.17	355	4	
57	6.45	361	2	
82				228.37 °C
43	7.61	347	15	
33	7.51	345	15	
32	0.87	411	4	
120	6.34	286	2	
94	6.73	302	16	
110	6.5	301	16	
168	6.15	423	16	
141				207.26 °C
138	6.2	282	16	

-102-

Comp. Nr.	R _t	(MH) ⁺	Procedure	Physico-chemical data
142	6.22	340	16	
139	5.63	298	16	
137	6.38	346	16	
169	6.02	391	16	
170	6.2	401	16	
171	5.9	373	16	
172	5.88	387	16	
173	6.42	399	16	
111	5.14	403	17	168.8-171.0 °C

Comp. Nr.	R _t	(MH) ⁺	Procedure	Melting point (°C)
4	0.96	391	4	
124	0.84	363	4	155.5-159.7 °C
109	0.9	427	4	213.6-219.8 °C
167	1.04	433	4	248.7-249.4 °C
164	1.03	453	4	215.5-218.9 °C
166	0.98	454	4	245.9-247.3 °C
int. 23	1.11	349	4	172.8-175.0 °C
131	0.99	390	4	
122	0.82	312	4	126.2-126.8 °C
113	0.89	377	4	249.6-257.1 °C
165	0.98	454	4	
108	1.02	458	4	222.5-223.4 °C
98	1.22	363	4	105.1-105.5 °C
136	1.22	364	4	205.3-205.8 °C
int. 30	1.03	406	4	156.8-163.5 °C
163	0.92	391	4	237.2-244.0 °C (Buchi visual)

C. Pharmacological example

Example C.1 : Ca^{2+} flux imaging

Stable expression in mammalian cells in general and rat GH4C1 cells in particular, of cDNA clones encoding the human $\alpha 7$ wild-type sequence (h $\alpha 7$ -wt nAChR) and in which the coding region is placed downstream of a promoter results in the appearance of functional $\alpha 7$ nAChRs on the surface of the mammalian cells. This technique has provided a powerful means of assessing the function of $\alpha 7$ wild-type protein. Given the fact that the cation permeability of the $\alpha 7$ nicotinic receptor preferentially favours calcium, fluorescent imaging of Ca^{2+} flux through the h $\alpha 7$ -wt nAChR stably expressed in the GH4C1 cell line was used as a first means of assaying modulator activity of the compounds of the present invention.

Materials

a) Assay buffer

Hanks buffered saline solution (HBSS, Invitrogen, Belgium), supplemented with 10 mM HEPES (Invitrogen, Belgium), $CaCl_2$ to a final concentration of 5 mM, 0.1 % Bovine serum albumin (Sigma-Aldrich NV, Belgium), 2.5 mM probenecid (Sigma-Aldrich NV, Belgium).

b) Calcium-sensitive dye - Fluo-4AM

Fluo-4AM (Molecular Probes, USA) was dissolved in DMSO containing 10% Pluronic acid (Molecular Probes, USA) to give a stock solution which was aliquoted and could be stored at $-20^{\circ}C$ until later use. On the day of the experiment Fluo-4AM stock was defrosted and diluted in DMEM/F12 (Invitrogen, Belgium) containing 2.5 mM probenecid and 0.1% BSA to give a final concentration of 2 μM .

c) 96-well plates

BD Biocoat poly-D-lysine 96-well black/clear bottom plates (BD Biosciences, Belgium)

d) Calcium flux measurement

A Fluorimetric Imaging Plate Reader (FLIPR, Molecular Devices Corporation, Sunnyvale, USA) was used to measure intracellular free-calcium flux signals

Method

Monolayers of h $\alpha 7$ -wt nAChR-expressing cells were grown in multi-well plates, in particular black-sided, transparent bottomed 96 well plates coated with poly-D-lysine for 24 hours prior to loading with a fluorescent calcium indicator, in a particular embodiment loading with fluo-3 or fluo-4AM for up to 90 minutes, in an even more

particular embodiment loading with fluo-4AM for up to 90 minutes, and in a preferred embodiment loading with fluo-4AM for 60 minutes.

- PAM activity was detected in real time by applying the compounds to be tested to the loaded cells along with a $\alpha 7$ nicotinic receptor agonist during constant monitoring of cellular fluorescence in a FLIPR. Compounds giving peak fluorescent responses greater than the response due to agonist alone, were considered to be $\alpha 7$ nAChR PAM's. In a particular embodiment, the $\alpha 7$ nicotinic receptor agonist was choline, a more particular embodiment choline applied at a sub-maximal concentration of 100 μ M. In a further setting of the present invention the compounds to be tested were applied prior to the $\alpha 7$ nicotinic receptor agonist, in a particular embodiment up to 20 minutes prior to the agonist, a more particular embodiment up to 10 minutes prior to the agonist, and an even more particular embodiment 10 minutes prior to the agonist.
- A control response to choline was calculated on each plate from the difference in peak fluorescence in wells receiving either choline or assay buffer alone. Compounds of the present invention were tested at a concentration range from 0.1 μ M to 30 μ M. Compounds were considered to have an interesting activity when their efficacy was at least 1.1 when tested at a concentration of 10 μ M (the efficacy of 100 μ M choline was defined as 1 in the absence of a PAM). Analogously, more preferred compounds have an efficacy of at least 1.5 relative to choline, even more preferred compounds at least 2.0, still more preferred compounds at least 3.0 and most preferred compounds at least 4.5. In a most preferred embodiment of the invention, compounds also have a potentiating effect on the response to choline when measured by whole-cell patch clamp electrophysiology in GH4C1 cells stably over-expressing the human wild-type $\alpha 7$ receptor.

- Table 1 lists the results for the compounds of the present invention in the Ca^{2+} flux imaging assay. The activity ranges are defined as follows; A denotes an activity range from 1.1 till 1.5, B denotes an activity range from 1.5 till 2.0, C denotes an activity range from 2.0 till 3.0, D denotes an activity range from 3.0 till 4.5 and E denotes an efficacy from at least 4.5.

Table 1

Compound No.	Activity Range
1	C
2	D
3	D
4	D
5	D
6	C
7	C
8	C
9	C
10	A
11	D
20	C
12	C
21	D
13	C
22	B
int. 3	D
23	D
14	C
24	D
15	D
25	C
int. 1	C
26	C
19	C
16	C
27	C
17	A
28	A
18	B
int. 6	E
31	B
32	C
33	D
38	D
34	C
39	C
35	C

Compound No.	Activity Range
40	C
36	C
41	A
37	C
42	B
43	B
44	C
29	A
30	C
79	B
80	C
81	C
82	B
83	C
84	C
85	C
86	D
87	C
88	C
89	E
90	C
91	C
45	D
46	C
47	C
49	E
50	D
51	C
52	C
53	D
54	A
55	B
56	C
57	C
58	C
59	B
60	B
61	C

Compound No.	Activity Range
62	D
62	B
64	D
65	C
66	D
67	C
68	E
int. 12	C
69	D
70	D
71	B
72	C
73	C
74	B
75	C
76	C
77	C
78	B
174	E
173	D
150	E
172	E
171	E
170	E
169	D
133	E
140	E
161	E
106	E
97	E
103	E
157	E
102	E
146	E
158	E
153	E
163	E
162	E
156	E
149	E

Compound No.	Activity Range
152	E
145	E
107	E
160	E
147	E
119	E
96	E
154	E
118	E
int. 20	E
159	E
151	E
110	E
155	E
148	E
104	E
143	E
144	E
int. 19	E
117	E
116	E
105	E
int. 30	E
136	E
95	E
135	E
129	E
128	E
125	E
98	E
130	E
114	E
108	E
165	E
100	D
99	D
126	E
134	E
123	D
132	E

Compound No.	Activity Range
113	E
122	E
115	E
131	E
112	E
int. 23	D
int. 25	C
166	E
164	E
167	D
109	E
124	E

Compound No.	Activity Range
127	E
93	E
101	D
139	D
142	E
138	E
141	C
137	D
94	D
111	E
120	C
168	E

Example C.2 : Patch-clamp current recording

Patch-clamp recording from mammalian cells has provided a powerful means of assessing the function of membrane-bound proteins thought to be subunits of ligand-gated ion channels. Activation of such proteins by endogenous or exogenous ligands cause opening of a pore associated with the receptor through which ions flow down their electrochemical gradient. In the case of the h α 7-wt nAChR-expressing GH4C1 recombinant cell line the preferential permeability to calcium of this receptor means that calcium flows into the cell upon activation by ACh, choline and other nicotinic ligands giving rise to a calcium current. Since this receptor rapidly desensitizes in the presence of agonist it is important an application system is used which is capable of very rapid switching of solutions (< 100 ms) to prevent partial or full desensitisation of receptor responses coincident with the time of agonist application. Consequently, a second convenient technique to assess the enhancement of nicotinic efficacy is patch-clamp recording from h α 7-wt nAChR-expressing GH4C1 cells coupled with a rapid-application system.

Materials

a) Assay buffers

The external recording solution consisted of 152 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 1 mM Calcium, 10 mM HEPES ; pH 7.3. The internal recording solution consisted of 140 mM CsCl, 10 mM HEPES, 10 mM EGTA, 1 mM MgCl₂, pH 7.3.

b) Patch-clamp recording was carried out using a Patch-clamp amplifier (Multiclamp 700A, Axon Instruments, CA, USA). h α 7-wt nAChR-expressing GH4C1 cells were patch-clamp in the whole cell configuration (Hamill et al, 1981) with a

borosilicate glass electrode of 1.5-3 M Ω tip resistance when filled with the internal recording solution. Recordings were made on cells with membrane resistance >500 M Ω and more preferably 1 G Ω and series resistance <15 M Ω with at least 60% series resistance compensation. Membrane potential was clamped at -70 mV.

5 c) Agonists

ACh, choline, were purchased from Sigma-Aldrich NV, Belgium.

d) Compound application

A 16-channel Dynflow DF-16 microfluidics system (Celletricon, Sweden) for rapid switching of solutions (switching resolution time <100 ms) was used to apply control, agonist and PAM compounds to h α 7-wt nAChR-expressing GH4C1 cells.

Method

h α 7-wt nAChR-expressing GH4C1 cells were plated in external recording solution in the Dynaflo perfusion chamber and were allowed to settle for up to 20 minutes.

15 Individual cells were whole-cell patched and gently lifted off the chamber bottom with the patch pipette into a continuously-flowing perfusion stream (12 μ l/min) of external recording solution. PAM activity was detected in real time by pre-applying the compounds to be tested to the loaded cells followed by an α 7 nicotinic receptor agonist during constant monitoring of cellular membrane current. Compounds giving current

20 responses greater than the response due to agonist alone, were considered to be α 7 nAChR PAM's. In a particular embodiment, the α 7 nicotinic receptor agonist was activated by a non-selective nicotinic agonist, in a more particular embodiment the agonist was choline, and an even more particular embodiment choline applied at a sub-maximal concentration of 1 mM. In a further setting of the present invention the


25 compounds to be tested were applied prior to the α 7 nicotinic receptor agonist, in a more particular embodiment up to 30 seconds prior to the agonist and even more particularly 5 seconds prior to the agonist. A control response was calculated from the area under the curve of the current elicited in each cell to an application of submaximal choline for 250 ms. Area under the curve is the integration of net current over time and

30 is a common representation of the total ion flux through the channel. Increases in agonist efficacy elicited by a positive modulator were calculated as percent potentiation of "area under curve" (AUC) of the agonist response. Potentiation greater than control AUC caused by compounds of the invention indicates that they are expected to have useful therapeutic activity. EC50 values, maximal effect, and Hill slopes were

35 estimated by fitting the data to the logistic equation using GraphPad Prism (GraphPad Software, Inc. , San Diego, CA).

CLAIMS

1. A compound of formula



a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein

n is 0, 1, 2, 3 or 4;

m is 0, 1, 2, 3 or 4;

R¹ each independently represents halo; hydroxy; cyano; C₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl-;

R² each independently represents halo; hydroxy; amino; cyano; mono- or di(C₁₋₆alkyl)amino; C₁₋₆alkyl; HO-C₁₋₆alkyl-; amino-C₁₋₆alkyl-; HO-C(=O)-C₁₋₆alkyl-; polyhaloC₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; amino-C(=O)-; polyhaloC₁₋₆alkyl-O- or C₁₋₆alkyl-C(=O)-NH-;

Z is Het¹; C₁₋₆alkyloxy-C(=O)-; HO-C₁₋₄alkyl-, C₁₋₆alkyl-C(=O)-NH-C₁₋₄alkyl-; C₃₋₆cycloalkyl-C(=O)-NH-C₁₋₄alkyl-; cyano-C₁₋₄alkyl- formylamino-C₁₋₄alkyl-; Het⁴-C₁₋₄alkyl-; Ar⁴-C₁₋₄alkyl-; R^xR^yN-C(=O)-C₁₋₄alkyl-; halo; R^uR^vN-C(=O)-; C₁₋₆alkyl-O-C₁₋₆alkyl or Z represents C₁₋₆alkyloxy-C(=O)-C₂₋₄alkyl-;

Het¹ represents morpholinyl, thiomorpholinyl, imidazolyl, pyrrolidinyl or pyrazolyl;

Het⁴ represents morpholinyl, thiomorpholinyl, imidazolyl, pyrrolidinyl or pyrazolyl;

Het⁶ represents pyridyl;

Ar⁴ represents phenyl optionally substituted with halo, C₁₋₆alkyl, C₁₋₆alkyloxy, polyhaloC₁₋₆alkyloxy or polyhaloC₁₋₆alkyl;

R^x and R^y each independently represent hydrogen, C₁₋₆alkyl or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, thiomorpholinyl, piperidinyl or morpholinyl;

R^u and R^v each independently represent hydrogen, C₁₋₆alkyl or Het⁶ or R^u and R^v taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, thiomorpholinyl, piperidinyl or morpholinyl;


provided that ;

- Z is other than ethoxycarbonyl-;

- the compound is other than 4-phenyl-2-(phenylamino)-5-thiazoleacetonitrile [406470-24-4]; 5-[2-(4-morpholinyl)ethyl]-N,4-diphenyl-2-Thiazolamine [754921-77-2]; 5-Thiazolepropanoic acid, 2-[(4-bromophenyl)amino]-4-(4-methoxyphenyl)-, methyl ester (9Cl) [571149-21-8]; 5-Thiazolepropanoic acid, 2-[(4-chlorophenyl)amino]-4-(4-methoxyphenyl)-, methyl ester (9Cl) [406471-23-6]; 5-Thiazolepropanoic acid, 4-(4-methoxyphenyl)-2-[(4-methoxyphenyl)amino]-, methyl ester (9Cl) [406469-54-3]; 5-Thiazolepropanoic acid, 4-(4-methoxyphenyl)-2-[(2,3,4-trifluorophenyl)amino]-, methyl ester (9Cl) [402768-12-1]; 5-Thiazolepropanoic acid, 4-(4-methoxyphenyl)-2-(phenylamino)-, methyl ester (9Cl) [370840-06-5]; 5-Thiazoleethanol, 4-(4-chlorophenyl)-2-(phenylamino)- (9Cl) [117612-81-4] or 4-(4-fluorophenyl)-5-[2-(4-morpholinyl)ethyl]-N-phenyl-2-Thiazolamine [773792-81-7].
- 2. A compound according to claim 1 wherein;
 - n is 0, 1, 2, 3 or 4;
 - m is 0, 1, 2, 3 or 4;
 - R¹ each independently represents halo; hydroxy; cyano; C₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl-;
 - R² each independently represents halo; hydroxy; amino; cyano; mono-or di(C₁₋₆alkyl)amino; C₁₋₆alkyl; HO-C₁₋₆alkyl-; amino-C₁₋₆alkyl-; HO-C(=O)-C₁₋₆alkyl-; polyhaloC₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; amino-C(=O)-; polyhaloC₁₋₆alkyl-O- or C₁₋₆alkyl-C(=O)-NH-;
 - Z is Het¹; C₁₋₆alkyloxy-C(=O)-; HO-C₁₋₄alkyl-, C₁₋₆alkyl-C(=O)-NH-C₁₋₄alkyl-; C₃₋₆cycloalkyl-C(=O)-NH-C₁₋₄alkyl-; cyano-C₁₋₄alkyl- formylamino-C₁₋₄alkyl-; Het¹-C₁₋₄alkyl-; Ar⁴-C₁₋₄alkyl-; R^xR^yN-C(=O)-C₁₋₄alkyl-; or Z represents C₁₋₆alkyloxy-C(=O)-C₂₋₄alkyl-;
 - Het¹ represents morpholinyl, thiomorpholinyl, imidazolyl or pyrazolyl;
 - Het³ represents morpholinyl, thiomorpholinyl, imidazolyl or pyrazolyl;
 - Ar⁴ represents phenyl optionally substituted with halo, C₁₋₆alkyl, C₁₋₆alkyloxy or polyhaloC₁₋₆alkyl;
 - R^x and R^y each independently represent hydrogen, C₁₋₆alkyl or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, thiomorpholinyl, piperidinyl or morpholinyl;
 - provided that ;
 - Z is other than ethoxycarbonyl-;
 - the compound is other than 4-phenyl-2-(phenylamino)-5-thiazoleacetonitrile [406470-24-4]; 5-[2-(4-morpholinyl)ethyl]-N,4-diphenyl-2-Thiazolamine

- [754921-77-2]; 5-Thiazolepropanoic acid, 2-[(4-bromophenyl)amino]-4-(4-methoxyphenyl)-, methyl ester (9Cl) [571149-21-8]; 5-Thiazolepropanoic acid, 2-[(4-chlorophenyl)amino]-4-(4-methoxyphenyl)-, methyl ester (9Cl) [406471-23-6]; 5-Thiazolepropanoic acid, 4-(4-methoxyphenyl)-2-[(4-methoxyphenyl)amino]-, methyl ester (9Cl) [406469-54-3]; 5-Thiazolepropanoic acid, 4-(4-methoxyphenyl)-2-[(2,3,4-trifluorophenyl)amino]-, methyl ester (9Cl) [402768-12-1]; 5-Thiazolepropanoic acid, 4-(4-methoxyphenyl)-2-(phenylamino)-, methyl ester (9Cl) [370840-06-5]; 5-Thiazoleethanol, 4-(4-chlorophenyl)-2-(phenylamino)- (9Cl) [117612-81-4] or 4-(4-fluorophenyl)-5-[2-(4-morpholinyl)ethyl]-N-phenyl-2-Thiazolamine [773792-81-7].

3. A compound of formula



- a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein
- n is 0, 1, 2, 3 or 4;
- m is 0, 1, 2, 3 or 4;
- R¹ each independently represents halo; hydroxy; C₁₋₆alkyl; C₁₋₆alkyloxy; C₁₋₆alkylthio; C₁₋₆alkyloxycarbonyl; polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;
- R² each independently represents halo; hydroxy; amino; cyano; mono- or di(C₁₋₆alkyl)amino; C₁₋₆alkyl; HO-C₁₋₆alkyl-; amino-C₁₋₆alkyl-; HO-C(=O)-C₁₋₆alkyl-; polyhaloC₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; aminocarbonyl; polyhaloC₁₋₆alkyl-O- or C₁₋₆alkyl-C(=O)-NH-;
- Z is Het¹; C₁₋₆alkyloxy-C(=O)-; HO-C₁₋₄alkyl-; C₁₋₆alkyl-C(=O)-NH-C₁₋₄alkyl-; C₃₋₆cycloalkyl-C(=O)-NH-C₁₋₄alkyl-; cyano-C₁₋₄alkyl-; formylamino-C₁₋₄alkyl-; Het⁴-C₁₋₄alkyl-; Ar⁴-C₁₋₄alkyl-; R^xR^yN-C(=O)-C₁₋₄alkyl-; halo; C₁₋₆alkyl; C₁₋₆alkyl-O-C₁₋₆alkyl; mono- or di(C₁₋₄alkyl)amino-C₁₋₆alkyl; C₁₋₆alkyl-C(=O)-NH-C₁₋₆alkyl; C₁₋₆alkyl-S(=O)₂-NH-C₁₋₆alkyl;
- Het⁵-C(=O)-NH-C₁₋₆alkyl; Ar⁵-C(=O)-NH-C₁₋₆alkyl or Z represents C₁₋₆alkyloxy-C(=O)-C₂₋₄alkyl-;
- Het¹ represents morpholinyl, thiomorpholinyl, imidazolyl, pyrrolidinyl or pyrazolyl; Het⁴ represents morpholinyl, thiomorpholinyl, imidazolyl, pyrrolidinyl or pyrazolyl;

Het⁵ represents isoxazolyl or pyridyl wherein each of said ring systems may optionally be substituted with up to 3 substituents, each substituent independently being selected from halo or C₁₋₆alkyl;

Ar⁴ represents phenyl optionally substituted with halo, C₁₋₆alkyl, C₁₋₆alkyloxy, polyhaloC₁₋₆alkyloxy or polyhaloC₁₋₆alkyl;

Ar⁵ represents phenyl optionally substituted with halo, C₁₋₆alkyl, C₁₋₆alkyloxy, polyhaloC₁₋₆alkyloxy or polyhaloC₁₋₆alkyl;

R^x and R^y each independently represent hydrogen, C₁₋₆alkyl, C₁₋₆alkyl-O-C₁₋₆alkyl or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, thiomorpholinyl, piperidinyl or morpholinyl;

provided that the compound is other than

- 5-Thiazolemethanamine, 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-N,N-dimethyl-4-(3-pyridinyl)- (9Cl) [499984-77-9];
- 4-thiazolepropanamine, *N*-methyl-2-(phenylamino)-5-(2-pyridinyl)- [743384-14-7]; or
- when the pyridyl ring is attached at position 3 or 4 to the thiazole ring, Z is other than hydroxyl-C₁₋₂alkyl, halo, methyl,ethoxycarbonyl-, methoxycarbonyl-, dimethylaminomethyl-, dimethylaminoethyl-, ethylaminomethyl- or morpholinyl-C₁₋₂alkyl.

4. A compound according to claim 3 wherein;

n is 0, 1, 2, 3 or 4;

m is 0, 1, 2, 3 or 4;

R¹ each independently represents halo; hydroxy; C₁₋₆alkyl; C₁₋₆alkyloxy; C₁₋₆alkylthio; C₁₋₆alkyloxycarbonyl; polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl;

R² each independently represents halo; hydroxy; amino; cyano; mono-or di(C₁₋₆alkyl)amino; C₁₋₆alkyl; HO-C₁₋₆alkyl-; amino-C₁₋₆alkyl-; HO-C(=O)-C₁₋₆alkyl-; polyhaloC₁₋₆alkyl; C₁₋₆alkyl-O-; C₁₋₆alkylthio; C₁₋₆alkyl-O-C(=O)-; aminocarbonyl; polyhaloC₁₋₆alkyl-O- or C₁₋₆alkyl-C(=O)-NH-;

Z is Het¹; C₁₋₆alkyloxy-C(=O)-; HO-C₁₋₄alkyl-; C₁₋₆alkyl-C(=O)-NH-C₁₋₄alkyl-; C₃₋₆cycloalkyl-C(=O)-NH-C₁₋₄alkyl-; cyano-C₁₋₄alkyl-; formylamino-C₁₋₄alkyl-; Het⁴-C₁₋₄alkyl-; Ar⁴-C₁₋₄alkyl-; R^xR^yN-C(=O)-C₁₋₄alkyl-; or Z represents C₁₋₆alkyloxy-C(=O)-C₂₋₄alkyl-;

Het¹ represents morpholinyl, thiomorpholinyl, imidazolyl or pyrazolyl;

Het⁴ represents morpholinyl, thiomorpholinyl, imidazolyl or pyrazolyl;

Ar⁴ represents phenyl optionally substituted with halo, C₁₋₆alkyl, C₁₋₆alkyloxy or polyhaloC₁₋₆alkyl;


R^x and R^y each independently represent hydrogen, C₁₋₆alkyl or R^x and R^y taken together with the N atom to which they are attached form a 5 or 6 membered heterocycle selected from pyrrolidinyl, thiomorpholinyl, piperidinyl or morpholinyl;

provided that the compound is other than

- 5-Thiazolemethanamine, 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-N,N-dimethyl-4-(3-pyridinyl)- (9Cl) [499984-77-9] or

- when the pyridyl ring is attached at position 3 to the thiazole ring, Z is other than hydroxyl-C₁₋₂alkyl or morpholinyl-C₁₋₂alkyl.

5. A compound of formula



15 a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein

m is 0, 1, 2, 3 or 4; in particular m is 0, 1 or 2;

R¹ each independently represents halo; hydroxy; C₁₋₆alkyl; C₁₋₆alkyloxy; C₁₋₆alkylthio; C₁₋₆alkyloxycarbonyl; polyhaloC₁₋₆alkyl-O- or polyhaloC₁₋₆alkyl; in particular R¹ each independently represents halo; C₁₋₆alkyloxy- or polyhaloC₁₋₆alkyl; more in particular R¹ each independently represents chloro, methoxy or trifluoromethyl;

Z is C₁₋₆alkyloxy-C(=O)-; HO-C₁₋₄alkyl; C₁₋₆alkyl-C(=O)-; C₃₋₆cycloalkyl-C(=O)- or C₁₋₆alkyloxy-C(=O)-C₁₋₆alkyl; in particular Z is C₁₋₆alkyloxy-C(=O)-; HO-C₁₋₄alkyl or C₁₋₆alkyl-C(=O)-; more in particular Z is ethoxycarbonyl; methoxycarbonyl; HO-methyl; or methyl-C(=O)-; and

L is C₁₋₆alkyl; C₁₋₆alkyl-O-C₁₋₆alkyl or C₃₋₆cycloalkyl wherein said C₁₋₆alkyl; C₁₋₆alkyl-O-C₁₋₆alkyl or C₃₋₆cycloalkyl is optionally substituted with one or where possible two or more halo substituents; in particular L is methyl; propyl; isopropyl; methoxymethyl; methoxyethyl; difluoromethyl or trifluoromethyl

provided that the compound is other than

- Ethyl 2-[N-(3,5-di-*tert*.butyl-4-hydroxyphenyl)amino]-4-methylthiazole-5-carboxylate
- [2-(3,5-di-*tert*.butyl-4-hydroxyphenylamino)-4-methylthiazol-5-yl]methanol

- [2-(2,4,6-trichlorophenylamino)-4-trifluoromethylthiazol-5-yl]methanol
Methyl 2-[N-(4-chlorophenyl)amino]-4-methylthiazole-5-carboxylate.

6. A compound according to any one of claims 1 to 5 for use as a medicine.


7. Use of a compound according to any one of claims 1 to 5 for the manufacture of a medicament for the prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 5.

9. A process of preparing a composition as claimed in claim 8 wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as claimed in any one of claims 1 to 5.


10. A method of prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial by administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 5 or the composition of claim 8.

11. A compound of formula




substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying examples but excluding any comparative examples.

12. A compound of formula



substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying examples but excluding any comparative examples.

- 5 13. A compound of formula



substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying examples but excluding any comparative examples.

10

14. Use of a compound according to any one of claims 11 to 13 substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying examples but excluding any comparative examples.

- 15 15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 5 substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying examples but excluding any comparative examples.

20

16. A process of preparing a pharmaceutical composition substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying examples but excluding any comparative examples.

- 25 17. A method of prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the $\alpha 7$ nicotinic receptor is beneficial substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying examples but excluding any comparative examples.